Using Information Systems in Pharmacovigilance. Promotion of Avderse Drug Reaction Reporting by Fernanda Inês de Carvalho Pereira Ribeiro Vaz
Using	 Information	 Systems	 in	
Pharmacovigilance	
Promotion	of	Adverse	Drug	Reaction	Reporting	
 
 
 
 
 
 
 
 
 
 
 
Doctoral Program in Clinical and Health Services Research 
 
PhD Student 
Fernanda Inês de Carvalho Pereira Ribeiro Vaz 
 
 
Supervisor Co-supervisors 
Ricardo João Cruz Correia Cristina Maria Nogueira da Costa Santos 
 Jorge Manuel Junqueira Polónia 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  


 Professores Catedráticos: Professores Catedráticos Jubilados e Aposentados: 
Manuel Alberto Coimbra Sobrinho Simões Alexandre Alberto Guerra Sousa Pinto 
Maria Amélia Duarte Ferreira Álvaro Jerónimo Leal Machado de Aguiar 
José Agostinho Marques Lopes António Augusto Lopes Vaz 
Patrício Manuel Vieira Araújo Soares Silva António Carlos de Freitas Ribeiro Saraiva 
Alberto Manuel Barros da Silva António Carvalho Almeida Coimbra 
José Manuel Lopes Teixeira Amarante António Fernandes Oliveira Barbosa Ribeiro Braga 
José Henrique Dias Pinto de Barros António José Pacheco Palha 
Maria Fátima Machado Henriques Carneiro António Manuel Sampaio de Araújo Teixeira 
Isabel Maria Amorim Pereira Ramos Belmiro dos Santos Patrício 
Deolinda Maria Valente Alves Lima Teixeira Cândido Alves Hipólito Reis  
Maria Dulce Cordeiro Madeira Carlos Rodrigo Magalhães Ramalhão 
Altamiro Manuel Rodrigues Costa Pereira Cassiano Pena de Abreu e Lima 
Rui Manuel Almeida Mota Cardoso Daniel Filipe de Lima Moura 
José Carlos Neves da Cunha Areias Daniel Santos Pinto Serrão 
Manuel Jesus Falcão Pestana Vasconcelos Eduardo Jorge Cunha Rodrigues Pereira 
João Francisco Montenegro Andrade Lima Bernardes Fernando Tavarela Veloso 
Maria Leonor Martins Soares David Henrique José Ferreira Gonçalves Lecour de Menezes 
Rui Manuel Lopes Nunes Jorge Manuel Mergulhão Castro Tavares 
José Eduardo Torres Eckenroth Guimarães José Carvalho de Oliveira 
Francisco Fernando Rocha Gonçalves José Fernando Barros Castro Correia 
José Manuel Pereira Dias de Castro Lopes José Luís Medina Vieira 
António Albino Coelho Marques Abrantes Teixeira José Manuel Costa Mesquita Guimarães 
Joaquim Adelino Correia Ferreira Leite Moreira Levi Eugénio Ribeiro Guerra 
Raquel Ângela Silva Soares Lino Luís Alberto Martins Gomes de Almeida 
 Manuel António Caldeira Pais Clemente 
 Manuel Augusto Cardoso de Oliveira 
 Manuel Machado Rodrigues Gomes 
 Manuel Maria Paula Barbosa 
 Maria da Conceição Fernandes Marques Magalhães 
 Maria Isabel Amorim de Azevedo 
 Mário José Cerqueira Gomes Braga 
 Serafim Correia Pinto Guimarães 
 Valdemar Miguel Botelho dos Santos Cardoso 
 Walter Friedrich Alfred Osswald 
  
  
 
i 
 
Acknowledgements 
Reading for a PhD becomes a great adventure in one’s professional and personal life. It would 
have been impossible to achieve without the valuable help and encouragement of some special 
individuals to whom I am extremely grateful. 
I would like to express my deep gratitude to my supervisor, Professor Ricardo Correia, who was 
the first to encourage me to pursue this endeavour. His support, confidence and guidance 
enabled me to finish my PhD thesis with contentment. I believe that our conversations and the 
discussions on the topic of my thesis have been more enlightening than the thousands of scientific 
papers I have read over the past years. 
I also would like to thank my co-adviser Professor Cristina Santos for her support and assistance. 
Together with Professor Ricardo Correia, she always trusted my capacity and ability to successfully 
conclude these studies. It has been an enriching experience to work side-by-side on this project. 
In addition, I am grateful to Professor Jorge Polónia, my second co-adviser, for his confidence and 
dedication to this project, despite his very busy agenda, he always managed to find a moment for 
me. 
To Professor Altamiro da Costa Pereira, head of the Health Information and Decision Sciences 
Department and Director of the Doctoral Program in Clinical and Health Services Research, I 
would like to thank the opportunity that he provided by allowing me to accomplish this doctorate, 
during some of my working hours as a Coordinator for the Northern Pharmacovigilance Centre. 
We can’t do much without the support of our friends. These lines are for them, who were always 
by my side, supporting me, making me smile when facing and solving problems. I particularly 
would like to thank Ana Marta Silva, Camila Dias, Daniel Pereira, Patrícia Alves, Pedro Farinha, 
Pedro Rodrigues, Matilde Monteiro Soares, Madalena Oliveira (always by my side!) and Teresa 
Alves (as usual, in the same boat, at the same time…that’s our story!). I am also grateful to all my 
colleagues at the Health Information and Decision Sciences Department for the extraordinary 
work environment and their daily support. Working with kind people that share a common 
interest despite their different positions and backgrounds is not only extremely enriching but also 
makes a big difference. 
Finally, a big thank you to the most important people in my life: my family. Thank you very much 
Mum and Dad for your constant support, helping daily with the kids and for your unconditional 
love. All my love goes to my husband and children, who are my reason for living and my daily 
inspiration. Thank you for being there and for forgiving me all the absences while completing this 
PhD study. I love you all very much and day by day even more!   
ii 
 
 
List of Co-Authors 
Ricardo João Cruz-Correia 1, 2 
Cristina Maria da Costa Santos 1, 2 
Jorge Manuel Junqueira Polónia 1, 3 
Ana Marta Matos Silva 1, 3 
Altamiro Manuel da Costa Pereira 1, 2, 3 
Pedro Pereira Rodrigues 1,2 
Fabrício Barbosa 4 
Domingos Alves 5 
 
 
 
 
 
 
 
 
 
1. Centre for Research in Health Technologies and Information Systems (CINTESIS) University of Porto, Portugal. 
2. Health Information and Decision Sciences Department (CIDES), Faculty of Medicine, University of Porto, Portugal. 
3. Northern Pharmacovigilance Centre, Faculty of Medicine, University of Porto, Portugal. 
4. Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.  
5. Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil. 
 
  
iii 
 
Abbreviations 
ATC - Anatomical Therapeutic Chemical classification system. 
ADR - Adverse Drug Reaction(s) 
AERS - Adverse Events Reporting Systems 
AE - Adverse Events 
ARIMA - Autoregressive Integrated Moving Average 
CDSS - Clinical Decision Support Systems 
CIDES - Health Information and Decision Sciences Department 
CINTESIS - Centre for Research in Health Technologies and Information Systems 
CPARA - 
Catálogo Português de Alergias e Reações Adversas (Portuguese catalog of allergies and 
adverse reactions) 
EHR - Electronic Health Record(s) 
EPR - Electronic Patient Record(s) 
EMA - European Medicines Agency 
FMUP - 
Faculdade de Medicina da Universidade do Porto (Faculty of Medicina, University of 
Porto) 
FDA - Food and Drug Administration 
FIOCRUZ - Oswaldo Cruz Foundation 
GEDII - 
Grupo de Estudo da Doença Inflamatória Intestinal (Study Group of Inflammatory Bowel 
Disease) 
HL7 - Health Level Seven 
INFARMED - 
Autoridade Nacional do Medicamento e Produtos de Saúde, IP (National Authority of 
Medicines and Health Products, IP) 
IS - Information Systems 
ISO - International Organisation for Standardisation 
MA - Marketing authorization 
PPV - Positive Predictive Value  
RAM - Reações Adversas a Medicamentos (adverse drug reactions) 
SIRAI - 
Sistema de Informação de Reações Adversas e Incidentes (Information System for 
Adverse Reactions and Incidents) 
TTA - Time to causality assessment 
ULSM - Unidade Local de Saúde de Matosinhos (Health Local Unit of Matosinhos) 
UFN - Unidade de Farmacovigilância do Norte (Northern Pharmacovigilance Centre) 
USA - United States of America 
VPP - Valor Positivo Preditivo (Positive Predictive Value) 
WHO - World Health Organisation 
iv 
 
  
v 
 
Index of tables 
Table 1. Comparison of the variables included in three pharmacovigilance databases (Food and 
Drug Administration: FDA; European Medicines Agency: EMA and Portuguese Northern 
Pharmacovigilance Centre: UFN), grouped in main entities/sections (patients, problems, products 
and reporters) .................................................................................................................................. 27 
Table 2. Project identification .......................................................................................................... 43 
Table 3. Qualitative analysis of the projects .................................................................................... 46 
Table 4. Effect of Intervention on increased ADR reporting ............................................................ 47 
Table 5. Estimated values of each approach .................................................................................... 60 
Table 6. Number and costs of ADRreports obtained with each intervention .................................. 63 
Table 7. Number and costs of serious, ADR classified with a high degree of causality and 
unexpected ADR reports obtained with each intervention ............................................................. 64 
 
  
vi 
 
Index of figures 
Figure 1. Flowchart of study selection ............................................................................................. 41 
Figure 2. Number of publications by year ........................................................................................ 42 
Figure 3. Rate (ADR reports after/ADR reports before) of ADR report increase (95% IC) ............... 48 
Figure 4. Timeline of the studied approaches .................................................................................. 59 
Figure 5. Total number of ADR reports received in the Northern Pharmacovigilance Centre during 
the studied period, per trimester (in green, those obtained with protocols) ................................. 62 
Figure 6. Two examples of hyperlinks in a computer desktop (back image), and on an Electronic 
Patient Record (front image)............................................................................................................ 73 
Figure 7. Diagram describing the hospitals and hospital centres of the Portuguese northern region 
included and excluded from the study. ........................................................................................... 75 
Figure 8. Evolution of ADR reports (total and just on-line) in hospitals with the intervention. The 
quarters were adjusted for the time of intervention. 5 hospitals centres implemented the 
hyperlink on Dec. 2007, 2 on Jan. 2008, 1 on Feb., 1 on Mar., 1 on Apr. And 1 on May ................. 76 
Figure 9. Evolution of ADR reports in the excluded hospitals (with cooperation protocols) and in 
the hospitals that did not install the hyperlinks .............................................................................. 77 
Figure 10 Information flow .............................................................................................................. 86 
Figure 11 Screen shot of the ADR section on the GEDII electronic health record. .......................... 87 
Figure 12 Drugs involved in the reported ADR ................................................................................ 89 
Figure 13. Screen shot of the Bayesian network .............................................................................. 97 
Figure 14. UFN website 2005-2016 ................................................................................................ 104 
Figure 15. UFN website 2016 ......................................................................................................... 104 
Figure 16. Screen shot of the online patients reporting form (ADR screen). ................................ 106 
Figure 17. User interface of the ADR reporting app (first screen). ................................................ 107 
Figure 18. User interface of the ADR reporting app (suspected drug screen). .............................. 107 
  
 
 
To Clara and João, the two most extraordinary projects I have ever started! 
  
2 
 
  
3 
 
INDEX 
Acknowledgements ........................................................................................................................ i 
List of Co-Authors .......................................................................................................................... ii 
Abbreviations ............................................................................................................................... iii 
Index of tables ............................................................................................................................... v 
Index of figures ............................................................................................................................. vi 
Resumo da tese ............................................................................................................................. 5 
Thesis abstract............................................................................................................................... 9 
Achievements and background ................................................................................................... 13 
Chapter 1. General introduction ................................................................................................. 15 
1.1 Spontaneous adverse drug reaction reporting ................................................................ 15 
1.2 Thesis general aims .......................................................................................................... 17 
1.3 Thesis structure ................................................................................................................ 17 
Chapter 2 – State of the art ......................................................................................................... 19 
2.1 Abstract ............................................................................................................................ 19 
2.2 Pharmacovigilance Informatics ........................................................................................ 21 
2.3 How to Promote Adverse Drug Reaction Reports Using Information Systems – a Systematic 
Review and Meta-Analysis .......................................................................................................... 33 
Chapter 3 - Promoting ADR reports: Comparison of different approaches ................................ 53 
3.1 Abstract ............................................................................................................................ 56 
3.2 Introduction ..................................................................................................................... 57 
3.3 Methods ........................................................................................................................... 58 
3.4 Results .............................................................................................................................. 62 
3.5 Discussion ......................................................................................................................... 65 
Chapter 4 - Promoting spontaneous ADR reporting in Hospitals using a hyperlink to the on-line 
reporting form. ............................................................................................................................ 67 
4.1 Abstract ............................................................................................................................ 70 
4.2 Introduction ..................................................................................................................... 71 
4.3 Methods ........................................................................................................................... 72 
4.4 Results .............................................................................................................................. 76 
4.5 Discussion ......................................................................................................................... 77 
Chapter 5 – Using webservices to link electronic clinical records to pharmacovigilance databases
 ..................................................................................................................................................... 81 
5.1 Abstract ............................................................................................................................ 84 
5.2 Introduction ..................................................................................................................... 85 
5.3 Methods ........................................................................................................................... 86 
5.4 Results .............................................................................................................................. 88 
5.5 Discussion ......................................................................................................................... 90 
Chapter 6 - Decision support tool ............................................................................................... 93 
4 
 
6.1 Abstract ............................................................................................................................ 95 
6.2 Introduction ..................................................................................................................... 96 
6.3 Methods ........................................................................................................................... 96 
6.4 Preliminary results ........................................................................................................... 97 
Chapter 7 - Ongoing and future work ......................................................................................... 99 
7.1 Abstract ............................................................................................................................ 99 
7.2 Managing several players at several institutions dealing with the same adverse event. A 
pilot-study called SIRAI. ............................................................................................................. 100 
7.3 Social networks and portals for patients and healthcare professionals ........................ 103 
7.3.1 Creation of the personal area on the UFN website ................................................. 104 
7.3.2 ADR online reporting form for consumers ............................................................... 106 
7.4 App for ADR reporting .................................................................................................... 107 
Chapter 8 – General discussion ................................................................................................. 109 
References ................................................................................................................................. 111 
Annex ........................................................................................................................................ 117 
 
 
  Resumo / Abstract 
5 
 
Resumo da tese 
As decisões na área da segurança do medicamento são tomadas através de revisões regulares, 
baseadas sobretudo na informação disponibilizada pelos sistemas de farmacovigilância que 
assentam fundamentalmente na notificação espontânea de Reações Adversas a 
Medicamentos (RAM). Estas notificações são feitas de forma voluntária pelos profissionais de 
saúde e pelos utentes. O sistema de notificação espontânea de RAM tem a enorme mais-valia 
da deteção precoce dos problemas de segurança dos medicamentos, mas sofre da grande 
limitação decorrente da sub-notificação. Estima-se que apenas cerca de 10% das reações 
adversas que ocorrem sejam efetivamente notificadas às Autoridades Reguladoras, nos países 
desenvolvidos. Para combater este problema, os sistemas de farmacovigilância têm 
desenvolvido várias estratégias, devendo os sistemas de informação ser encarados como uma 
oportunidade nesta área, uma vez que constituem uma presença central no nosso quotidiano, 
nomeadamente ao nível das instituições de saúde. 
O objetivo desta tese é investigar estratégias para promover a notificação de RAM utilizando 
os sistemas de informação para facilitar o processo. Esta investigação é constituída por seis 
estudos, com os seguintes objetivos individualizados: 1) estabelecer o estado da arte sobre o 
uso de sistemas de informação na notificação espontânea de RAM; 2) comparar diferentes 
estratégias de promoção da notificação de RAM, determinando o seu custo/efetividade; 3) 
promover a notificação espontânea de RAM entre os profissionais de saúde que exercem 
atividade em hospitais, através de hyperlinks diretos para o formulário de notificação online; 4) 
implementar e avaliar o consumo de um webservice por um registo clínico eletrónico 
habitualmente utilizado por um grupo que participa num estudo multicêntrico na área da 
gastroenterologia; 5) aperfeiçoar o processo de avaliação de causalidade das notificações de 
RAM utilizando um modelo de apoio à decisão; 6) criar a área pessoal do notificador no 
website da unidade de farmacovigilância, tornando a notificação de RAM uma atividade 
motivadora e informativa.  
Para estabelecer o estado da arte sobre o tema em estudo, foi elaborada uma revisão 
sistemática (Capítulo 2) sobre a utilização dos sistemas de informação em farmacovigilância, 
através das bases de dados bibliográficas das áreas científicas da saúde e das tecnologias de 
informação. De um total de 3865 artigos selecionados na pesquisa inicial, 33 artigos foram 
incluídos na análise, descrevendo 29 projetos diferentes. Foi efetuada uma meta-análise com 7 
dos 29 projetos, para calcular a medida agregada do aumento da notificação de RAM, 
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obtendo-se o valor de 2.1 (significando que as intervenções duplicaram o número de RAM 
notificadas). 
No Capítulo 3, são analisadas e descritas as várias estratégias que têm sido adotadas na 
Unidade de Farmacovigilância do Norte no sentido de promover a notificação de RAM, no que 
diz respeito ao número e relevância das notificações de RAM obtidas e aos custos envolvidos. 
Os custos da notificação de RAM foram calculados adicionando os custos iniciais de 
implementação da estratégia com os custos de manutenção da mesma (para cada estratégia 
analisada). Este custo global foi dividido pelo número de notificações de RAM obtidas por cada 
intervenção, para determinar o seu custo/efetividade. Todas as estratégias aumentaram o 
número de notificações de RAM. O maior aumento foi verificado com os protocolos 
estabelecidos com departamentos hospitalares (321 notificações de RAM obtidas, com o custo 
de 1.96€ cada uma), seguido da intervenção educativa (265 notificações de RAM obtidas, a 
20.31€ cada uma) e pela inclusão de hyperlinks (135 notificações de RAM, com o custo de 
15.59€ cada uma). Relativamente às RAM graves, os protocolos foram a intervenção mais 
eficiente (2.29€ cada notificação), seguido da inclusão de hyperlinks (30.28€ cada notificação, 
sem custos de manutenção). Os protocolos obtiveram o melhor resultado relativamente à 
notificação de RAM inesperadas (5.12€ cada notificação), seguido da intervenção educativa 
(38.79€ por notificação). 
O Capítulo 4 descreve um estudo ecológico desenvolvido durante o período de 2006-2011 na 
região Norte de Portugal, que consistiu na inclusão de hyperlinks diretos para o formulário 
online de notificação de RAM nos registos clínicos eletrónicos e/ou nos ambientes de trabalho 
dos profissionais de saúde dos hospitais desta região. A mediana mensal das notificações de 
RAM (total e online) e respetivos âmbitos foram analisados antes e depois da intervenção em 
todos os hospitais neste estudo. Dezasseis centros hospitalares entraram no estudo (27 
hospitais), sendo que onze centros (18 hospitais) incluíram o hyperlink. Considerando os 
hospitais que colocaram o hyperlink no registo clínico eletrónico, a mediana mensal de 
notificação de RAM aumentou significativamente, de duas (âmbito 0-12) para cinco 
notificações (âmbito 1-17). A mediana mensal de notificação de RAM através do formulário 
online também aumentou significativamente, de uma notificação (âmbito 0-5) antes da 
intervenção para duas notificações (âmbito 1-17) depois da intervenção. Além disso, a 
notificação de RAM graves aumentou 3 vezes, e a notificação de RAM inesperadas aumentou 
4.5 vezes. Nenhum destes aumentos significativos foi observado nos hospitais que não 
incluíram o hyperlink. Também se observou um aumento significativo das visitas diárias ao 
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website da Unidade de Farmacovigilância do Norte, de 10 visitas diárias antes da intervenção 
para 27 depois da intervenção (p<0.001). 
No Capítulo 5 encontra-se detalhado o processo de desenvolvimento de um serviço 
informático – chamado webservice – que foi implementado num registo clínico eletrónico em 
utilização por um grupo de gastroenterologistas. Foi feito um estudo entre 2013 e 2015, para 
analisar a tendência de notificação de RAM e o tipo de RAM notificadas por esse grupo de 
médicos. De abril de 2013 a fevereiro de 2015, foram enviadas 167 notificações de RAM para a 
Unidade de Farmacovigilância do Norte, através deste webservice, significando 10% do total de 
RAM recebidas no mesmo período. Destas 167 notificações, 118 eram casos graves (1 deles 
colocou a vida do doente em risco). Para medir o impacto da intervenção, foram considerados 
apenas os médicos do grupo que pertencem à região Norte de Portugal. Estes médicos 
notificaram 9 RAM durante os 23 meses anteriores à implementação do webservice e 121 RAM 
nos 23 meses posteriores à sua implementação, significando um aumento de 81%. 
Para aperfeiçoar o processo de avaliação de causalidade das notificações de RAM, foi 
desenvolvida uma rede Bayesiana - descrita no Capítulo 6 - baseada na avaliação que tinha 
sido feita pelo avaliador especialista da Unidade de Farmacovigilância do Norte, ao longo de 12 
anos, às notificações de RAM recebidas nesta Unidade. Os resultados desta rede foram 
comparados com os resultados da introspeção global, com base numa coorte de validação 
independente, para sensibilidade, valor preditivo positivo (VPP) e tempo de avaliação de 
causalidade. A causalidade foi classificada, de acordo com os graus de causalidade definidos 
pela Organização Mundial de Saúde, como: Definitiva, Provável, Possível ou Condicional. A 
coorte de derivação era constituída por 593 notificações de RAM (10.1% classificadas com o 
grau Definitiva, 58.4% com o grau Provável, 25.6% com o grau Possível e 5.9% com o grau 
Condicional) e a coorte de validação por 463 notificações (7.5% classificadas com o grau 
Definitiva, 79.5% com o grau Provável, 9.5% com o grau Possível e 2.8% com o grau 
Condicional). Foi obtida elevada exatidão para as notificações com o grau Definitivo 
(sensibilidade 69.4% e VPP de 71.4%) e com o grau Provável (sensibilidade 91.1% e VPP 
87.3%), e mais baixa para as notificações classificadas com o grau de Possível (sensibilidade de 
25% e VPP de 28.9%) e Condicional. A rede revelou tendência para sobrestimar a causalidade 
(96.9% dos erros nos casos classificados pelo avaliador com o grau Possível foram avaliados 
pela rede com o grau Provável) ou para atribuir o grau imediatamente abaixo (90.8% dos erros 
nos casos classificados pelo avaliador com o grau Definitivo foram classificados pela rede com 
o grau Provável; 69.7% dos erros nos casos com o grau Provável foram classificados pela rede 
com o grau Possível). A mediana e respetivo intervalo interquartil (Q1:Q3) do tempo de 
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avaliação de causalidade foi de 4 dias (2:8) utilizando a rede e de 8 dias (5:14) através da 
introspeção global.  
O Capítulo 7 (concretamente, o subcapítulo 7.3.1) descreve o trabalho que continua a ser feito 
na criação da área pessoal do notificador no website da Unidade de Farmacovigilância do 
Norte. Atualmente, esta área já apresenta ao utilizador as suas próprias notificações de RAM 
submetidas online. Pretende-se ainda desenvolver um modelo de comunicação entre a 
unidade de farmacovigilância e os seus notificadores, fornecendo informação técnica sobre a 
reação adversa notificada e o medicamento suspeito. Após ter este modelo operacional, 
pretendemos (como trabalho futuro) avaliá-lo através de uma série de indicadores (por 
exemplo: aumento das notificações de RAM, aumento das visitas ao site, entre outros). Este 
trabalho não foi ainda concluído. 
Muito trabalho pode ser desenvolvido para melhorar as atividades de farmacovigilância 
através dos sistemas de informação. Soluções promissoras podem passar pela integração das 
bases de dados de farmacovigilância nos registos clínicos eletrónicos usados habitualmente 
pelos profissionais de saúde, evitando que estes tenham trabalho adicional para submeter 
uma notificação de RAM. A inclusão de hyperlinks diretos nos registos clínicos eletrónicos e/ou 
nos ambientes de trabalho dos computadores dos profissionais de saúde para o formulário de 
notificação online de RAM é uma forma simples e custo-efetiva de alterar o comportamento 
dos profissionais de saúde relativamente à notificação de RAM e pode ser facilmente 
implementado nas instituições de saúde. Os sistemas de informação podem ainda ajudar na 
melhoria das atividades de rotina em farmacovigilância, melhorando a comunicação entre as 
Unidades de farmacovigilância e os seus notificadores. É também possível acelerar o processo 
de imputação de causalidade e subsequente feedback, utilizando métodos Bayesianos. 
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Thesis abstract 
Decisions in the area of drug safety are made through regular reviews, based on available 
information from pharmacovigilance systems, which are mostly based on Adverse Drug 
Reactions (ADR) reports, voluntarily made by healthcare professionals and consumers. The 
ADR reporting system has the great value of early detection of drug safety problems, but also 
has a major limitation due to under-reporting. It is estimated that only about 10% of ADR that 
occur are actually reported to regulatory authorities in developed countries. To counter this 
problem, pharmacovigilance systems have been instituted to ensure that detected ADR are 
effectively reported to the regulatory authorities. The use of information systems is currently 
central in most of our lives, namely in healthcare institutions, and therefore represents an 
opportunity. 
The aim of this thesis is to investigate strategies to promote ADR reporting using information 
systems to facilitate the process. It comprises the following six study aims: 1) to assess the 
state of the art regarding the utilisation of information systems in spontaneous ADR reporting; 
2) to compare different approaches promoting ADR reporting and to determine their 
cost/effectiveness; 3) to promote spontaneous ADR reporting among healthcare professionals 
working in hospitals using hyperlinks to ADR online reporting forms; 4) to implement and 
evaluate the consumption of a webservice by the usual electronic health record used by a 
gastroenterologist multicentre study group; 5) to improve the ADR report causality assessment 
using a decision support tool and 6) to create a personal area in a pharmacovigilance website 
for each person that submits an ADR, aiming to turn the ADR reporting act into a motivating 
and informative activity. 
A systematic review was performed regarding the use of information systems in 
pharmacovigilance, in bibliographic databases of the scientific fields of healthcare and 
information technology, as described in Chapter 2. From a total of 3865 articles, 33 articles 
were included in the analysis, describing 29 different projects. We also performed a meta-
analysis on 7 of the 29 projects, to calculate the aggregated measure of increased ADR 
reporting, with an overall measure of 2.1 (meaning that the interventions doubled the number 
of ADR reports). 
Several approaches taken by the Northern Pharmacovigilance Centre to promote ADR 
reporting are analysed and described in Chapter 3, regarding the number and relevance of 
ADR reports obtained and the costs involved. The costs of ADR reporting were calculated by 
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adding the initial costs and the running costs of each intervention. These costs were divided by 
the number of ADR reports obtained with each intervention, to assess its cost/effectiveness. 
All the approaches increased the number of ADR reports. The biggest increase was noted with 
protocols in hospital departments (321 ADR reports obtained, costing 1.96€ each), followed by 
an educational approach (265 ADR reports, 20.31€/report) and a hyperlink approach (136 ADR 
reports, 15.59€/report). According to serious ADR, the protocol approach was the most 
efficient, costing 2.29€/report, followed by the hyperlink approach at 30.28€/report (with no 
running costs). Concerning ADR unexpectedness, the best result was found with the protocol 
approach (5.12€/report), followed by the educational approach (38.79€/report). 
Chapter 4 describes an ecological study performed in northern Portuguese hospitals from 
2006 to 2011. We included hyperlinks to the online ADR report form either on Electronic 
Patient Records or on computer desktops. The median of spontaneous ADR reports (total and 
online) per month and the respective ranges were analysed before and after the intervention 
in all hospitals in this study. Sixteen hospital centres were involved in the study (27 hospitals). 
Eleven centres (18 hospitals) included the hyperlinks. Considering the hospitals with hyperlink 
access to the Electronic Patient Records, the median ADR reports per month increased 
significantly, from two (range 0-12) to five reports (range 1-17). The median of ADR reports per 
month using the online form also increased significantly, from one (range 0-5) before the 
intervention to two (range 1-17) after it. Moreover, serious ADR increased by 3-fold, and non-
previously described ADR increased by 4.5-fold. None of these significant increases were 
observed in the hospitals where the hyperlink was not installed. We also found a significant 
increase in daily UFN website visits, from 10 before the intervention to 27 after it (p < 0.001). 
Chapter 5 focuses on the creation of a webservice and its implementation in an electronic 
health record already in use by a group of gastroenterologists. A study was performed 
between 2013 and 2015 to analyse the trends of ADR reporting and also the type of ADR 
reported. From April 2013 to February 2015, 167 ADR reports were sent to the Northern 
Pharmacovigilance Centre through the webservice, meaning 10% of the total of ADR reports 
received in the same period. Of these 167 ADR, 118 cases were serious (one of them life-
threatening). According to the northern region of Portugal, the studied physicians reported 9 
ADR during the 23 months prior to webservice implementation and 121 ADR during the 23 
months after webservice implementation, i.e. an increase of 81%. 
To improve the process of causality assessment, a Bayesian network was developed, as 
described in Chapter 6. Network development was based on completely filled ADR reports, 
evaluated by the Portuguese Northern Pharmacovigilance Centre expert over 12 years, and 
  Resumo / Abstract 
11 
 
compared with global introspection on an independent validation cohort for sensitivity, 
positive predictive value (PPV) and time to causality assessment (TTA). Causality was classified 
as Definitive, Probable, Possible or Conditional, according to the World Health Organisation 
causality assessment. The derivation cohort included 593 ADR reports (10.1% Definitive, 58.4% 
Probable, 25.6% Possible and 5.9% Conditional) with a validation cohort including 463 reports 
(7.5%, 79.5%, 9.5% and 2.8%, respectively). High accuracy was reached for reports with 
Definitive causality (69.4% sensitivity, 71.4% PPV) and Probable causality (91.1%, 87.3%), but 
this was lower for reports with Possible (25%, 28.9%) and Conditional (15.4%, 50%) 
classification. The network tends to overrate causality (96.9% of errors in Possible cases 
classified as Probable) or give the level immediately below (90.8% of errors in Definitive cases 
classified as Probable; 69.7% of errors in Probable cases classified as Possible). The median 
(Q1:Q3) TTA was 4 (2:8) days using the network and 8 (5:14) days using global introspection. 
The creation of a personal area within the UFN website was created and is described in 
Chapter 7 (specifically, subchapter 7.3.1). We intend to design a model of communication 
between the pharmacovigilance centre and its users, providing technical information about 
the reported adverse reaction and the suspected drug. We expect to have the model in 
operation on the UFN website and evaluate its use through a set of indicators (e.g. increase in 
ADR reports, increase of website visits, etc.). This work is ongoing. 
Much work can be done using  information systems to improve pharmacovigilance. The 
authors see this as a promising solution the integration of pharmacovigilance databases with 
the habitually used electronic health records, avoiding an extra workload to submit an ADR 
report. The inclusion of hyperlinks to on-line ADR reporting forms on computer desktops and 
in Electronic Health Records is an easy and cost-effective way to change healthcare 
professional behaviours regarding spontaneous ADR reporting and can be easily implemented 
in healthcare institutions. Information systems can also improve pharmacovigilance routine 
activities, improving the communication between pharmacovigilance centres and its reporters. 
It is possible to accelerate the process of causality assessment and subsequent feedback using 
Bayesian methods. 
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Achievements and background 
Working in pharmacovigilance for the last 12 years, it was fairly easy to choose this PhD 
theme, as I have always aimed to change the paradigm of spontaneous adverse drug reaction 
(ADR) reporting, from the idea of a passive and boring process to something appealing and 
simple to do. Considering the increasing use of information systems (IS) among healthcare 
institutions, it became clear that we could use IS to change the way people see the 
pharmacovigilance system. In this process, the contribution of my supervisor, Prof. Ricardo 
Correia, was crucial as he who always aroused my curiosity regarding the use of IS to promote 
spontaneous ADR reporting. 
The development of this PhD thesis allowed me to face some challenges related to the 
differences between the structure of healthcare professionals’ knowledge and the specific 
needs of electronic records. In this sense, I have participated in some discussion groups, both 
national and internationally (namely the FHIR/OpenEHR[1] and HL7[2] working groups), aiming 
to create a standard way in which information should be kept in the ADR registry. 
In June 2014, I participated in the HL7 pharmacy group meeting, where the International 
Organisation for Standardisation (ISO) draft of the international standard for ‘Requirements for 
electronic prescriptions’ was discussed. This document remained under discussion for several 
months. 
Contributions were also made to the last OpenEHR discussion, which took place in July 2014. It 
was focused on ADR definition, its characteristics and what should be kept during the 
registration of a ADR. At the moment, discussion is ongoing regarding the clinical content of 
the archetypal adverse reaction (FHIR/OpenEHR). Variables such as substance, status, 
seriousness, reaction type and certainty are under debate. 
Nationally, important input was provided by this PhD team to the review of national legislation 
for the registration of allergies and adverse reactions (the Portuguese Catalogue for Allergies 
and Adverse Reactions - CPARA, in Portuguese). For this purpose, we created an archetypal 
Open EHR for the registry of ADR and allergies. 
Another study developed during the PhD period, but not included in this thesis, was the 
creation of a list of ‘alert drugs’ to help hospital pharmacies detect ADR. For this purpose, a list 
of drugs was developed, adapted from Otero et al [3] and Classen et al [4], that should alert 
pharmacists to potentials ADR when the drugs are prescribed by physicians. The drugs 
included were chosen because they are used as specific treatments for ADR or as antidotes. 
Achievements and background 
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This list is now available on the Northern Pharmacovigilance Centre website[5] and, at the time 
of its disclosure, it was widely disseminated. It includes 16 drugs and their corresponding 
identifier codes to allow for easier integration on the IS used by pharmacies. 
 
With all these small studies, together with the work developed to conclude this PhD thesis, it is 
my aim to increase the ADR reporting rate and to start changing the paradigm of 
pharmacovigilance in Portugal. 
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Chapter 1. General introduction 
1.1 Spontaneous adverse drug reaction reporting 
Most pharmacovigilance systems are based on spontaneous reporting of ADR[6]. Although 
there are some criticisms about this method and its known limitations, I strongly believe that 
spontaneous ADR reporting remains as an irreplaceable method of tracking a drug’s safety 
profile. 
Spontaneous ADR reporting has several limitations, as it suffers from incomplete data and, in 
many cases, inadequate data quality. Also, it depends on the motivation of healthcare 
professionals and consumers to report, which is not always easy to promote. The consequence 
of this is underreporting, which is a huge problem in all developed countries. It is estimated 
that only about 10% of the ADR that occurr are effectively reported to the regulatory 
authorities[7]. Another problem related to spontaneous ADR reporting is the difficulty of 
identification. If it is difficult to identify that an adverse event was caused by a drug, it will be 
even harder to report it. 
However, this method as many advantages that should be highlighted. First of all, it involves all 
the drugs available to the whole population, during all the entire drug life cycle, unlike the 
situation with clinical trials. Rare and chronic ADR are mainly detected after drug 
commercialisation and, most of the time, through spontaneous ADR reporting.[8] 
In recent years, data mining processes have been developed and tested in pharmacovigilance 
activities, through the detection of associations between drugs and adverse events. Although 
this could be a very efficient method to detect adverse events, we believe that important 
information, spontaneously reported as an ADR, would never be equal the information 
recovered from big databases. In fact, when one decides to report an ADR, the event/reaction 
is usually carefully described. Besides, ADR reporting systems emphasise among healthcare 
professionals and consumers the concept and the importance of drug safety surveillance. 
Moreover, this method allows for describing how the adverse event affected the well-being of 
the patient[9]. 
For all these reasons, I believe that data mining processes and computerised searches for ADR 
stored in databases will never replace spontaneous ADR reporting, but will rather complement 
it.  
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1.2 Thesis general aims 
Globally, this thesis main aims are: to analyze strategies performed to increase spontaneous 
ADR reporting, to create tools to facilitate ADR reporting using IT and to create tools to 
improve pharmacovigilance activities. A secondary aim is to create the personal area on UFN 
website. 
 
1.3 Thesis structure 
This PhD Thesis is organised into eight chapters, some of them in the form of published or 
submitted scientific papers.  
The two first chapters include the Introduction and the State of the Art, setting our studies 
within the framework of international research. Both of these chapters were published in 
scientific publications, the first published as an encyclopaedia chapter and the second as a 
scientific paper. 
The four subsequent chapters (3-6) describe studies performed as part of our research 
programme; two of them were published in scientific journals and one as an oral 
communication at a scientific international meeting. 
Therefore, the document refers to some ongoing and future work, beyond the limits of the 
PhD, but within the same scope. Finally, the last chapter consists of the Discussion. 
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Chapter 2 – State of the art 
2.1 Abstract 
Many studies have been performed worldwide to improve pharmacovigilance activities, some 
of them using information systems (IS). This chapter intends to frame our research within the 
state of the art (subchapter 2.2), covering the introduction and background of the thesis. We 
have also performed a systematic review with a meta-analysis on the use of IS to promote ADR 
reporting (subchapter 2.3). 
The first work presented on this section was published, in an extended version, as an 
encyclopaedia chapter in the Encyclopaedia of E-Health and Telemedicine; a reprint can be 
found in the Annex. The systematic review was published at BMC Medical Informatics & 
Decision Making and a reprint can also be found in the Annex. 
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Introduction 
All medicines have adverse effects, most of them unknown until the drug commercialization. 
As so, it is crucial to keep strategies to monitor the drug safety. Pharmacovigilance is the 
activity of drug surveillance, after its launch in the market, with the main goal of public health 
protection, ensuring that the drug benefit outweighs its risks. Worldwide, pharmacovigilance 
systems are mostly based on spontaneous Adverse Drug Reactions (ADR) reports made by 
healthcare professionals and consumers. Spontaneous ADR reporting has been described as an 
essential method to detect drug safety signals; however, underreporting is a major issue 
undermining the effectiveness of spontaneous reports. Several studies suggest that less than 
10% of detected ADR are effectively reported to medicines regulatory authorities [e.g. Food 
and Drug Administration (FDA), European Medicines Agency (EMA), etc][7, 10]. 
Tools used in pharmacovigilance are continually evolving and, worldwide, Information Systems 
(IS) to promote ADR reporting or to detect ADR occurred in healthcare institutions have been 
tested and used, such as software that allow voluntary and automated detection of ADR, tools 
that analyse clinical databases or Web sites that actively inform healthcare professionals[11]. 
In addition to signal detection, IS can also be used to encourage and facilitate reporting of 
suspected ADR, such as the creation of on-line reporting forms, development of tools to collect 
safety data from electronic health records (EHR), among others. 
In this chapter, it will be described some tools to automatically detect ADR, or encourage ADR 
spontaneous report. 
Background 
Adverse Drug Reactions (ADR) (defined as a response to a medicinal product which is noxious 
and unintended [6]) are a well-recognized public health problem worldwide, and a major cause 
of death and hospitalization in developed countries[12]. It is estimated that about 6,5% of the 
hospitalizations are related to ADR[13]. Besides, in the USA, about 100.000 people die each year 
due to ADR[12], and in Europe this annual mortality rate increases to 197.000[14]. ADR can be 
expressed in many ways and with different degrees of seriousness. An anaphylactic shock 
caused by penicillin is an example of a serious ADR (a serious ADR is any untoward medical 
occurrence that at any dose: results in death, requires inpatient hospitalisation or prolongation 
of existing hospitalisation, results in persistent or significant disability/incapacity or is life-
threatening[6]). Another type of ADR, not always recognized as such, is the drug 
ineffectiveness, for example, a vaccination failure. This can be (or not) related with a product 
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quality issue and should be reported when detected in order to allow the regulatory 
authorities to take appropriate decisions. 
Rare and long term ADR are difficult to detect during the drug development stage. Only when 
the drug begins to be used by a large population after marketing authorization it is possible to 
detect new ADR not previously identified during clinical trials. In reality, it is known that the 
safety of a new drug cannot be established until it has been on the market for several years[8]. 
Exceptionally, in a pandemic scenario, drug launch is urgent and, in this particular case, can be 
justifiable that drug safety profile is not well established. In this scenarios, it is even more 
important that all the detected ADR are reported (serious or not, expected or not). It is, 
therefore, essential to keep drugs under close surveillance, after its commercialization, 
through a pharmacovigilance system, to continuously evaluate their safety profile. In most of 
the European countries, pharmacovigilance system is based on spontaneous ADR reports, 
which is passive method, made by healthcare professionals and, since July 2012, also by 
consumers [15]. These reports can be made using paper, telephone, e-mail or through an on-
line form and consist of a description of an Adverse Event (AE) apparently caused by a 
medicine. 
To reverse the problem of underreporting of ADR, which is felt in most developed countries, 
several strategies have been tested[10, 16, 17]. Particularly, some studies were developed focused 
on educational interventions to raise awareness on the importance of ADR reporting[18-20] and 
showed to be very effective increasing the quantity and relevance of spontaneous ADR reports 
(among health professionals). However, these studies involved a large financial and personal 
outlay and the authors concluded that the effect was lost after a few months[10, 21]. 
In a recent American study, the authors developed a signal-detection strategy that combines 
the Adverse Event Reporting System (AERS) of the regulatory Authority (FDA) and EHR, by 
requiring signaling in both sources, with promising results[22]. Another study used the 
unstructured clinical notes included in EHR to detect ADR through a computerized system. The 
authors concluded that data mining can be used for hypothesis generation and for rapid 
analysis of suspected AE risk[23]. 
With a similar aim, a recent study used a physician’s network, created through a mailing list, to 
send regular emails to doctors, with humorous component attached with informative 
component, recalling the importance of reporting their suspected ADR[24]. The results showed 
that this type of intervention has impact on the number of ADR reports made by these 
professionals (the study did not assess the relevance of reported ADR). In France, it is being 
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done a work that tries to facilitate the act to ADR reporting, habitually considered a tedious 
process by health professionals. The authors are using the information contained in EHR to 
make the semi-automatic filling of ADR notification forms. The objectives of this ongoing study 
is to increase the rate of ADR report, as well as improving the quality of information submitted 
to regulatory authorities[25]. 
Information Systems in Pharmacovigilance 
Although some authors consider that ADR spontaneous reports suffers from latency and 
inconsistency, it is still considered as the most valuable method to early detect drugs safety 
problems. In fact, most of the decisions concerning to drug safety are triggered by daily ADR 
spontaneous reports. As so, Regulatory Authorities consider as crucial importance to achieve 
the greatest number of ADR reports possible and with high data quality. 
The promotion of ADR report among healthcare professionals is a huge task, as it is necessary 
to regularly recall the importance of ADR reporting and, simultaneously, develop tools to 
facilitate this duty. Pharmacovigilance centres worldwide develop several strategies to 
continuously promote the importance of ADR reporting, as workshops, post-graduate courses, 
and also to make it easier, as development of online reporting forms, inclusion of electronic 
reporting systems into the hospital Information Systems (HIS), direct hyperlinks to online 
reporting forms, among others. 
Along with the promotion of spontaneous ADR reporting, some systems are being tested to 
detect signals of adverse reactions in large databases, as hospitals databases, epidemiologic 
databases, or even among social networks. 
Although the adoption of different strategies, it is consensual the need to obtain the highest 
quantity and quality of information about the safety of marketed drugs, for the protection of 
public health. 
Another important issue in this field is the need to discuss/harmonize what should be recorded 
during an ADR report.  
When analyzed the databases from the FDA, EMA and the Portuguese Northern 
Pharmacovigilance Centre (UFN, in portuguese), all of them with the same purpose of 
recording ADR reports, it was possible to realize that the variables are different between the 3 
databases, as seen in the Table 1.  
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Table 1. Comparison of the variables included in three pharmacovigilance databases (Food and Drug Administration: FDA; 
European Medicines Agency: EMA and Portuguese Northern Pharmacovigilance Centre: UFN), grouped in main 
entities/sections (patients, problems, products and reporters) 
Section Variable FDA EMA UFN 
Patient 
Patient identifier    
Age at the time of event    
Date of birth    
Sex    
Weight    
Problem 
What kind of AE, product 
problem or error did you 
encounter? 
- Adverse event 
- Product use error  
- Product problem 
- Problem with Different Manufacturer 
of the Same Medicine 
--- --- 
Outcomes Attributed to AE 
- Death 
- Life-threatening 
- Congenital anomaly/birth defect 
- Disability or permanent damage 
- Hospitalization 
- Required intervention to prevent 
permanent impairment/damage 
- Other serious 
- Fatal 
- Not recovered 
- Recovered with 
sequelae 
- Recovering 
- Recovered 
- Unknown 
- Fatal 
- Not recovered 
- Recovered with 
sequelae 
- Recovering 
- Recovered 
- Unknown 
ADR Seriousness 
--- - Yes 
- No 
- Death 
- Life-threatening 
- Congenital anomaly 
- Results in persistent 
or significant 
incapacity  
- Hospitalization 
- Other serious 
Date of event    
Describe events, problem, or 
product use error 
   
Relevant test/laboratory 
data, including dates 
 --- --- 
Product 
Product name    
Label strength    
Manufacturer    
Date of use    
Reason for use    
Problem went away after use 
stopped or dose reduced? 
- Yes 
- No 
- Does not apply 
---  
Problem returned after 
person started taking or using 
the product again? 
- Yes 
- No 
- Does not apply 
---  
Do you still have the product 
in case we need to evaluate 
it? 
- Yes 
- No 
- Returned to Manufacturer 
--- --- 
Reporter Reporter name  ---  
Address    
or list of options: Variable exists; ---: Variable does not exist. 
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For example, the concept of outcome for the FDA form as a similar meaning to the concept of 
seriousness for the two European databases analyzed. On the other hand, for these two 
databases, outcome means the evolution of the patient regarding the adverse scenario. 
Active debate is maintained about this subject, aiming to create a standard to the information 
that should be kept during the ADR registry. 
Promotion of Adverse Drug Reaction Reporting 
Integration of pharmacovigilance system databases with other healthcare IS seems to be an 
obvious way to improve the knowledge about drugs safety. In fact, healthcare providers insert 
a lot of information in their EHR about ADR, which is not shared with pharmacovigilance 
systems. Every approach that promotes drug safety surveillance without increasing the 
workload of healthcare professionals, one of the main reasons for not reporting ADR, should 
be considered. 
The creation and implementation of webservices to collect this information is one of the 
possible solutions for this problem. This solution is being tested in a Portuguese multi-center 
research project, in the field of gastrointestinal diseases[26], with promising preliminary results 
(See chapter 5). In this case, the physicians insert the usual clinic information during the 
appointment with the patient, and then, they only have to authorize the transmission of 
anonymized information about drug-related problems to the pharmacovigilance system. This 
tool allows ADR reporting without the need to fill the ADR reporting form and with no 
additional administrative work for the physician other than the normal registry of clinic patient 
data.  
This solution is also available to be included in commercial prescription software. For the 
implementation of these webservices, it was necessary to map the form entries used by the 
doctors with the online ADR reporting form developed by the pharmacovigilance system, so 
that the information is correctly collected. This mapping would be easier if a standard as the 
one described in the previous section was already in use. 
An ADR electronic reporting system included into a IS was developed in a Spanish hospital[27], 
allowing healthcare professionals (pharmacists, physician and nurses) to report suspected ADR 
through their usual IS. The biggest advantage of this system is that some data (already 
included in the IS) appears as default values into the form, which expedites the system and 
reduces transcription errors[28]. All the reports made by this system are reviewed by a 
pharmacist, which is responsible to confirm the included data and to report the case to 
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pharmacovigilance system. This might be a disadvantage, as some cases may be lost and not 
actually sent to regulatory authorities. 
Another strategy that can be easily adopted is the inclusion of hyperlinks in the EHR to the 
online ADR reporting form. This solution was tested between 2006 and 2010, in an ecological 
study performed in 16 Portuguese hospitals centres[16]. The hyperlinks were included in either 
EHR or on computer desktops. Considering the hospitals with hyperlink included in the EHR, 
the median ADR reports per month significantly increased, from two (range 0–12) to five 
reports (range 1–17). The median of ADR reports per month using the online form also 
increased significantly, from one (range 0–5) before the intervention to four (range 1–17) after 
it. Moreover, serious ADR increased 3-fold, and non-previously described ADR increased 4.5-
fold. None of these significant increases were observed in the hospitals where the hyperlink 
was not installed. It was also found a significant increase in daily pharmacovigilance centre 
website visits, from ten before the intervention to 27 after it (p<0.001). The increase in ADR 
reporting shows that the inclusion of hyperlinks to online ADR reporting forms is an easy way 
to change health professional behavior with regard to spontaneous ADR reports. Furthermore, 
this solution seems to be cost effective, when compared with other strategies to increase ADR 
report, as it has no running costs (after the hyperlink implementation, there are no additional 
costs to the pharmacovigilance system). (See chapter 4) 
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Clinical Decision Support and Alerting Systems 
Informatics can be used in pharmacovigilance activities to support and alert healthcare 
professionals during their daily work. With the IS extensively used in health care institutions, 
all the improvements that can enhance patient safety should be taken into account. Clinical 
Decision Support Systems (CDSS), providing intelligently filtered knowledge in real-time, 
should be used in this area to improve public health and health care[29]. Besides, systems that 
triggered alerts of possible ADR can also be integrated in the IS with the same goal. 
Many systems are used and tested worldwide to alert health providers about suspected ADR, 
which can help in the detection of drug safety problems. The exploitation of computer 
programs used in hospitals as a support in the detection of possible ADR[3, 4] is one of these 
systems. With this purpose, work has been developed in order to create lists of drugs used as 
ADR signals to support the detection of ADR in hospitals. The included drugs were chosen as 
they are mostly used as antidotes or therapeutic interventions for possible ADR. Furthermore, 
there are also lists of diagnosis that triggers an alert for possible ADR in the computer systems. 
These diagnoses indicate diseases that are mainly caused by drugs and, therefore, are signals 
of possible ADR. Besides the drugs and diagnosis, also laboratory values can help in ADR 
detection. In fact, some ADR are characterized by laboratory abnormalities, so the monitoring 
of these values can be an improvement in the promotion of drug safety among hospitalized 
patients. The main goal is to incorporate the described lists in the software used in the hospital 
pharmacies in order to be triggered an ADR alert each time an alerting drug is prescribed, or 
each time an alerting diagnosis is made or even each time a laboratory result reaches a 
suspected toxicity value[30, 31]. 
It has been advocated that EHR should be provided with CDSS in order to maximize its benefits 
to patient safety[29]. These CDSS are being used to inform physicians during the prescription 
about identified drug-drug interactions[32], patient allergies[33] or to support the prescribing 
decision[34, 35]. CDSS integrated in the computerized physician order entry (CPOE) can 
effectively prevent potential harmful medication errors and ADR [36, 37]. 
In particular, a Dutch CDSS is being in use at the hospital pharmacy to support hospital 
pharmacist to select patients at risk of ADR, and its effectiveness was evaluated[38]. For this 
purpose, the system retrieves data from IS, and uses clinical rules. During the study period, the 
CDSS generated 2650 safety alerts, 270 (10%) of them were considered as relevant. In these 
cases, the pharmacist contacted the physician or nurse and in 204 (76%) cases this led to an 
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advice to prevent a possible ADR. Most alerts were generated with clinical rules linking 
pharmacy and laboratory data (1685 alerts). 
 
Pharmacovigilance should use informatics to promote and complement spontaneous ADR 
reporting. Worldwide, some strategies has been performed to reach this goal, as described in 
the next sub-chapter (sub-chapter 2.3). 
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Abstract 
Background: Adverse drug reactions (ADRs) are a well-recognized public health problem and a 
major cause of death and hospitalization in developed countries. The safety of a new drug 
cannot be established until it has been on the market for several years. Keeping drug reactions 
under surveillance through pharmacovigilance systems is indispensable. However, 
underreporting is a major issue that undermines the effectiveness of spontaneous reports. Our 
work presents a systematic review on the use of information systems for the promotion of 
ADR reporting. The aim of this work is to describe the state of the art information systems 
used to promote adverse drug reaction reporting. 
Methods: A systematic review was performed with quantitative analysis of studies describing 
or evaluating the use of information systems to promote adverse drug reaction reporting. 
Studies with data related to the number of ADRs reported before and after each intervention 
and the follow-up period were included in the quantitative analysis. 
Results: From a total of 3865 articles, 33 articles were included in the analysis; these articles 
described 29 different projects. Most of the projects were on a regional scale (62%) and were 
performed in a hospital context (52%). A total of 76% performed passive promotion of ADR 
reporting and used web-based software (55%). A total of 72% targeted healthcare 
professionals and 24% were oriented to patient ADR reporting. We performed a meta-analysis 
of 7 of the 29 projects to calculate the aggregated measure of the ADR reporting increase, 
which had an overall measure of 2.1 (95% IC 1.7-2.6), indicating that the interventions doubled 
the number of ADRs reported. 
Conclusions: We found that most of the projects performed passive promotion of ADR 
reporting (i.e., facilitating the process). They were developed in hospitals and were tailored to 
healthcare professionals. These interventions doubled the number of ADR reports. We believe 
that it would be useful to develop systems to assist healthcare professionals with completing 
ADR reporting within electronic health records because this approach seems to be an efficient 
method to increase the ADR reporting rate. When this approach is not possible, it is essential 
to have a tool that is easily accessible on the web to report ADRs. This tool can be promoted by 
sending emails or through the inclusion of direct hyperlinks on healthcare professionals’ 
desktops.  
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Background 
Adverse drug reactions (ADRs) are a well-recognized public health problem worldwide and a 
major cause of death and hospitalization in developed countries[12]. Rare and long-term ADRs 
are difficult to detect during the drug development stage. Detecting new ADRs not previously 
identified during clinical trials is only possible when the drug begins to be used by a large 
population after marketing authorization (MA). The safety of a new drug cannot be established 
until it has been on the market for several years [8]. As such, it is indispensable to keep drug 
reactions under close surveillance after commercialization through a pharmacovigilance 
system to continuously evaluate the drug’s safety profile. In most countries, the 
pharmacovigilance system is based on spontaneous ADR reports made by healthcare 
professionals and consumers [15]. These reports can be made using paper, telephone, e-mail or 
through an on-line form and consist of a description of an adverse event apparently caused by 
a medicine. Spontaneous ADR reporting has been described as an efficient method to detect 
drug safety signs [39]; however, underreporting is a major issue that undermines the 
effectiveness of spontaneous reports. Several studies have suggested that less than 10% of 
detected ADRs are effectively reported to medicine regulatory authorities [10, 40]. 
Worldwide, systems using informatics to promote ADR reporting or to detect the occurrence 
of ADRs in healthcare institutions have been tested and used, such as computer programs that 
allow voluntary and automated detection of ADR [4, 41] informatics tools created to analyse 
clinical databases [42] or websites that actively inform healthcare professionals [43].  
In addition to signal detection, information and communication technologies can also be used 
to encourage and facilitate reporting of suspected ADR.  
In the present work, a systematic review is presented on the use of information systems in 
pharmacovigilance. Our main goal is to describe the state of the art information systems for 
the passive or active promotion of adverse drug reaction reporting. 
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Methods 
Eligible studies 
Studies describing or evaluating the use of information systems to promote adverse drug 
reaction reports were selected. 
Review team 
The review team is composed of two pharmacists who are experts in pharmacovigilance (Inês 
Ribeiro Vaz (IV) and Ana Marta Silva (AS)) and the computer scientist Ricardo Cruz Correia (RC), 
who is an expert in medical informatics. 
Search methods 
Studies were searched in April 2014 in the bibliographic databases. We developed a search 
query that included the concepts adverse drug reaction, adverse drug reaction reporting 
system, pharmacovigilance and information system. Only articles written in English, 
Portuguese or French were included. We did not establish any criteria for the publication date. 
Four distinct bibliographic databases were searched: Medline (via PubMed); ISI (ISI Web of 
Knowledge); IEEE (IEEE Xplore) and Scopus. The query search string used in Medline® was 
((ADR OR "adverse drug reaction" OR "adverse drug reactions" OR "adverse drug event" OR 
"adverse drug events" OR "adverse dug effect" OR "adverse drug effects") OR 
“pharmacovigilance”). A similar query was used in the other databases and was adapted to the 
search engine. 
Selection of studies for the review 
The first selection was based on the study title and abstract (when available). Two reviewers 
on the review team (IV and AS) were involved in study selection and read all titles/abstracts. 
The study was considered eligible when at least one of the reviewers decided that the 
title/abstract mentioned the key concept of using information systems for ADR reporting. In 
cases of disagreement, a consensus meeting was held with the third reviewer (RC) to decide 
whether the article should be selected. 
The second phase of study selection was based on the full text. The team leader (IV) reviewed 
each full-text article. In this stage, articles were excluded based on the following criteria: (1) 
the articles were only focused on medication errors; (2) the articles focused on ADR detection; 
(3) the articles were studies without any information system implemented; (4) the articles 
were studies concerning data quality; (5) the articles were studies focused on website 
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usability; (6) the articles were only the authors’ reflections on the theme; (7) the articles were 
studies only related to incidents that occurred in health institutions; (8) the articles were 
studies concerning signal detection and (9) the articles were studies concerning electronic 
transmission between the authority and other institutions (pharmaceutical companies or 
regional pharmacovigilance centres). 
The articles remaining after this review were included in the final statistical analysis. 
These articles were grouped into research projects to avoid the distortion created by multiple 
papers describing the same project (Figure 1). All statistical analyses were based on the 
projects and not on the articles. 
Definition of variables 
The variables examined in these reviews were related to the projects, papers and information 
systems described in each project. 
We used the following data for project identification: (1) project number; (2) Information 
system name (if any); (3) country; (4) publication date; (5) type of study and (6) reference(s). 
According to the description of the projects, the following variables were analysed:  
1. Area covered by the project (i.e., region, country, or hospital) 
2. Type of action promoted by the project (passive promotion of ADR reporting or active 
promotion of ADR reporting) 
3. Type of software (i.e., web-based or mobile) 
4. Type of institution (i.e., regulatory authority or universities) 
5. Target (healthcare professionals or patients) 
6. Type of medicine (all, vaccines, chemotherapy, or others) 
7. Type of ADR (all/serious ADRs based on the World Health Organization seriousness 
criteria[44]) 
Statistical analysis 
The inclusion criteria for the quantitative analysis were the availability of data related to the 
number of ADRs reported before and after each intervention and a follow-up period.  
Studies that only disclosed the increased ADR rate and studies that reported zero ADRs before 
the project implementation were excluded because it was not possible to perform the analysis 
in these cases. 
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For each study with available data, the rate of ADRs reporting increase (quotient between ADR 
reports after and ADR reports before) and the respective 95% confidence intervals were 
calculated. A rate of ADR reporting increase equal to 2 indicated that the ADR reports doubled 
after the intervention. Conversely, a rate of ADR reporting increase equal to 1 indicated that 
the number of ADR reports after the intervention was equal to the number of ADR reports 
before the intervention. The aggregated rate of the ADR reporting increase was calculated 
with the inverse variance method using a random effects model and a forest plot was 
presented. The confidence intervals, aggregated rate of ADRs and forest plot were performed 
using a Microsoft Excel spreadsheet. The description of the Microsoft Excel spreadsheet and 
the respective statistical methods used were described by Neyeloff[45]. 
Results 
Our search method found 2519 articles in PubMed, 68 in IEEE, 2603 in ISI and 192 in Scopus. 
After eliminating duplicate articles, 3835 articles were selected. 
Two reviewers (IV and AS) read all 3835 titles/abstracts. In cases of disagreement, which 
occurred with 151 articles, a consensus meeting was held with the third reviewer (RC) to 
decide whether the article should be selected. 
A total of 643 studies were excluded because they were not related to pharmacovigilance, 85 
were excluded because they were not related to information systems and 2993 were excluded 
for other reasons (mostly because their focus was on data mining in large databases instead of 
ADR reporting).  
A total of 114 of the 3835 articles were selected in this first selection based on the title and 
abstract. 
The team leader (IV) reviewed each of the 114 full-text articles. After this review, 33 articles 
remained for the final statistical analysis. At this stage, most of the articles were excluded 
because: (1) they were only related to medication errors; (2) they were focused on ADR 
detection; (3) they were studies without any information system implemented; (4) they were 
studies concerning data quality; (5) they were studies focused on website usability; (6) they 
were only authors’ reflections on the theme; (7) they were studies only related to incidents 
that occurred at health institutions; (8) they were studies concerning signal detection or (9) 
they were studies concerning electronic transmission between the authority and other 
institutions (pharmaceutical companies or regional pharmacovigilance centres). 
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These 33 articles were grouped into 29 distinct research projects to avoid the distortion 
created by multiple papers describing the same project (Figure 1.). All statistical analyses was 
based on projects and not on articles. 
 
 
 
 
Figure 1. Flowchart of study selection 
 
 
Table 2 lists all 29 projects, their country, the number of publications, the publication year and 
the journal. The country with the most published projects was the USA (11), followed by the 
United Kingdom (3). 
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Trends 
There was an increasing trend in publication, especially after 2009, as seen in Figure 2. 
 
 
Figure 2. Number of publications by year 
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Table 2. Project identification 
Project number 
System name 
(if any) 
Country 
Number of 
publications 
Publication 
date(s) 
References Journals 
4  USA 1 1992 [4] Hospital pharmacy 
28  France 1 2001 [46] Fundamental & Clinical Pharmacology 
11  Japan 1 2002 [47] Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan 
17  USA 1 2004 [48] American Journal of Health-System Pharmacy 
2  USA 3 2005, 2007 [49-51] 
Journal of Clinical Oncology, Journal of American Medical 
Information Association 
22  USA 2 2005, 2006 [52, 53] 
Biosecurity and Bioterrorism-Biodefense Strategy Practice and 
Science, Health Expectations 
10  USA 1 2007 [54] Journal of the American Medical Informatics Association 
9 MEADERS USA 2 2007, 2010 [55, 56] Annals of Family Medicine, AMIA Annual Symposium proceedings 
21  Spain 1 2008 [27] Annals of Pharmacotherapy 
7  Sweden 1 2009 [57] European Journal of Clinical Pharmacology 
5  Canada 1 2010 [58] International Journal of Medical Informatics 
13  Canada 1 2010 [59] Vaccine 
18  USA 1 2010 [60] Pharmacoepidemiology and Drug Safety 
19  United Kingdom 1 2010 [61] Archives of Disease in Childhood 
23 ALIAS USA 1 2010 [62] Contemporary Clinical Trials 
27  Taiwan 1 2010 [63] Value in Health 
8  United Kingdom 1 2011 [64] Journal of Psychiatric and Mental Health Nursing 
12  Serbia 1 2011 [65] Drug Safety 
14  France 1 2011 [66] Therapie 
15  USA 1 2011 [67] Paediatrics 
6  United Kingdom 1 2012 [68] Drug Safety 
16  Korea 1 2012 [69] Yonsei Medical Journal. 
20  Portugal 1 2012 [16] Drug Safety 
25  USA 1 2012 [70] 
2012 Ninth International Conference on Information Technology: 
New Generations 
1  Cambodge 1 2013 [71] Journal of Medical Internet Research 
3  Netherlands 1 2013 [72] Studies in health technology and informatics 
24 SALUS France 1 2013 [73] Studies in health technology and informatics 
26  Spain 1 2013 [74] International Journal of Clinical Pharmacy 
29  Denmark 1 2013 [75] European Journal of Hospital Pharmacy-Science and Practice 
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Qualitative analysis 
The qualitative variables analysed in each project are listed in Table 3 and described below. 
Globally, we found that there was an increase in the publication of projects over the study 
period, with 4 projects published before 2001, 4 projects between 2005 and 2007, 8 projects 
between 2008 and 2010 and 13 projects between 2011 and 2013. 
Geographic area covered by the projects 
Most of the projects were regional (62%), followed by national projects (34%). We found only 
1 international project based on Facebook®. This international project was developed in the 
last time period (2011-2013). 
Areas covered by the projects 
Most of the projects (52%) were developed in hospitals, followed by community projects 
(21%). A total of 14% covered primary care institutions and 10% (3 projects) were developed 
for use in any type of healthcare institution. One project was dedicated to a multicentre 
clinical trial. We also found that all of the projects oriented to the community were developed 
in the last three years (2011-2013). 
Types of actions promoted by the projects 
The majority of the projects passively promoted ADR reporting (76%); the remainder actively 
promoted reporting (24%). 
Types of software 
More than half of the projects (55%) used web-based technology and 41% used electronic 
health records. Only one project used mobile phone technology. There was an increasing trend 
in software using web-based technology over all of the time intervals considered. The mobile 
technology appeared during the last time period. 
Types of institutions promoting the studies 
Most of the projects were promoted by hospitals and universities (31% ex aequo). There were 
4 projects developed by national institutions (not regulatory) and 5 projects implemented by 
regulatory authorities. 
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Targets 
A total of 72% of the projects were geared to healthcare professionals, 24% to patients and 
one project was geared to both targets. Most of the projects targeting patient ADR reporting 
were developed in the last years considered (2011-2013). 
Types of medicine 
Most of the projects (72%) covered all medicines, but 17% were specific to vaccines. There 
were also projects specific to reporting ADRs due to chemotherapy, human albumin and 
radiopaque agents (1 project for each of these medicines). 
Types of ADR 
Only a small percentage of the projects were specific for serious adverse drug reactions. The 
majority (93%) covered all ADR.  
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Table 3. Qualitative analysis of the projects 
Variable 
Time period Total 
(%) 
Project numbers <2004 
4 projects 
2005-2007 
4 projects 
2008-2010 
8 projects 
2011-2013 
13 projects 
Geographic area covered by the project       
Regional 4 3 5 6 18 (62) 
2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 
17, 20, 21, 22, 26, 27, 28, 29 
National 0 1 3 6 10 (34) 1, 3, 6, 9, 15, 18, 19, 23, 24, 25 
International 0 0 0 1 1 (3) 12 
Area covered by the project       
Hospital 4 2 5 4 15 (52) 
2, 4, 5, 8, 11, 13, 17, 18, 20, 21, 
22, 26, 27, 28, 29 
Community 0 0 0 6 6 (21) 1, 3, 12, 14, 15, 16 
Primary care 0 2 1 1 4 (14) 6, 7, 9, 10 
Other healthcare institutions (different 
from hospitals or primary care) 
0 0 1 2 
3 (10) 
19, 24, 25 
Clinical trials 0 0 1 0 1 (3) 23 
Type of action promoted by the project       
Passive promotion of ADR reporting 3 3 6 10 22 (76) 
4, 5, 6, 8, 9, 10, 11, 14, 15, 16, 
17, 18, 19, 20, 21, 22, 23, 24, 
25, 26, 27, 29 
Active promotion of ADR reporting 1 1 2 3 7 (24) 1, 2, 3, 7, 12, 13, 28 
Type of software       
Web-based 1 3 6 6 16 (55) 
2, 3, 5, 7, 9, 12, 13, 14, 15, 16, 
19, 20, 22, 23, 27, 28 
System inside the Electronic Health 
Record 
3 1 2 6 12 (41) 
4, 6, 8, 10, 11, 17, 21, 24, 25, 
26, 18, 29 
Mobile 0 0 0 1 1 (3) 1 
Type of institution promoting the study       
Hospital 2 1 3 3 9 (31) 2, 4, 8, 17, 18, 21, 26, 27, 29 
University 1 1 3 4 9 (31) 5, 10, 11, 12, 13, 19, 20, 24, 25 
National institution 0 2 0 2 4 (14) 1, 9, 15, 22 
Regulatory authority 1 0 1 3 5 (17) 6, 7, 14, 16, 28 
Other* 0 0 1 1 2 (7) 3, 23 
Target       
Healthcare professionals 4 2 7 8 21 (72) 
4, 6, 7, 8, 9, 10, 11, 13, 14, 16, 
17, 18, 19, 21, 23, 24, 25, 26, 
27, 28, 29. 
Patients 0 2 1 4 7 (24) 1, 2, 3, 5, 12, 20, 22 
Healthcare professionals and patients 0 0 0 1 1 (3) 15 
Type of medicine       
All 4 1 5 11 21 (72) 
3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 16, 
17, 18, 19, 20, 21, 24, 25, 26, 
28, 29  
Vaccines 0 2 1 2 5 (17) 1, 10, 13, 15, 22 
Chemotherapy 0 1 0 0 1 (3) 2 
Human albumin 0 0 1 0 1 (3) 23 
Radiopaque agents 0 0 1 0 1 (3) 27 
Type of ADR       
All 4 4 8 11 27 (93) 
2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 17, 18, 19, 20, 21, 
22, 23, 24, 25, 26, 27, 28, 29 
Serious 0 0 0 2 2 (7) 1, 3 
*Other institutions are: Clinical trial team (project 23) and website producer (project 3) 
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Quantitative analysis 
From the 29 projects analysed, seven projects met the criteria for inclusion in the quantitative 
analysis (meta-analysis). The criteria used were the availability of data related to the number 
of ADR reported before and after each intervention and a follow-up period. 
From the seven projects included in the quantitative analysis, six had the same follow-up 
period (12 months) and only one (project 14) differed on this item (18 months of follow-up). 
The results are described in Table 4. 
 
Table 4. Effect of Intervention on increased ADR reporting 
Study ADR reports before ADR reports after Rate CI lower CI upper 
Project 14 287 415 1,44 -0,18 3,07 
Project 7 89 111 1,25 -0,51 3,00 
Project 29 30 162 5,4 4,56 6,24 
Project 6 3279 4716 1,44 -0,20 3,072 
Project 17 118 294 2,49 1,25 3,73 
Project 27 20 62 3,1 1,99 4,21 
Project 20 82 212 2,58 1,37 3,80 
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We performed a meta-analysis with these seven projects to calculate the aggregated measure 
of the ADR reporting increase. The overall measure was 2.1 (95% IC 1.7-2.6), which indicated 
that the interventions performed in the analysed projects doubled the number of ADR reports 
(Figure 3). 
 
 
Figure 3. Rate (ADR reports after/ADR reports before) of ADR report increase (95% IC) 
 
Projects 14, 7 and 6, which had similar ADR reporting increases, used different approaches. 
The authors of project 14 assessed an online ADR reporting form, in project 7 the authors send 
repeated e-mails with ADR information to healthcare professionals and project 6 evaluated the 
inclusion of a reporting system inside the clinical information system. 
Four of the information systems that contributed to the improvement of ADR reporting used 
web-based technology. Two used an online reporting form (Project 14 [66] and Project 27 [63]) to 
facilitate ADR reporting. A Swedish group opted to evaluate the effect of repeated emails to 
health care professionals that contained attached ADR information (Project 7 [57]). A 
Portuguese study tested the inclusion of hyperlinks to the online ADR reporting form on 
hospitals’ electronic patient records (Project 20 [16]) to facilitate access to the ADR form. 
-1 0 1 2 3 4 5 6 7
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Three projects explored the use of electronic health records to directly report the ADRs 
(projects 29, 6 and 17). Among these, project 29 [75], which had the best result in terms of the 
ADR reporting increase, was a system that completed the ADR report whenever a physician 
required assistance.  
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Discussion 
Although a limited number of projects was included in our work (n=29), our data suggest that 
the number of projects that aimed to promote ADR reporting using information technologies 
increased over time. 
Study selection was performed as a manual review; this approach caused a huge workload 
because we obtained more than 3000 articles. An optimized query would reduce the workload 
but lose sensitivity. 
As expected, most of the projects that aimed to promote adverse drug reactions reporting 
were developed in hospitals and tailored to healthcare professionals. In fact, most of the 
serious ADRs were detected in hospitals and reported by healthcare professionals[72]. For 
example, in Europe direct reporting (ADRs reported by patients) has only been allowed for 
every country since 2012[76]. This finding may also explain why most of the projects that 
targeted direct ADR reporting were developed in the last three years of the study period 
(2011-2013)[65, 67, 71, 72].  
Most of the authors chose to develop systems for the passive promotion of ADR reporting 
because busy healthcare professionals only submit their suspected ADR if it does not increase 
their workload[55, 77]. Active promotion of ADR reporting is difficult and not always ethically 
acceptable because no material reward can be given to the reporters. Thus, projects that 
aimed to actively promote ADR reporting involved teaching sessions[50] or e-mails containing 
ADR information[46, 57, 59, 72]. 
Our results suggested that there was an increasing trend in the use of web-based software to 
promote ADR reporting, which could be explained by the dissemination of internet use. 
Nevertheless, mobile technology was also appearing. 
Most of the retrieved projects covered all medicines and ADR, whereas only a few were 
specific. However, we found 5 projects dedicated to vaccine adverse reactions[52, 54, 59, 67, 71] and 
in the last three years two projects were developed to specifically report serious ADR[71, 72]. 
The institutions that primarily promoted this work were universities and hospitals because 
universities have the know-how to perform these actions and hospitals have specific needs to 
be solved. However, regulatory authorities have been increasing their involvement in the 
development of this type of project. 
A limitation of this study is that a grey literature search was not performed. However, we think 
that this lack does not cause a large bias because regulatory authorities are less likely to 
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produce this type of project. When regulatory authorities are involved in projects of this scope, 
they usually associate with universities and hospitals that have a greater incentive to publish. 
Based on our quantitative analysis, we can conclude that all of the projects analysed increased 
the ADR reporting numbers (most by approximately two-fold). We found two projects that 
increased ADR reporting by more than two-fold [63, 75], perhaps because their basal values were 
much lower compared with the other five projects. A similar effect was noted previously in 
two other studies when the same population of health care professionals was exposed to the 
same educational interventions two different times [18, 20]. After the first intervention, the 
authors achieved a much higher effect and ADR reporting increased compared to the second 
intervention due to the differences in the initial values. 
In our quantitative analysis, we found a limitation concerning the aggregation of the 
information because we found only 7 studies that provided data concerning its impact on the 
increase in ADR reporting. These data were not available for the other studies even after we 
contacted the authors. However, we did not identify any variable that could distinguish these 7 
projects from the other 22 projects. We must reiterate the importance of providing 
quantitative data when publishing studies focused on interventions that aim to promote ADR 
reporting. 
Worldwide underreporting of ADR is a major concern, and many institutions are aware that it 
is feasible to use information systems to improve ADR reporting. The most commonly used 
platform is web-based and exhibits an increasing trend, but interventions inside electronic 
health records also have the potential to improve pharmacovigilance activities and particularly 
ADR reporting. Direct ADR reporting is being increasingly taken into account when the aim is to 
improve information on drug safety. 
Based on our results, we believe that it would be useful to adopt a system to assist healthcare 
professionals with completing ADR reporting within electronic health records because this 
approach seems to be an efficient method to increase the ADR reporting rate. When this 
approach is not possible, it is essential to have a tool that is easily accessible on the web to 
report ADR. This tool can be promoted by sending emails or through the inclusion of direct 
hyperlinks on healthcare professionals’ desktops. 
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Conclusions 
Our systematic review allowed us to note some facts about interventions that aim to improve 
ADR reporting using information systems. According to our aggregation analysis, these 
interventions doubled the number of ADR reports. We also found that most projects passively 
promoted ADR reporting (facilitating the reporting process) and the countries involved in this 
type of project were Northern America countries (USA and Canada), European countries and in 
a smaller number Far East countries. 
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3 Promoting ADR reports: Comparison of different approaches 
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3.1 Abstract 
Objective: To describe different approaches to promote adverse drug reaction reporting 
among health care professionals, determining their cost/effectiveness. 
Methods: We analyzed and compared several approaches taken by the Northern 
Pharmacovigilance Centre (Portugal) to promote adverse drug reaction reporting. Approaches 
were compared regarding the number and relevance of adverse drug reaction reports 
obtained and costs involved. Costs by report were estimated by adding the initial costs and the 
running costs of each intervention. These costs were divided by the number of reports 
obtained with each intervention, to assess its cost-effectiveness. 
Results: All the approaches seem to have increased the number of adverse drug reaction 
reports. We noted the biggest increase with protocols (321 reports, costing 1.96 € each), 
followed by first educational approach (265 reports, 20.31 €/report) and by the hyperlink 
approach (136 reports, 15.59 €/report). Regarding the severity of adverse drug reactions, 
protocols were the most efficient approach, costing 2.29 €/report, followed by hyperlinks 
(30.28 €/report, having no running costs). Concerning unexpected adverse drug reactions, the 
best result was obtained with protocols (5.12 €/report), followed by first educational approach 
(38.79 €/report). 
Conclusions: We recommend implementing protocols in other pharmacovigilance centers. 
They seem to be the most efficient intervention, allowing receiving adverse drug reactions 
reports at lower costs. The increase applied not only to the total number of reports, but also to 
the severity, unexpectedness and high degree of causality attributed to the adverse drug 
reactions. Still, hyperlinks have the advantage of not involving running costs, showing the 
second best performance in cost per adverse drug reactions report. 
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3.2 Introduction 
Adverse drug reactions (ADR) are inherent to medicines use [78], and most of them can only be 
detected after the commercialization of the drug [8]. In fact, during clinical trials, rare reactions 
are hardly detected, as well as the ones associated with chronic utilization of the drug. It is also 
difficult to predict the drug effect among special populations (pregnant, children, elderly), as 
they usually are not part of the clinical research. 
Because of these limitations, post-marketing surveillance is essential, which is why most 
countries have pharmacovigilance centres for monitoring of detected ADR. The fundamental 
tool used by these centres is the spontaneous report of ADR, made by healthcare professionals 
and consumers. This method consists in describing an adverse episode suspected to be caused 
by one or more drugs, and provides valuable information to the regulatory health authorities, 
which is important for the decisions about marketed medicines. The biggest problem of this 
method is the underreporting, ie, ADR are detected but not reported to national regulatory 
health authorities. Most developed countries suffers from this problem [10, 40], and Portugal is 
not an exception [19]. Worldwide, many approaches have been completed to combat the major 
problem of ADR underreporting, such as regular visits to health professionals [79], questionnaire 
studies [80], educative interventions (including workshops, meetings and presentations) [19, 81, 82], 
among others. 
This study aims to describe several approaches that intended to improve ADR reporting and 
determine the cost-effectiveness of each one of them. 
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3.3 Methods 
From its creation (in 2000) to 2003, Northern Pharmacovigilance Centre, a Portuguese regional 
pharmacovigilance centre, had an extremely low rate of ADR reports, about 43 ADR reports 
per year/1 million of inhabitants. We realize this value is very low, when compared with the 
World Health Organization (WHO) recommendation for an Optimal National Centre which is, 
at least, 200 reports per year/1 million of inhabitants1. 
To reach its objectives, in 2004, the Centre established a collaboration protocol (protocol 
approach) with the Immunoallergology Department of a Central Hospital (located on the same 
street as the Centre), in order to collect every suspected case of ADR emerged in appointments 
related to drug allergies. This collaboration includes regular visits of the pharmacovigilance 
staff to the Immunoallergology department, to collect the detected cases in ADR report forms, 
under the physician supervision. Then, the form is signed by the physician and it follows the 
normal course of all the ADR spontaneous reports. This approach was replicated two more 
times, in 2007 and 2009, in two other immunoalergology departments, one from a specialized 
hospital (pediatric hospital, located at 6 km from the Centre), and another from a central 
hospital (located 11 km from the Centre). These three protocols remain active. 
A study conducted in 2004 provided educational interventions (educational approach) for 
physicians and pharmacists [19, 20]. Those interventions were based on a previous case-control 
study that identified the reasons for underreporting [83, 84]. The educational approach includes 
workshops about pharmacovigilance at health care professionals’ working places. 
Since the effect of educational interventions decreased over time, the authors of the 
previously described work promote reinforcement interventions (educational and telephone 
approach). We started a new study in 2007, also among physicians and pharmacists. This study 
consisted not only in outreach interventions (workshops), but also in telephone interviews [17, 
18]. The phone interviews followed a script about ADR and the importance of reporting. Details 
are described in a previous publication [18].  
Meanwhile, we propose a new approach: the inclusion of a hyperlink (hyperlink approach) to 
an online ADR reporting form on hospitals' electronic patient records (EPRs). The main aim of 
this study, performed from 2006 to 2010 was to evaluate the impact of these hyperlinks on the 
number of spontaneous ADR reports[16]. The inclusion of hyperlinks began in December 2007 
and continued over the following five months. 
                                                          
1
 Farmacovigilância em Portugal. Lisboa: INFARMED - Autoridade Nacional do Medicamento e Produtos de 
Saúde, I.P.; 2004. 
Chapter 3. Promoting ADR reports: Comparison of different approaches 
59 
 
The temporal distribution of all these approaches is shown in Figure 4 
 
 
Figure 4. Timeline of the studied approaches 
 
In the present work, we analyzed the number of ADR reports obtained with each one of the 
described approaches. We know exactly which ADR reports were originated at the three 
departments participating in the protocol intervention and analyzed them separately. Four 
physicians were involved.  
The first educational intervention (in 2004) involved three hospitals, 26 healthcare centres and 
73 pharmacies. About 900 healthcare professionals attended these interventions [19]. About 
340 healthcare professionals (physicians and pharmacists) attended the second intervention 
(second workshop + telephone, both in 2007). Five healthcare centres, two hospitals and 40 
pharmacies received the telephone intervention, and 16 healthcare centres, 2 hospitals and 23 
pharmacies were intervened with the 2nd educational intervention. 
For the hyperlinks, we estimated 15,000 health care professionals potentially affected by the 
intervention, as this is the total number of professionals working at the 12 participating 
hospital centers (corresponding to 22 hospitals). It was the first exposure to any intervention 
for eight of these hospital centers. 
The variables analyzed were: type of approach, ADR relevance, initial costs of the 
interventions, running costs of the interventions, and costs per ADR report. Each of these 
variables is described as follows. 
Type of approach: hyperlink approach, protocol approach, educational and telephone 
approach. 
Number of ADR reports obtained with each intervention: the difference between ADR reports 
received two years after the intervention and ADR reports received two years before the 
intervention. 
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ADR relevance: we adopted the following criteria: (1) ADR seriousness; (2) ADR expectedness; 
and (3) causality attributed to the ADR report. A serious ADR is any untoward medical 
occurrence that results in death, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent, or significant disability or incapacity, or is life-
threatening2. An unexpected ADR is the one which the nature or severity is not consistent with 
domestic labeling or market authorization, or expected from characteristics of the drug2. 
According to the causality attributed we considered that an ADR was more relevant if it was 
evaluated with one of the 2 higher degrees of causality: Definitive/certain or probable (the 
evaluation of the likelihood that a medicine was the causative agent of an observed adverse 
reaction)2. 
Interventions initial costs: We consider as initial costs the expenses needed for the 
establishment of the approach, as educational material and staff working hours. These costs 
are described in Table 5. 
 
Table 5. Estimated values of each approach 
Approach 
Initial costs Annual running costs 
Value Description Value Description 
protocol approach 150€ pharmacovigilance and 
clinical services staff 
working hours  
240€ fuel, material and 
pharmacovigilance and 
clinical staff working 
hours 
hyperlink approach 2120€ pharmacovigilance and 
software development 
staff working hours 
--- --- 
educational approach 200€ educational material and 
pharmacovigilance staff 
working hours 
2500€ fuel, material and 
pharmacovigilance staff 
working hours 
telephone approach 400€ telephone calls during the 
pilot-study and 
pharmacovigilance staff 
working hours 
800€ telephone calls, 
material and 
pharmacovigilance staff 
working hours 
 
Interventions running costs: Annual running costs are the expenses needed for the 
continuation of the projects, as fuel, material and staff working hours. These costs are 
described in table 1. In our study, we did not consider the normal (daily) costs of ADR reports 
processing, as we only meant to compare the costs involved to obtain ADR reports. 
                                                          
2
World Health Organization. The Uppsala Monitoring Centre Uppsala WHO Collaborating Centre for 
International Drug Monitoring [09 Aug 2013]; Available from: http://www.who-
umc.org/DynPage.aspx?id=22682. 
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Costs per ADR report: Costs for ADR report were calculated adding initial costs and running 
costs. Initial cost per ADR report were obtained by dividing initial costs by the difference 
between the ADR reports received two years after the intervention and ADR reports received 
two years before the intervention (which we consider to have been the number of reports 
earned with each intervention). Running costs were obtained by dividing the running costs of 
the two-year intervention by the number of notifications earned with each intervention. To 
assess the cost/effectiveness of each intervention, we considered these added costs (initial + 
running costs), as this total means the total cost of each ADR obtained in two years following 
each intervention. 
 
The pharmacovigilance center website uses a web server and has audit trails that read each 
site visit since 2006. These audit trails are processed using the Webalizer program 
(www.webalizer.org) to estimate site hits, user logins and visits. ADR reports obtained by these 
approaches are included in a database. We collect them by selecting the report date and 
origin. 
We presented the total number of reports received in each quarter during the period studied. 
For each health institution, ADR reports made before and after the intervention, if any, were 
measured. 
To examine whether each intervention increased the ADR report trend, an interrupted time 
series analysis using autoregressive integrated moving average (ARIMA) was performed using 
quarter data of ADR reports, as well as each intervention (first and second educational 
approach, telephone approach, and hyperlink approach) as dichotomous variables (before and 
after intervention). 
We performed an additional analysis with the hyperlinks approach, to consider the institutions 
exposed to any type of intervention for the first time. With this sub-analysis we intended to 
isolate the ADR reports obtained with each intervention. 
This study was approved by the local Ethics Committee of the Faculdade de Medicina of the 
Universidade do Porto (Process PCEDCSS-FMUP 08/2014, approved in May 7, 2014). 
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3.4 Results 
We found an increasing trend in the number of ADR reports received by the Northern 
Pharmacovigilance Centre (UFN) during the studied period: 2000-2012. The number of annual 
ADR reports increased from the year in which the first interventions were made (2004) to the 
end of the study period (Figure 5). 
 
 
Figure 5. Total number of ADR reports received in the Northern Pharmacovigilance Centre during the studied 
period, per trimester (in green, those obtained with protocols) 
 
Excluding the ADR reports obtained with the protocols approaches, the only intervention that 
significantly increased the ADR report trend was the first educational approach, in the first 
quarter of 2004 (p<0.001). 
We did not found a significantly increase in the ADR report trend in the second educational 
approach in second quarter of 2007 (p=0.203). The telephone approach also failed to 
significantly increase ADR reporting in third quarter of 2007 (p=0.243). With the hyperlink 
approach we observed a slight increase in the ADR reporting, although without statistical 
significance (p=0.193). 
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All the approaches increased the number of ADR reports, when we compare the two years 
before with the two years after the interventions. We noted the biggest increase with the 
protocol approach (321 ADR reports obtained), followed by the first educational approach, 
with 265 ADR reports obtained, and by the hyperlink approach, with 136 ADR reports. For the 
hyperlink approach, we isolated the institutions exposed to an intervention for the first time; 
these cases obtained 141 ADR reports. 
According to the initial costs involved, our results suggest that the protocol approach is the 
most cost-effective, costing 0.47€ per ADR report, followed by the first educational approach 
costing 0.78€ per ADR report. Analyzing running costs, the hyperlinks approach is the most 
favorable, having none. On the other hand, we can conclude that the second educational 
approach is the intervention that entails more costs, with 123.81€ per report (Table 6.) 
 
Table 6. Number and costs of ADRreports obtained with each intervention 
Approach Intervention  ADR  Costs (€) per report 
Before  After   
2 years 1 year  1 year 2 years  Initial costs Running costs 
(2 years) 
Total 
 
Protocols  0 0  204 117  0.47 1.49 1.96 
           
Hyperlinks  153 120  277 132  15.59 0.00 15.59 
           
Hyperlinks NPE*  68 47  146 110  15.03 0.00 15.03 
           
Educational 1st workshop 36 24  257 68  0.78 19.53 20.31 
 Pharmacies 2 8  110 25  1.60 40.00 41.60 
 Healthcare centres 25 7  102 17  2.29 57.47 59.77 
 Hospitals 9 9  45 26  3.77 94.34 98.11 
           
Phone Interview  47 26  87 34  8.33 33.33 41.67 
 Pharmacies 23 10  37 14  22.22 88.88 111.11 
 Healthcare centres 3 1  8 2  66.67 266.67 333.33 
 Hospitals 21 15  42 18  16.67 66.67 83.33 
           
Educational  2nd workshop 54 40  106 30  4.76 119.05 123.81 
 Pharmacies 39 25  69 18  8.70 217.39 226.09 
 Healthcare centres 10 13  26 6  22.22 555.55 577.78 
 Hospitals 5 2  11 6  20.00 500.00 520.00 
* NPE: Not Previously Exposed. Considering only the institutions without any previous intervention 
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Regarding the relevance of ADR reports, we analyzed the seriousness, expectedness and 
degree of causality attributed to the ADR report. Regarding serious ADR, the protocol 
approach was the most cost-effective, costing 2.29€ per report. The hyperlink approach 
obtained the second lowest value (30.28€ per report), having no running costs cost. We found 
similar results for the relevance criterion of causality assessment. Concerning ADR 
expectedness, the best result belonged to the protocol approach (5.12 € per report), followed 
by the first educational approach (38.79€ per report). (Table 7) 
 
Table 7. Number and costs of serious, ADR classified with a high degree of causality and unexpected ADR reports obtained with 
each intervention 
Approach Intervention ADR  Costs (€) per report 
Before  After   
2 years 1 year  1 year 2 years  Initial costs Running costs 
(2 years) 
Total 
 
           
Serious           
  Protocols  0 0  180 94  0.54 1.75 2.29 
  Hyperlinks  113 96  193 86  30.28 0.00 30.28 
  Educational 1st workshop 12 15  111 42  1.59 32.68 34.27 
  Phone Interview  29 19  55 21  14.29 57.14 71.43 
  Educational 2nd workshop 37 23  44 8  --- --- --- 
           
High degree of causality          
  Protocols  0 0  165 66  0.65 2.08 2.73 
  Hyperlinks  114 86  232 109  15.03 0.00 15.03 
  Educational 1st workshop 14 17  169 47  1.08 27.03 28.11 
  Phone Interview  40 17  65 26  11.76 47.06 58.82 
  Educational 2nd workshop 37 27  74 22  6.25 156.25 162.5 
           
Unexpected           
  Protocols  0 0  70 53  1.22 3.90 5.12 
  Hyperlinks  63 40  69 37  706.67 0.00 706.67 
  Educational 1st workshop 10 7  111 40  1.49 37.30 38.79 
  Phone Interview  17 11  22 7  400.00 1600.00 2000.00 
  Educational 2nd workshop 24 17  28 6  --- --- --- 
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3.5 Discussion 
Although there is some overlap of interventions, making it difficult sometimes to differentiate 
the gains from each one of them, our results show that, in general, all interventions increased 
the number of ADR reports when comparing two years before with two years after. 
Protocols in hospital immunoallergology departments seem to be the most efficient 
intervention. In fact, this intervention is the one that allows obtaining ADR reports with lower 
costs involved, with an increase not only in the total number of ADR reports, but also in the 
severity, unexpectedness, and high degree of causality attributed to the ADR. 
Nevertheless, these protocols have the disadvantage of increasing the reports of ADR in 
patients of a specific population (patients with allergies), which can bias the global 
pharmacovigilance data. We started to establish these protocols at the request of one of the 
immunoallergology department, but we are trying to establish similar protocols in other 
departments (as oncology departments, hospital pharmacies, among others), to solve the bias 
issue. 
On the other hand, hyperlinks approach has the great advantage of not involving running 
costs, and seems to have the second best performance in costs per ADR report. Even when we 
consider only the hospitals exposed to an intervention for the first time (to avoid the overlap 
effect), this behavior remains. 
We also conclude that the first educational intervention was much more efficient than the 
second one. In fact, the second intervention seemed to be counterproductive, as shown by the 
results of serious and unexpected ADR reports (these numbers decreased after the 
intervention). We already had this conviction since this intervention was performed. In fact, in 
most health care institutions where the second intervention took place, we found 
professionals less receptive than in the first intervention, as they already knew the subject and 
did not seem to believe they needed another workshop about it. 
Unfortunately, we are not able to compare our results with other authors’ results, as we failed 
to find any study addressing the issue of ADR report costs. Many studies proposed strategies 
to improve ADR reports [57, 66, 75] and some authors have already studied the costs of an ADR[85, 
86]. However, no one had studied the costs involved in obtaining ADR reports before, which is 
the novelty of our work.  
Although there might be some overlap and eventual contamination among the interventions, 
we believe that this did not introduce an important bias in our conclusions. First, we knew 
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exactly which reports were originated at the departments participating in the protocols. 
Moreover, we included in our results the ADR reports obtained after the hyperlink inclusion in 
the hospitals that had an intervention for the first time. Thus, we could infer that the gain in 
ADR reports after hyperlink inclusion was caused by this intervention. Furthermore, there is no 
problem of overlapping for the first educational approach (workshops in 2004) because this 
was the first intervention made. The only interventions for which we cannot resolve the 
overlapping limitation is the second educational intervention and the phone intervention. 
However, these two interventions were planned as complementary to the first one. 
We believe that our work can help pharmacovigilance centers worldwide choose the best set 
of interventions to promote adverse drug reactions report. This choice must be based on the 
particular characteristics of each center, such as available staff and budget, geographic 
location, proximity to hospitals, among others. 
Based on our results, we recommend the implementation of protocols with hospital 
immunoallergology departments, as they seem to be the most cost-effective intervention, 
followed by hyperlinks to ADR reporting forms, and the promotion of educational 
interventions to health care professionals for the first time. 
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Hospitals using a hyperlink to the on-line reporting form: An 
ecological study in Portugal 
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4.1 Abstract 
Background: Spontaneous Adverse Drug Reactions (ADR) reporting has been described as an 
efficient method to detect drug safety signs. However, underreporting is a major issue 
undermining the effectiveness of spontaneous reports. Among hospitalized patients, adverse 
drug reactions are a particularly serious problem, because these patients are often treated 
with more than one drug, and with new and aggressive drugs. 
Objective: In order to promote spontaneous ADR reporting by healthcare professionals 
working in northern region Portuguese hospitals, we propose the inclusion of a hyperlink to an 
on-line ADR reporting form on the Electronic Patient Records (EPR) of hospitals. The main aim 
of this work is to evaluate the impact of these hyperlinks in the number of spontaneous ADR 
reports to Northern Pharmacovigilance Centre (UFN – Unidade de Farmacovigilância do 
Norte). We also assess the number of UFN web site daily visits before and after the hyperlinks 
inclusion. 
Methods: An ecologic study was performed in the Northern Portuguese Hospitals from 2006 
to 2010. The hyperlinks were included either in EPR or computers desktops. The median of 
spontaneous ADR reports (total and on-line) per month and respective range were presented 
before and after the intervention in all hospitals. The comparisons were performed using the 
Mann-Whitney U test. 
Results: There were 16 hospital centres involved in the study. Eleven centres (18 hospitals) 
included the hyperlinks. Considering the hospitals with hyperlink, the median ADR reports per 
month significantly increased, from 2 (range 0-12) to 5 reports (range 1-17). The median of 
ADR reports using the on-line form per month also increased significantly, from 1 (range 0-5) 
before the intervention to 4 (range 1-17) after it. Moreover, serious ADR increased 3 fold, and 
non-previously described ADR increased 4.5 fold. None of these significant increments were 
observed in the other hospitals without the hyperlink. We also found a significant increase of 
UFN web site daily visits from 10 before the intervention to 27 after it (p<0.001). 
Conclusions: The increase in ADR reporting shows that the inclusion of hyperlinks to on-line 
ADR reporting forms is an easy and cost-effective way to change health professional 
behaviours on ADR spontaneous report. 
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4.2 Introduction 
Background 
Adverse Drug Reactions (ADR) are a well-recognized public health problem worldwide, and a 
major cause of death and hospitalization in developed countries [12]. In fact, rare and long term 
ADR are difficult to detect during the drug development stage. Only when the drug begins to 
be used by a large population after Marketing Authorization (MA), it is possible to detect new 
ADR not previously identified during clinical trials. In reality, it is known that the safety of a 
new drug cannot be established until it has been on the market for several years [8]. As such, it 
is indispensable to keep drug reactions under close surveillance, after its commercialization, 
through a pharmacovigilance system.  
In Portugal, this system is based on spontaneous ADR reports made by healthcare 
professionals and, since 2012, also by consumers[15]. These reports can be made using paper, 
telephone, e-mail or through an on-line form[87]  and consist of a description of an adverse 
event supposedly caused by a medicine. Spontaneous ADR reporting has been described as an 
efficient method to detect drug safety signs [39]. However, underreporting is a major issue 
undermining the effectiveness of spontaneous reports. Several studies suggest that less than 
10% of detected ADR are effectively reported to medicines regulatory authorities [10, 40]. 
Besides, spontaneous ADR report rate in Northern Portugal was 90 reports/million inhabitants 
in 2009, which is highly unsatisfactory according the World Health Organization 
recommendations (200 reports/million inhabitants [88]).  
Worldwide, systems using informatics to promote ADR reporting or to detect ADR occurred in 
healthcare institutions have been tested and used, such as computer programs that allow 
voluntary and automated detection of ADR[4, 89], informatics tools created to analyse clinical 
databases[90], or Web sites that actively inform healthcare professionals[43].  
Among hospitalized patients, adverse drug reactions are a particularly serious problem. In fact, 
these patients are often treated with more than one drug, and with new and aggressive drugs. 
In spite of this, there are no specific systems for monitoring or reporting ADR in Portuguese 
hospitals. According to the characteristics of Portuguese Healthcare Professionals, we believe 
that making the reporting system easier would increase considerably the number of ADR 
reports. 
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Intending to promote spontaneous ADR reporting by healthcare professionals working in 
hospitals, we propose the inclusion of a hyperlink to an on-line ADR reporting form [part of the 
Northern Pharmacovigilance Centre (UFN) web site] on the Electronic Patient Records (EPR) or 
on the desktop of hospital computers. With this system, we expected to reach not only the 
physicians, but also the pharmacists and nurses working at the hospitals. In Portuguese 
hospitals, pharmacists has an important role in ADR detection and reporting, because 
physicians discuss with them the adverse events that occurred during medical treatment, 
asking for alternative drugs available at the pharmacy. Besides, some pharmacists are part of 
the clinical visit and detect ADR. 
Aim 
Our main aim is to evaluate the impact of the hyperlinks implemented in Portuguese hospitals 
in the number of ADR reported by these hospitals using the hyperlink or not, and in the visits 
to the UFN web site. 
 
4.3 Methods 
Intervention 
Hyperlinks to the ADR on-line reporting UFN form were proposed to the 18 Northern 
Portuguese Hospitals Centres. The hyperlinks can be included either in healthcare professional 
specific software (typically EPR or Pharmacy specific applications used by doctors, nurses and 
pharmacists), or at the computer desktop (see Figure 6 for examples of both situations). It 
should be noticed that most of the Portuguese EPR are web-based and so the hyperlink opens 
the UFN form in a new browser window. 
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Figure 6. Two examples of hyperlinks in a computer desktop (back image), and on an Electronic Patient Record 
(front image) 
 
The on-line reporting UFN form requires the health professional to login with their personal 
account. The patient data is collected in an anonymous way (only the initials of the patient 
name are required aiming to help the health professional identify each case) and the data is 
secured in an Oracle database with proper access restrictions.  
In the beginning of October 2007 a letter was sent to the chief physicians of the 18 Northern 
Portuguese Hospital Centres suggesting the inclusion of the hyperlink. If there was no answer 
in two weeks, clinical administration boards were reminded by telephone. Thirteen centres 
forwarded this issue to the respective informatics departments and only one to the 
pharmaceutical department. Five of them have not answered until the end of 2010. After the 
approval by the hospital board and the forward to the respective departments, UFN made a 
third contact in order to explain technical doubts and to send the specific hyperlink of each 
Hospital. 
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Study design and data collection 
An ecologic study was carried out in the Northern Portuguese Hospitals from 2006 to 2010. 
The number of spontaneous ADR reports and on-line spontaneous ADR reports originated in 
hospitals were analysed before and after an intervention without a control group. Five hospital 
centres implemented the hyperlink on December 2007 and the other 6 implemented it during 
the next 5 months. We considered 23 months before and the 31 months after each hospital 
implementation. 
The UFN web site uses an Apache web-server having the web logs related to the site visits 
recorded since January 2006. These logs were initially processed using Webalizer software 
(www.webalizer.org) to calculate site hits, users and visits. 
Telephonic interviews with the informatics departments of each hospital were performed to 
collect where each institution putted the hyperlink to the UFN website, and screen-shots 
illustrating the interventions were taken. 
Variables 
The main variables collected for analysis were: 
• Date – date and time of the ADR report; 
• Hospital – institutions were the ADR was detected; 
• Health professional – type of the health professional that reported (doctor, nurse, 
pharmacist and others); 
• Seriousness – seriousness of ADR grouped in “Serious” or “Non-serious” according to 
the WHO criteria; 
• Previous knowledge – was the ADR previously described on the Summary of Product 
Characteristics or not. 
Bias 
From the initial 18 centres (31 hospitals), we excluded 4 hospitals that established other 
cooperation protocols with UFN in order to avoid possible confounder’s bias (see Figure 7). For 
the other 16 hospitals, we believe that there were no external interventions that could 
potentially explain the observed results. 
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Figure 7. Diagram describing the hospitals and hospital centres of the Portuguese northern region included and 
excluded from the study. 
 
Statistical methods 
The number of spontaneous ADR reports and on-line spontaneous ADR reports per month 
were compared between the two periods (before and after the intervention). The number of 
ADR reports per quarter before and after the installation of the hyperlinks was presented 
graphically (see Figure 8). The number of ADR reports per quarter in the excluded hospitals 
and in the hospitals that did not participate (did not installed the hyperlinks) was also 
presented graphically. 
Median values of number of daily UFN web site visits were reported because of the skewed 
distribution of data. The number of daily UFN web site visits was compared before and after 
the intervention using the Mann-Whitney U test.  
A significance level of 0.05 was used. 
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4.4 Results 
Participants 
From the 16 centres involved in the study, 11 centres (18 hospitals) included the hyperlinks. 
Eight centres included the hyperlink only in the EPR, two centres included the hyperlink in the 
computer desktop and one included in both desktop and EPR (see Figure 7). From the 18 
involved hospitals one is a University hospital and three are specialized hospitals.  
Main results 
Considering the 16 centres that implemented the project, the median of ADR reports per 
month, significantly increased after the project implementation. In fact, before the 
intervention the median of total ADR reports per month was 2, range from 0 to 12, and 31 
months after the intervention was 5, range from 1 to 17 (p=0.043). Four months after the 
project implementation the median number of reports per month was 4. 
Considering only the reports using the on-line form, before the project implementation the 
median of total on-line ADR reports per month was 1, range from 0 to 5, and after the 
intervention was 4, range from 1 to17 (p=0.009). 
Figure 8 shows the number of ADR reports per quarter before and after the intervention and 
Figure 9 presents the number of ADR reports per quarter in the excluded hospitals and in the 
hospitals that did not installed the hyperlinks. 
 
Figure 8. Evolution of ADR reports (total and just on-line) in hospitals with the intervention. The quarters were 
adjusted for the time of intervention. 5 hospitals centres implemented the hyperlink on Dec. 2007, 2 on Jan. 2008, 1 
on Feb., 1 on Mar., 1 on Apr. And 1 on May 
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Figure 9. Evolution of ADR reports in the excluded hospitals (with cooperation protocols) and in the hospitals that 
did not install the hyperlinks 
 
The 11 included centres, reported 17 in 23 months serious ADR using the on-line form before 
the intervention, and 69 in 31 months (increase of 3 fold) after the intervention. Before the 
intervention these centres reported 7 non-previously described ADR using the on-line form 
and reported 42 after (increase of 4.5 fold). 
The hospital with the larger increase of ADR reports submitted on-line was the one that 
included the hyperlink in both EPR and desktop, with a mean of 3 on-line reports per year 
before the intervention and 18 after. The three hospitals that included the hyperlink in the 
desktop (one of them simultaneously with EPR) were in the top five of hospitals with higher 
increasing of ADR reports submitted on-line. 
There were no ADR reports sent both by paper and on-line by the same professional. 
Other analysis 
There was a significantly increase of UFN web site daily visits after the intervention (p<0.001). 
Before there was a median of 10 UFN web site daily visits and after increased to 27.  
4.5 Discussion 
Our results show that the inclusion of hyperlinks to an on-line ADR reporting form on the EPR 
does change health professional behaviours on ADR report. In reality, there was an increase in 
ADR reporting in the hospitals involved in this project both in the total amount of ADR reports 
(more than 2 fold), in the amount of ADR reports submitted on-line (4 fold), in serious ADR 
reported on-line (3 fold) and non-previously described (more then 4 fold). Additionally, daily 
visits to the UFN website increased about 3 fold after the intervention. 
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A similar intervention based on changing the EPR of a hospital to facilitate ADR reporting is 
presented in Ortega et al.[27]. The measured impact was higher as they moved from zero to 1.6 
ADR per month in just one hospital when compared with our ADR reporting growth. We argue 
that this difference may be due to the fact that they were able to fine-tune the EPR to increase 
ADR reporting as they had more control over the application, whilst in our case we were 
limited to placing hyperlinks in existing heterogeneous EPR. Therefore, our approach seems 
more easily widespread as hospitals are known to have many different information systems[91] 
and a national pharmacovigilance institution is probably not able to impose the changes 
described in Ortega el al.[27] to most commercial EPR. 
In the study by Figueiras et al.[92], which was performed in the same region as our own, an 
educational intervention to improve physician reporting is described, namely by performing 
outreach visits to groups of health professionals. Their results present a very expressive 
increase (90 fold) in ADR reporting in the intervention group, and 30 fold in serious ADR. When 
compared with our results, it is clear that the educational intervention has proven to be much 
more effective, but also to need more resources (human and financial). Also, the effectiveness 
of these interventions appears to decrease through time. In the study Pedrós et al.[93], an 
educational (periodic meetings) and economic incentives intervention was initiated in 2003. 
Their results present an increase of 5.6 folds in all ADR, and 2 fold in serious ADR. Their impact 
is similar to our study but again using more financial resources. 
When compared with other types of interventions, being those just educational[92] or 
combined with economic incentives[93], our intervention seems to have less impact although 
more long-lasting and less expensive. 
As an additional outcome, we can see that the hospital with higher increasing of ADR reports 
submitted on-line was the one that included the hyperlink in the EPR and desktop, 
simultaneously. According to our results, the computer desktop seems more efficient than the 
EPR to place the hyperlink. It is the authors’ opinion that these improvements could also be 
effective in other countries, because we think they are more related to generic usage of 
graphical user interfaces than to local practices. 
It should also be noticed that making the ADR forms easily accessible might also potentiate 
other future ADR reporting promotion initiatives that can now take advantage of the visibility 
to the users of the hyperlink. Therefore, we argue that our solution is cost-effective, 
appropriate for widespread use in many healthcare institutions and for consistent increase 
over time.  
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Limitations 
In some hospitals, we found out that although the hyperlink was included, the professionals 
did not know about it. In the near future we aim to increase the knowledge of the hyperlink by 
informing more actively health professionals using flyers to send to the hospitals, posters to be 
placed, and an e-mail showing specifically how to find the hyperlink. Another problem 
detected was the impossibility to use the hyperlink in some hospitals because the users did not 
have permission to access to Internet.  
Future work 
To solve the problem of not being able to access the Internet, we are now developing Web-
services [94] to be used by other systems available at hospitals intranets. With this tool, it will 
not be necessary to access the UFN web site, and health care professionals can simply use the 
existing information systems as proposed in Ortega et al. [27]. With this future work, we expect 
to eliminate all the technical obstacles to ADR report, further increasing the reporting rate. 
Meanwhile, we also aim to implement this project in Northern Portugal primary care 
healthcare centres and providing the hyperlink to general practitioners and nurses. 
Conclusions 
The inclusion of hyperlinks in computer desktops and EPR to on-line ADR reporting forms is an 
easy and cost-effective way to change health professional behaviours on ADR spontaneous 
report. Actually, daily visits to the UFN website significantly increased after the hyperlinks 
inclusion, but, even more important, the amount and relevance of ADR reports significantly 
increased after the hyperlink inclusion in the hospitals involved in this project.  
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5.1 Abstract 
Purpose: Adverse drug reaction (ADR) reporting is an efficient method to assess the safety of 
drugs. However, underreporting is a major issue undermining the effectiveness of this method. 
Among patients with inflammatory bowel disease (IBD), ADR are a serious problem, because 
these patients are often treated with new and potent drugs. Electronic registries usually 
include information on ADR, recorded by physicians. To promote ADR reporting by 
gastroenterologists working in a multicentre IBD study group, we proposed the utilisation of a 
webservice in their usual electronic health records (EHR) to collect ADR. The aim of this work 
was to describe the impact of this intervention on the number of ADR reported to the 
regulatory authority through a regional pharmacovigilance centre. 
Methods: A study was performed between 2013 and 2015. A webservice was created and 
implemented in an EHR in use. We analysed the trends and type of ADR reported through this 
service. 
Results: From April 2013 to February 2015, 167 ADR reports were sent to the Northern 
Pharmacovigilance Centre through the webservice, comprising 10% of the total ADR reports 
received in the same period. Of these, 118 cases were serious (one was life-threatening). In the 
northern region of Portugal, GEDII physicians reported 9 ADR during the 23 months previous to 
webservice implementation and 121 ADR during the 23 months after webservice 
implementation, i.e. an increase of 81%. 
Conclusions: This solution allowed for reporting 167 ADR during the first 23 months of 
implementation, simply by clicking a button included in the usual EHR used by 
gastroenterologists. These results suggest that information systems (IS) should facilitate the 
reporting of ADR.  
.  
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5.2 Introduction 
All medicines have adverse effects, some of them unknown until the drug is commercialised. 
Thus, it is crucial to implement strategies to monitor drug safety. Pharmacovigilance is the 
activity of drug surveillance, after its launch onto the market, with the main goal of public 
health protection, ensuring that the drug benefit outweighs its risks. Worldwide, 
pharmacovigilance systems are mostly based on spontaneous ADR reports made by healthcare 
professionals and consumers. Spontaneous ADR reporting has been described as an essential 
method to detect drug safety signals; however, underreporting is a major issue undermining 
the effectiveness of spontaneous reports. Several studies suggest that fewer than 10% of 
detected ADR are effectively reported to medicine regulatory authorities (e.g. Food and Drug 
Administration - FDA, European Medicines Agency - EMA, etc.). [7, 10] 
It is known that one of the main reasons why healthcare professionals do not report ADR is 
due to an increase in their workload [48, 54]. So, in order to reduce ADR reporting efforts, 
information systems (IS) to promote ADR reporting or to detect ADR in healthcare institutions 
have been tested and used, such as software for voluntary and automated detection of ADR, 
tools that analyse clinical databases or web-sites that actively inform healthcare 
professionals[11]. Information and communication technologies can also be used to facilitate 
and promote ADR reporting, such as the creation of on-line reporting forms and the 
development of tools to collect safety data from electronic health records (EHR), among 
others[16, 27]. 
In Portugal, there is a multi centre research project, in the field of gastric diseases (Study 
Group of Inflammatory Bowel Disease – GEDII)[26] whose members use the same electronic 
health record to collect patient information. As these patients are often treated with new and 
potent drugs (e.g. immunomodulating agents), the EHR has a field related to medication and 
ADR. Since the group members already fill in this field, it was considered an advantage to 
create a tool to send the data to the pharmacovigilance system. 
 
Aim 
The aim of this work was to implement and describe the implementation of a webservice in an 
EHR to collect ADR reports and analyse the number of ADR reports sent to the Portuguese 
regulatory authority (INFARMED), through a regional pharmacovigilance centre.   
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5.3 Methods 
Intervention 
The multi-centre research project, the Study Group of Inflammatory Bowel Disease – GEDII[26], 
has its own electronic health record (EHR) to collect patient information, with a field related to 
medications and ADR.  
The GEDII members asked for a collaboration with the Northern Pharmacovigilance Centre 
(UFN in Portuguese) and the Health Information and Decision Sciences Department (CIDES) of 
the Faculty of Medicine to develop a tool to allow for easy reporting of ADR included in the 
EHR to the pharmacovigilance system. The two entities had, at the time, released a new 
information service (a webservice) to collect suspected adverse reactions directly from 
prescription and medical records. This system was easily adapted to the EHR used by the GEDII 
group. 
The Northern Pharmacovigilance Centre, as part of the Portuguese Pharmacovigilance System, 
receives ADR reports from healthcare professionals (and, since 2012, from consumers as well) 
through an on-line form, a paper form, e-mail and by telephone. Since 2013, UFN has also 
received ADR reports through the webservice. 
The webservice anonymises patient data (converting the full name of the patient into initials), 
according to the data protection standards of the Portuguese Pharmacovigilance System. 
Figure 10 shows the information flow from the electronic health record to the 
pharmacovigilance system. 
 
 
Figure 10 Information flow 
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To use this service, there is a button asking the doctor if he/she will allow the information to 
be sent to the pharmacovigilance database (see Figure 11). If the physician does not allow for 
this information to be sent to the system, it will only be stored in the health record. 
 
 
Figure 11 Screen shot of the ADR section on the GEDII electronic health record. 
 
Study design and data collection 
The webservice was implemented in the GEDII electronic health record (used only by 
gastroenterologists) in April 2013. There are 15 hospitals using this information system, 
covering a total of 4031 patients. The database has 39 registered users, which means that, 
potentially, 39 physicians could report ADR through this information system[26]. 
In order to use this webservice, it is necessary to access a specific URL, provided by the 
Northern Pharmacovigilance Centre and CIDES. The service was incorporated in the GEDII 
software to collect the ADR already stored by the physicians in the system. Each physician, in 
the context of the patient, sends the ADR to the Regional Pharmacovigilance Centre.  
“Do you want this information to be sent to the 
National Pharmacovigilance System?” (Yes/No) 
List of adverse 
drug reactions 
Drug 
Patient Demographics 
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After the ADR report is received by the Regional Pharmacovigilance Centre, their technical staff 
process the report according to the pharmacovigilance guidelines[14], sending it to the 
Portuguese Regulatory Authority (INFARMED). 
If the doctor does not want to send the information to the pharmacovigilance system, it will 
only be stored in the medical history. 
To analyse the trends and type of ADR reported through this service, we performed a 
descriptive analysis on the number and seriousness of ADR reported. The seriousness was 
assessed using the World Health Organisation seriousness criterion[6]. According to this 
criterion, a serious ADR is any untoward medical occurrence that at any dose: results in death, 
requires inpatient hospitalisation or prolongation of existing hospitalisation, results in 
persistent or significant disability/incapacity or is life-threatening.  
 
5.4 Results 
From April 2013 to February 2015, physicians from GEDII reported 167 ADR through the 
described webservice.  
Of the 167 reported ADR, 118 (71%) were serious ADR, considering the World Health 
Organisation seriousness criterion[6]. One of the cases was life-threatening and none were 
fatal. 
To calculate the increase in ADR reporting in this period, we used data from the northern 
region, which is the delimited area of the Northern Pharmacovigilance Centre, as we did not 
have access to national ADR reporting data. Thus, considering the physicians from the GEDII 
group that work at the northern region of Portugal, 9 ADR were reported during the 23 
months prior to webservice implementation and 121 ADR were reported during the 23 months 
after webservice implementation, i.e. an increase of 81%. 
 
Drugs involved in the reported ADR 
Most of the cases had one only suspected drug, but in six cases there were two suspected 
drugs involved. 
Of the reported ADR, 106 cases (63%) were presumably due to azathioprine, 23 cases (14%) to 
infliximab, 14 cases (8%) to adalimumab and 9 (5%) cases to methotrexate (Figure 12). 
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Figure 12 Drugs involved in the reported ADR 
 
All of these drugs are classified as antineoplastic and immunomodulating agents, according to 
the WHO Anatomical Therapeutic Chemical (ATC) classification system[95]. Azathioprine, 
infliximab and adalimumab are immunosuppressants and methotrexate is an antimetabolite. 
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5.5 Discussion 
Worldwide, many systems use electronic health records to facilitate adverse event reporting, 
with the same goal as our work, which is to not overload healthcare professionals with 
additional administrative work to report ADR [27, 55, 64]. These systems can be included in the 
EHR and be easily completed [64] or can actively help in form filling with the automatic input of 
certain information already included in the EHR[27]. During the ALIAS (Albumin in Acute Stroke 
Trial) experience, authors decided to integrate an electronic safety reporting module into the 
existing web-based system to deal with safety reporting obligations of a multicentre clinical 
trial[62]. This system pre-populates the reporting form with the existing information, which 
needs to be completed and validated by clinical staff. The ASTER pilot study also brought an 
important contribution to the development of these systems, as it triggered ADR within the 
EHR, collected patient data, populated the ADR reporting form and made the report available 
to the physician for review [60]. This work is different from ours, because it asks the clinician to 
provide additional information on the adverse event and then submits the report. All these 
systems incur extra work on the part of physicians, which is difficult to eliminate. The novelty 
of our work is the detail of allowing the physician to report ADR without any additional 
administrative work beyond the usual clinical registry. In addition, the EHR remained the same, 
without the need to change the physicians’ routine. This system adapts to the routines of the 
healthcare professionals and not vice versa, which can explain the increasing of ADR reporting 
among the studied group. 
It is also important to note that most of the reported ADR were serious. In fact, the studied 
group deals with innovative and powerful drugs that often cause serious adverse events. This 
finding reinforces the importance of our work, as Pharmacovigilance Systems seek mainly 
information about serious (and unexpected) ADR[88]. 
Our study has some limitations, such that it only included gastroenterologists. However, this 
webservice is available to be used in several software. Even so, it is currently in use only in two 
software systems: the one described in this study and an electronic prescription software 
system. Another issue is that our study does not have a control group, which limits the 
conclusions drawn. For this reason, the only comparison that the authors were able to perform 
was for the number of ADR reports made by the same group of gastroenterologists before the 
webservice implementation. 
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Conclusions 
The simple solution described in our work allowed for reporting 167 ADR during the first 23 
months of implementation, simply by clicking a button included in the usual electronic health 
record used by gastroenterologists. Our results suggest that doctors would report more ADR if 
they do not have to take on any further workload to do it. We propose that IS used to support 
multicentre studies should be used to report detected ADR. 
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6.1 Abstract 
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6.2 Introduction 
In the same line as other our studies, we aimed to improve the feed-back given to the reporter 
according to the causality assessment made in each report (causal relationship judgment). 
Pharmacovigilance systems are mostly based on suspected ADR reported by health 
professionals and users. Thus, regulatory health authorities have adopted methods of causal 
attribution, which allow for the assessment of the probability that a drug was the causative 
agent of the ADR. Worldwide, many methods are used for causality assessment of ADR, such 
as expert judgements (also called global introspection), algorithms and Bayesian 
approaches[96]. The Portuguese pharmacovigilance system has adopted the method of global 
introspection [88], during which one or several experts express their judgment on the possible 
causal relationship between the suspected drug and the ADR. This judgement is based on 
expert knowledge and background, considering all available data about the ADR. This method 
has some limitations related to its reproducibility[96] and compliance with legal deadlines, as it 
depends on the availability of experts. 
Aim 
Our objective was to design and implement a decision support system based on a Bayesian 
network that will expedite the response to the reporter. This work also improved the process 
of ADR report causality assessment according to: (1) time spent on the process and (2) 
reproducibility. 
6.3 Methods 
The Bayesian network was developed based on completely-filled ADR reports, evaluated by a 
Portuguese Northern Pharmacovigilance Centre expert over 12 years, and compared with 
global introspection on an independent validation cohort for sensitivity, positive predictive 
value (PPV) and time to causality assessment (TTA). Causality was classified as Definitive 
(Certain), Probable, Possible or Conditional, according to the WHO causality assessment. 
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6.4 Preliminary results 
The derivation cohort included 593 ADR reports (10.1% Definitive, 58.4% Probable, 25.6% 
Possible, 5.9% Conditional) with a validation cohort including 463 reports (7.5%, 79.5%, 9.5%, 
2.8%). High accuracy was reached for reports with Definitive causality (69.4% sensitivity, 71.4% 
PPV) and Probable causality (91.1%, 87.3%), but the accuracy was lower for reports with 
Possible (25%, 28.9%) and Conditional (15.4%, 50%) degrees of causality. The network tends to 
overrate causality (96.9% of errors in Possible cases classified as Probable) or give the level 
immediately below (90.8% of errors in Definitive cases classified as Probable; 69.7% of errors 
in Probable cases classified as Possible). The median (Q1:Q3) TTA was 4 (2:8) days using the 
network and 8 (5:14) days using global introspection. 
This network has been in use at the Northern Pharmacovigilance Centre since April 2014. The  
appearance of the system is shown in Figure 13. 
 
Figure 13. Screen shot of the Bayesian network 
 
The preliminary results of this work were presented, as an oral communication, at the World 
Health Organisation Winter Meeting, at Utrecht University, in January 2015. 
Currently, the model is being improved to fit a recent directive from the Portuguese 
pharmacovigilance system concerning the assessment of cases of drug ineffectiveness. 
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Chapter 7 - Ongoing and future work 
7.1 Abstract 
Some of the studies that were part of the thesis plan were not finished within the thesis 
development period, and are still in development. Furthermore, some other studies, not 
initially planned, were started by the research team. In fact, our investigation addresses a 
broad topic and many ideas were conceptualized during the daily work in pharmacovigilance 
and research activities.  
One of the unplanned works is being performed within a local health unit, in order to develop 
an information system to facilitate information exchange about ADR within the healthcare 
unit. This work started in June 2014 and is currently being tested by healthcare professionals 
at the institution (subchapter 7.2). 
In the course of our quotidian activity, we found that websites and social networks are 
excellent media to disseminate information about pharmacovigilance and drug safety issues. 
This belief was further supported during the performance of the systematic review. In line with 
this, we started to design a personal area on our website (sub-subchapter 7.3.1), and we also 
developed an online ADR reporting form for consumers (sub-subchapter 7.3.2) and start to 
develop a mobile application for ADR reporting (Chapter 7.4).  
The expected results of this works are detailed in the following subchapters.   
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7.2 Managing several players at several institutions dealing with 
the same adverse event. A pilot-study called SIRAI. 
 
Introduction 
In June 2014, this PhD team proposed the development of a pilot study within the local health 
unit of Matosinhos, Portugal (ULSM in Portuguese) to test some strategies regarding the use of 
IS on the information exchange about ADR. 
The first goal of this study was to design an information system (a single database) that will 
gather all the information about ADR that is disseminated around the institution, allowing for 
better use by healthcare professionals. Subsequently, the included ADR will be automatically 
submitted to the regulatory authority (National Authority of Medicines and Health Products; 
INFARMED, IP) through a regional pharmacovigilance centre (the Northern Pharmacovigilance 
Centre), with the permission of each healthcare professional. 
When the database is in full use, an intervention study will be performed, with the following 
main outcomes: (1) the number of databases integrated into the single database, (2) the 
number of ADR included in the single database and (3) the number of ADR reports submitted 
to the regulatory authority by health professionals from the hospital. 
To measure the submitted ADR reports, the Northern Pharmacovigilance Centre database will 
be used, which is registered in the Portuguese commission for data protection, and follows the 
confidentiality and data protection guidelines imposed by the Portuguese pharmacovigilance 
system. 
This study was approved by the local ethics committee and the hospital’s board of directors. 
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Methods 
In June 2014, a working group was created to design the information system. This expert group 
was composed of: 
- two physicians: one an expert in primary care and the other an expert in hospital care who 
is also responsible for the risk management department at the institution 
- two pharmacists: one an expert in hospital pharmacy and the other an expert in 
pharmacovigilance 
- two nurses 
- two informaticians: one responsible for the hospital informatics department and the other 
one from the Faculty of Medicine. 
From June 2014 to June 2015, this working group met in person 10 times. During these 
meetings, a discussion took place regarding the type of database that is most appropriate for 
the institution’s healthcare professionals, and its contents were approved.  
The screens were designed and improved between meetings, according to the group’s 
opinions. The content was also developed with the contribution of each participant. Namely, 
lists of adverse reactions, severity criteria and routes of administration were developed and 
approved, to facilitate form completion. 
To meet the needs of health professionals at the institution, we also developed a form to 
report incidents with medical devices. This form based on the INFARMED paper form. 
In February 2015, the first version of the prototype was shown, and a name was assigned to 
the information system: SIRAI3. The system is currently being tested. 
  
                                                          
3
 The acronym means Sistema de Informação de Reações Adversas e Incidentes (Information System for 
Adverse Reactions and Incidents). 
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Workflow 
The project aims to promote ADR reports identified in the ULSM to the regulatory authority, 
through the following tasks:  
Task #1: Design and implementation of an information system for the management of 
information on drug safety. 
Task #2: Integration in a single database of all the ADR detected at the institution (ULSM). 
Task #2.1: Identification of databases that could include information about ADR 
detected at ULSM. 
Task #3: Submission of the ADR collected in the database referred in #2 to the regulatory 
authority through the Northern Pharmacovigilance Centre. 
Task #4: Feedback on ADR reports will be send to the reporters. 
Expected results 
As the main outcome, we have developed a functional information system on drug safety that 
is being used at the institution. 
The intervention impact will be measured on the number of ADR submitted to the regulatory 
authority. In the last four years, healthcare professionals from ULSM reported about 22-43 
ADR each ear, without a regular trend. As we strongly believe that, during daily activities, many 
more ADR are detected by these healthcare professionals, so we expect that the number of 
ADR submitted will increase by about 50% each year. 
In addition to the number of ADR reports, an increase in relevance is also expected. 
Established relevance criteria include ADR seriousness, ADR expectedness and the causality 
degree attributed to the ADR. 
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7.3 Social networks and portals for patients and healthcare 
professionals 
Internet users are increasing and many of them use the web for issues related to health. 
According to Cybercitizen Health® Europe[97], in 2012, 72% of European online adult consumers 
(ages over 18) were social health users (which means individuals that “have conducted any of 
the following activities online for health within the past 12 months: used a community, group 
or social networking website, or conducted any social-related activity online such as reading or 
posting on health blogs, message boards or health ratings websites”). Additionally, 44% of 
European online consumers use social networking for issues related to health, 33% read or 
posted patient testimonials and 34% used health ratings or reviews. 
To take advantage of this reality, it is important to adopt strategies to use the internet in the 
promotion of pharmacovigilance and ADR reporting, using for this purpose social networks and 
portals for patients and healthcare professionals. 
Social networks are excellent media and can be used to disseminate information about 
pharmacovigilance and drug safety issues. In 2011, Knezevic et al. studied the use of social 
networks, such as Facebook®, to increase spontaneous ADR reporting. This study tested if the 
creation of a group in Facebook® increased ADR detection and reporting by its members[65]. 
For this purpose, an open group (available to the general public) was created where regular 
information about ADR was posted. During the experience period (seven months), 21 ADR 
were reported, by 2% of the total group members (n=1034). Among the 1034 members, 370 
provided their educational profile (88% had a university degree and 12% a high school degree). 
For those with a university degree, 67% had a degree in medicine, dentistry or pharmacy. 
None of the 21 ADR reported were serious or unexpected. Based on their results, the authors 
stated that Facebook® can be useful for improving spontaneous ADR reporting. 
In line with this, UFN created its own Facebook® page in October 2013, and currently stands at 
876 “likes” (in april 2016). On this public page, we publish information about drug safety and 
also about our events (open classes and post-graduate courses, among others). We also 
publish images and messages promoting spontaneous ADR reporting and emphasising the 
importance of this subject. In the future, we expect that this will be a source of debate about 
ADR reports, with the creation of an online forum and maybe part of a study similar to the one 
performed by Knezevic et al.[65]. 
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7.3.1 Creation of the personal area on the UFN website 
Websites of pharmacovigilance centres and regulatory authorities are important for providing 
information about drug safety and to promote ADR reporting, both by patients and healthcare 
professionals. Some of these websites also provide online ADR reporting forms. In these cases, 
it is essential that the provided form is simple, intuitive, quick to fill in and with few mandatory 
fields. Otherwise, the experience of reporting may seem too complicated for the users and 
discourage them [43]. 
Thus, we aimed to create a model of communication between our pharmacovigilance centre 
and its reporters (health professionals) through our website. With this model, we wanted to 
turn ADR reporting into an informative and motivating activity. 
To develop this project, the first step was to redesign the former Northern Pharmacovigilance 
Centre website, in order to make it more appealing and user-friendly (Figure 14 and Figure 15): 
 
 
 
Figure 14. UFN website 2005-2016 
 
 
 
Figure 15. UFN website 2016 
 
The new website was launched on 18 January 2016. On the new website, we created a 
reporter area dedicated to healthcare professionals. This area compiles all the ADR reports 
submitted online by each healthcare professionals, and are only available after authentication, 
to ensure the confidentiality. 
Our aim was to provide our users also with feedback after submitting their ADR report. Each 
healthcare professional will have access to a report that compiles the research results 
generated by the ADR report. The search will be conducted using selected information 
sources, each time a healthcare professional reports an ADR through the ADR online form. The 
results of the searches will be presented in the form of ADR frequency, ADR absolute value, 
ADR expectedness and percentage of ADR by age and gender. 
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We selected the following information sources to perform the searches: 
• The European database of suspected ADR4, which provides information on absolute 
number and percentage of ADR by sex, age and other criteria. 
• The WHO Global Database of Individual Case Safety Reports (Vigilyze®)5, which 
provides information on the number of cases reported, describing each case 
individually. 
• Medscape®6, which provides information on the frequency (%) of ADR. 
• The Medicines & Healthcare Product Regulatory Agency7 (MHRA), which provides 
information on the number of cases reported. 
 
We are still working, together with software development staff, to conclude the creation of 
the personal area on our website.  
  
                                                          
4
 www.adrreports.eu  
5
 www.vigilyze.who-umc.org 
6
 http://reference.medscape.com/medscapetoday 
7
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency  
Chapter 7 – Ongoing and future work 
106 
 
7.3.2 ADR online reporting form for consumers 
In Portugal, consumers have been allowed to directly report their own suspected ADR since 
July 2012 [76]. To facilitate the ADR reporting process among consumers, we have started to 
develop an ADR report online form for consumers in Portugal, taking advantage of our website 
redesign. 
To develop the consumer’s online form, we used the printable form as a standard. The form 
was carefully developed and adjusted for patient reporting. A heuristic evaluation of the form 
was performed to obtain the final version, which is already finished (see Figure 16, designed by 
Natacha Oliveira) and available on the Northern Pharmacovigilance Centre website[5]. 
 
 
Figure 16. Screen shot of the online patients reporting form (ADR screen).  
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7.4 App for ADR reporting 
During this study, the idea arose of developing a smartphone application for ADR reporting. 
For this purpose, the user interface has been designed (as seen in Figure 17 and Figure 18, 
both designed by Natacha Oliveira), consistent with the new image of the UFN website. This 
project is in the implementation phase. 
 
Figure 17. User interface of the ADR reporting app (first screen). 
 
 
Figure 18. User interface of the ADR reporting app (suspected drug screen). 
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Chapter 8 – General discussion 
These studies have allowed us to realise that much work can be done using informatics to 
improve pharmacovigilance. 
Worldwide underreporting of ADR is a major concern, and many institutions are aware that it 
is feasible to use IS to improve ADR reporting. Currently, the most commonly used 
technological platform is web-based and shows an increasing trend, but interventions within 
electronic health records also have the potential to improve pharmacovigilance activities, 
particularly ADR reporting. ADR directly reported by consumers (direct ADR reporting) is being 
increasingly taken into account when the aim is to improve information on drug safety[98]. 
Most international studies that aimed to promote ADR reporting were developed in hospitals 
and tailored to healthcare professionals. In fact, most serious ADR are detected in hospitals 
and reported by healthcare professionals[72]. Additionally, in Europe, direct reporting (ADR 
reported by patients) has only been allowed in all countries since 2012[76]. This may also 
explain why most of the projects that target direct ADR reporting have only been recently 
developed[65, 67, 71, 72].  
As with most of international groups, we developed systems for the passive promotion of ADR 
reporting because most busy healthcare professionals only submit their suspected ADR if it 
does not increase their workload[55, 77]. Active promotion of ADR reporting is difficult and not 
always ethically acceptable because no material reward can be given to the reporters. Thus, 
projects have aimed to actively promote ADR reporting involving teaching sessions[50] or e-
mails containing ADR information[46, 57, 59, 72]. 
Based on our research, we believe that it would be useful to adopt systems to assist healthcare 
professionals with completing ADR reporting within electronic health records because this 
approach seems to be an efficient method to increase the ADR reporting rate[75]. When this 
approach is not possible, it is essential to have tools that are easily accessible to healthcare 
professionals (e.g. on the web) to report ADR. These tools can be promoted by sending emails 
or through the inclusion of direct hyperlinks on healthcare professionals’ desktops, which is a 
simple and cost-effective way to change the behaviour of healthcare professionals regarding 
spontaneous ADR reporting, as seen in Chapters 3 and 4, and can be easily implemented and 
disseminated in healthcare institutions[16]. 
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We also see as a promising solution the integration of pharmacovigilance databases within the 
habitually used electronic health records, avoiding extra workload to submit an ADR, as 
described in Chapter 5. ADR collected this way would then be sent to the relevant authority 
through regional pharmacovigilance centres, which would provide feedback related to the 
reported ADR. This strategy increased the ADR report rate in the studied group and could be 
easily replicated among other healthcare groups.  
Furthermore, we propose that pharmacovigilance websites can be explored to create personal 
areas for each person that submits an ADR report, aiming to turn ADR reporting into a 
motivating and informative activity. It should provide technical information about the reported 
adverse reaction and the suspected drug, thereby improving feedback. 
Besides the promotion of ADR reporting, Information Systems can also improve 
pharmacovigilance routine activities by upgrading the communication between 
pharmacovigilance centres and reporters. We have concluded that it is possible to accelerate 
the process of causality assessment and subsequent feedback using Bayesian models (Chapter 
6). We believe these models could be linked to the electronic reporting form, turning causality 
assessments into a semi-automatic process, and it is our aim to perform such an intervention, 
as future work, on our website. 
Pharmacovigilance should adapt to technological developments, benefiting reporters (both 
healthcare professionals and consumers) by facilitating the ADR reporting act and turning it 
into a valuable and appealing activity. Additionally, Information Systems can benefit 
pharmacovigilance staff, simplifying some of the required procedures, making them faster and, 
where possible, semi-automatic. 
 
Overall conclusion 
Despite the fact that the personal area on our website is still being built jointly with the 
software development staff (as described in sub-chapter 7.3.1), we can consider that the main 
objectives of the thesis have been achieved. Having analysed several strategies to increase 
ADR reporting (chapters 2 and 3), we have not only created a decision support system to 
improve pharmacovigilance activities (chapter 6) but also developed new tools to facilitate 
ADR reporting (three tools have been designed and two of which fully implemented, as seen in 
chapters 4, 5 and sub-chapter 7.2). 
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INTRODUCTION TO PHARMACOVIGILANCE INFORMATICS
All medicines have adverse effects, most of them unknown until the drug commercialization. As so, it is 
crucial to keep strategies to monitor the drug safety. Pharmacovigilance is the activity of drug surveil-
lance, after its launch in the market, with the main goal of public health protection, ensuring that the drug 
benefit outweighs its risks. Worldwide, pharmacovigilance systems are mostly based on spontaneous 
Adverse Drug Reactions (ADR) reports made by healthcare professionals and consumers. Spontane-
ous ADR reporting has been described as an essential method to detect drug safety signals; however, 
underreporting is a major issue undermining the effectiveness of spontaneous reports. Several studies 
suggest that less than 10% of detected ADR are effectively reported to medicines regulatory authorities 
[e.g. Food and Drug Administration (FDA), European Medicines Agency (EMA), etc] (Hazell & Shakir, 
2006; McGettigan, Golden, Conroy, Arthur, & Feely, 1997).
Tools used in pharmacovigilance are continually evolving and, worldwide, Information Systems (IS) 
to promote ADR reporting or to detect ADR occurred in healthcare institutions have been tested and 
used, such as software that allow voluntary and automated detection of ADR, tools that analyse clinical 
databases or Web sites that actively inform healthcare professionals (Molokhia, Tanna, & Bell, 2009).
In addition to the signal detection, ICT can also be used to encourage and facilitate reporting of 
suspected ADR, such as the creation of on-line reporting forms, development of tools to collect safety 
data from electronic health records (EHR), among others.
In this chapter, it will be described some tools to automatically detect ADR, or encourage ADR 
spontaneous report.
BACKGROUND ON PHARMACOVIGILANCE
Adverse Drug Reactions (ADR) defined as a response to a medicinal product which is noxious and 
unintended (WHO) are a well-recognized public health problem worldwide, and a major cause of death 
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and hospitalization in developed countries(Lazarou, Pomeranz, & Corey, 1998). It is estimated that about 
6,5% of the hospitalizations are related to ADR(Pirmohamed et al., 2004). Besides, in the USA, about 
100.000 people die each year due to ADR(Lazarou et al., 1998), and in Europe this annual mortality rate 
increases to 197.000(European Medicines Agency, 2014). ADR can be expressed in many ways and with 
different degrees of seriousness. An anaphylactic shock caused by penicillin is an example of a serious 
ADR (a serious ADR is any untoward medical occurrence that at any dose: results in death, requires 
inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant 
disability/incapacity or is life-threatening(WHO). Another type of ADR, not always recognized as such, 
is the drug ineffectiveness, for example, a vaccination failure. This can be (or not) related with a product 
quality issue and should be reported when detected in order to allow the regulatory authorities to take 
appropriate decisions.
Rare and long term ADR are difficult to detect during the drug development stage. Only when the 
drug begins to be used by a large population after marketing authorization it is possible to detect new 
ADR not previously identified during clinical trials. In reality, it is known that the safety of a new drug 
cannot be established until it has been on the market for several years(Lasser et al., 2002). Exceptionally, 
in a pandemic scenario, drug launch is urgent and, in this particular case, can be justifiable that drug 
safety profile is not well established. In this scenarios, it is even more important that all the detected 
ADR are reported (serious or not, expected or not). It is, therefore, essential to keep drugs under close 
surveillance, after its commercialization, through a pharmacovigilance system, to continuously evaluate 
their safety profile. In most of the European countries, pharmacovigilance system is based on spontane-
ous ADR reports, which is passive method, made by healthcare professionals and, since July 2012, also 
by consumers (Ministério da Saúde, 2006). These reports can be made using paper, telephone, e-mail 
or through an on-line form and consist of a description of an Adverse Event (AE) apparently caused by 
a medicine.
To reverse the problem of underreporting of ADR, which is felt in most developed countries, several 
strategies have been tested(M. T. Herdeiro et al., 2012; McGettigan et al., 1997; Ribeiro-Vaz, Santos, da 
Costa-Pereira, & Cruz-Correia, 2012). Particularly, some studies were developed focused on educational 
interventions to raise awareness on the importance of ADR reporting(Figueiras A., Herdeiro T, Polonia 
J, & JJ, 2006; M. T. Herdeiro, Polonia, Gestal-Otero, & Figueiras, 2008; Ribeiro-Vaz, Herdeiro, Polonia, 
& Figueiras, 2011) and showed to be very effective increasing the quantity and relevance of spontane-
ous ADR reports (among health professionals). However, these studies involved a large financial and 
personal outlay and the authors concluded that the effect was lost after a few months(McGettigan et al., 
1997; Nazario, Feliu, & Rivera, 1994).
In a recent American study, the authors developed a signal-detection strategy that combines the Adverse 
Event Reporting System (AERS) of the regulatory Authority (FDA) and EHR, by requiring signaling in 
both sources, with promising results(Harpaz et al., 2013). Another study used the unstructured clinical 
notes included in EHR to detect ADR through a computerized system. The authors concluded that data 
mining can be used for hypothesis generation and for rapid analysis of suspected AE risk(LePendu et 
al., 2013).
With a similar aim, a recent study used a physician’s network, created through a mailing list, to send 
regular emails to doctors, with humorous component attached with informative component, recalling 
the importance of reporting their suspected ADR(Goldstein, Berlin, Saliba, Elias, & Berkovitch, 2013). 
The results showed that this type of intervention has impact on the number of ADR reports made by 
these professionals (the study did not assess the relevance of reported ADR). In France, it is being done 
a work that tries to facilitate the act to ADR report, habitually considered a tedious process by health 
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professionals. The authors are using the information contained in EHR to make the semi-automatic filling 
of ADR notification forms. The objectives of this ongoing study is to increase the rate of ADR report, 
as well as improving the quality of information submitted to regulatory authorities(Pares, Declerck, 
Hussain, Ng, & Jaulent, 2013).
INFORMATION SYSTEMS IN PHARMACOVIGILANCE
Issues, Controversies, and Problems
Although some authors consider that ADR spontaneous reports suffers from latency and inconsistency, 
it is still considered as the most valuable method to early detect drugs safety problems. In fact, most of 
the decisions concerning to drug safety are triggered by daily ADR spontaneous reports. As so, Regula-
tory Authorities consider as crucial importance to achieve the greatest number of ADR reports possible 
and with high data quality.
The promotion of ADR report among healthcare professionals is a huge task, as it is necessary to 
regularly recall the importance of ADR reporting and, simultaneously, develop tools to facilitate this duty. 
Pharmacovigilance centres worldwide develop several strategies to continuously promote the importance 
of ADR reporting, as workshops, post-graduate courses, and also to make it easier, as development of 
online reporting forms, inclusion of electronic reporting systems into the Hospital Information Systems 
(HIS), direct hyperlinks to online reporting forms, among others.
Along with the promotion of spontaneous ADR reporting, some systems are being tested to detect 
signals of adverse reactions in large databases, as hospitals databases, epidemiologic databases, or even 
among social networks.
Although the adoption of different strategies, it is consensual the need to obtain the highest quantity 
and quality of information about the safety of marketed drugs, for the protection of public health.
Another important issue in this field is the need to discuss/harmonize what should be recorded dur-
ing an ADR report.
When analyzed the databases from the FDA, EMA and the Portuguese Northern Pharmacovigilance 
Centre (UFN), all of them with the same purpose of recording ADR reports, it was possible to realize 
that the variables are different between the 3 databases, as seen in the Table 1.
For example, the concept of outcome for the FDA form as a similar meaning to the concept of seri-
ousness for the two European databases analyzed. On the other hand, for these two databases, outcome 
means the evolution of the patient regarding the adverse scenario.
Active debate is maintained about this subject. The authors participate in some discussion groups, 
both national and internationally [namely the FHIR/OpenEHR(OpenEHR, 2014) and HL7(Health Level 
Seven, 2014) working groups], aiming to create a standard to the information that should be kept during 
the ADR registry.
Authors also participate, in June 2014, in the HL7 pharmacy group meeting, where was discussed the 
International Organization for Standardization (ISO) draft of international standard for ‘Requirements 
for electronic prescriptions’. This document is still under discussion until February 2015.
The last OpenEHR discussion took place in July 2014 and was focused in the ADR definition, its 
characteristics and what should be kept for the registration of a suspected ADR. At the moment, it is 
in discussion the clinical content of the Archetype Adverse Reaction (FHIR/OpenEHR). Variables as 
substance, status, seriousness, reaction type, certainty are under debate.
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Table 1. Comparison of the variables included in 3 pharmacovigilance databases (Food and Drug Ad-
ministration: FDA; European Medicines Agency: EMA and Portuguese Northern Pharmacovigilance 
Centre: UFN), grouped in main entities/sections (patients, problems, products and reporters)
Section Variable FDA EMA UFN
Patient Patient identifier ✓ ✓ ✓
Age at the time of event ✓ ✓ ✓
Date of birth ✓ ✓ ✓
Sex ✓ ✓ ✓
Weight ✓ ✓ ✓
Problem What kind of AE, product 
problem or error did you 
encounter?
• Adverse event 
• Product use error 
• Product problem 
• Problem with Different 
Manufacturer of the Same Medicine
--- ---
Outcomes Attributed to AE • Death 
• Life-threatening 
• Congenital anomaly/birth defect 
• Disability or permanent damage 
• Hospitalization 
• Required intervention to prevent 
permanent impairment/damage 
• Other serious
• Fatal 
• Not recovered 
• Recovered with sequelae 
• Recovering 
• Recovered 
• Unknown
• Fatal 
• Not recovered 
• Recovered with sequelae 
• Recovering 
• Recovered 
• Unknown
ADR Seriousness --- • Yes 
• No
• Death 
• Life-threatening 
• Congenital anomaly 
• Results in persistent or 
significant incapacity 
• Hospitalization 
• Other serious
Date of event ✓ ✓ ✓
Describe events, problem, or 
product use error
✓ ✓ ✓
Relevant test/laboratory data, 
including dates
✓ --- ---
Product Product name ✓ ✓ ✓
Label strength ✓ ✓ ✓
Manufacturer ✓ ✓ ✓
Date of use ✓ ✓ ✓
Reason for use ✓ ✓ ✓
Problem went away after use 
stopped or dose reduced?
• Yes 
• No 
• Does not apply
--- ✓
Problem returned after person 
started taking or using the 
product again?
• Yes 
• No 
• Does not apply
--- ✓
Do you still have the product 
in case we need to evaluate it?
• Yes 
• No 
• Returned to Manufacturer on
--- ---
Reporter Reporter name ✓ --- ✓
Address ✓ ✓ ✓
✓or list of options: Variable exists; ---: Variable does not exist
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PROPOSED SOLUTIONS AND RECOMMENDATIONS
Promotion of Adverse Drug Reaction Reporting
Integration with IS (Patient Records, Multi-Center Research Projects)
Integration of pharmacovigilance system databases with other healthcare IS seems to be an obvious way 
to improve the knowledge about drugs safety. In fact, healthcare providers insert a lot of information 
in their EHR about ADR, which is not shared with pharmacovigilance systems. Every approach that 
promotes drug safety surveillance without increasing the workload of healthcare professionals, one of 
the main reasons for not reporting ADR, should be considered.
The creation and implementation of webservices to collect this information is one of the possible 
solutions for this problem. This solution is being tested in a Portuguese multi-center research project, 
in the field of gastric diseases(Study Group of Inflammatory Bowel Disease, 2014), with promising 
preliminary results (5% of all of the ADR reports received in the 1st semester of 2014 were collected 
by webservice). In this case, the physicians insert the usual clinic information during the appointment 
with the patient, and then, they only have to authorize the transmission of anonymized information about 
drug-related problems to the pharmacovigilance system. This tool allows ADR reporting without the 
need to fill the ADR reporting form and with no additional administrative work for the physician other 
than the normal registry of clinic patient data.
This solution is also available to be included in commercial prescription software. For the implemen-
tation of these webservices, it was necessary to map the form entries used by the doctors with the online 
ADR reporting form developed by the pharmacovigilance system, so that the information is correctly 
collected. This mapping would be easier if a standard as the one described in the previous section was 
already in use.
An ADR electronic reporting system included into a HIS was developed in a Spanish hospital(Ortega 
et al., 2008), allowing healthcare professionals (pharmacists, physician and nurses) to report suspected 
ADR through their usual IS. The biggest advantage of this system is that some data (already included 
in the IS) appears as default values into the form, which expedites the system and reduces transcription 
errors(Cruz-Correia et al., 2009). All the reports made by this system are reviewed by a pharmacist, 
which is responsible to confirm the included data and to report the case to pharmacovigilance system. 
This might be a disadvantage, as some cases may be lost and not actually sent to regulatory authorities.
Another strategy that can be easily adopted is the inclusion of hyperlinks in the EHR to the online 
ADR reporting form. This solution was tested between 2006 and 2010, in an ecological study performed 
in 16 Portuguese hospitals centres(Ribeiro-Vaz et al., 2012). The hyperlinks were included in either EHR 
or on computer desktops. Considering the hospitals with hyperlink included in the EHR, the median 
ADR reports per month significantly increased, from two (range 0–12) to five reports (range 1–17). The 
median of ADR reports per month using the online form also increased significantly, from one (range 
0–5) before the intervention to four (range 1–17) after it. Moreover, serious ADR increased 3-fold, and 
non-previously described ADR increased 4.5-fold. None of these significant increases were observed 
in the hospitals where the hyperlink was not installed. It was also found a significant increase in daily 
pharmacovigilance centre website visits, from ten before the intervention to 27 after it (p<0.001). The 
increase in ADR reporting shows that the inclusion of hyperlinks to online ADR reporting forms is an 
easy way to change health professional behavior with regard to spontaneous ADR reports. Furthermore, 
this solution seems to be cost effective, when compared with other strategies to increase ADR report, 
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as it has no running costs (after the hyperlink implementation, there are no additional costs to the phar-
macovigilance system).
Clinical Decision Support and Alerting Systems
Informatics can be used in pharmacovigilance activities to support and alert healthcare professionals 
during their daily work. With the IS extensively used in health care institutions, all the improvements 
that can enhance patient safety should be taken into account. Clinical Decision Support Systems (CDSS), 
providing intelligently filtered knowledge in real-time, should be used in this area to improve public 
health and health care(Kilbridge & Classen, 2008). Besides, systems that triggered alerts of possible 
ADR can also be integrated in the IS with the same goal.
Many systems are used and tested worldwide to alert health providers about suspected ADR, which 
can help in the detection of drug safety problems. The exploitation of computer programs used in hos-
pitals as a support in the detection of possible ADR(Classen, Pestotnik, Evans, & Burke, 1992; Otero 
& Domínguez-Gil, 2000) is one of these systems. With this purpose, work has been developed in order 
to create lists of drugs used as ADR signals to support the detection of ADR in hospitals. The included 
drugs were chosen as they are mostly used as antidotes or therapeutic interventions for possible ADR. 
Furthermore, there are also lists of diagnosis that triggers an alert for possible ADR in the computer 
systems. These diagnoses indicate diseases that are mainly caused by drugs and, therefore, are signals 
of possible ADR. Besides the drugs and diagnosis, also laboratory values can help in ADR detection. 
In fact, some ADR are characterized by laboratory abnormalities, so the monitoring of these values can 
be an improvement in the promotion of drug safety among hospitalized patients.
The main goal is to incorporate the described lists in the software used in the hospital pharmacies 
in order to be triggered an ADR alert each time an alerting drug is prescribed, or each time an alerting 
diagnosis is made or even each time a laboratory result reaches a suspected toxicity value(Kilbridge et 
al., 2009; Levy et al., 1999).
It has been advocated that EHR should be provided with CDSS in order to maximize its benefits to 
patient safety(Kilbridge & Classen, 2008). These CDSS are being used to inform physicians during the 
prescription about identified drug-drug interactions(Phansalkar et al., 2013), patient allergies(Abookire 
et al., 2000) or to support the prescribing decision(Osheroff et al., 2007; Saxena, Lung, & Becker, 2011). 
CDSS integrated in the computerized physician order entry (CPOE) can effectively prevent potential 
harmful medication errors and ADR (Rommers, Teepe-Twiss, & Guchelaar, 2007, 2011).
In particular, a Dutch CDSS is being in use at the hospital pharmacy to support hospital pharmacist 
to select patients at risk of ADR, and its effectiveness was evaluated(Rommers, Zwaveling, Guchelaar, 
& Teepe-Twiss, 2013). For this purpose, the system retrieves data from IS, and uses clinical rules. Dur-
ing the study period, the CDSS generated 2650 safety alerts, 270 (10%) of them were considered as 
relevant. In these cases, the pharmacist contacted the physician or nurse and in 204 (76%) cases this led 
to an advice to prevent a possible ADR. Most alerts were generated with clinical rules linking pharmacy 
and laboratory data (1685 alerts).
Detection of Adverse Drug Reactions
Data mining is a general term for computerised extraction of potentially interesting patterns from large 
data sets, often based on statistical algorithms (WHO). Is an active method that complements the phar-
macovigilance system (Harpaz et al., 2012).
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Computational methods commonly referred as “signal detection” or “tracking” algorithms allow drug 
safety evaluators to analyze a large amount of data to find signs of potential ADR risks. These methods 
have been shown to have great significance.
FDA routinely uses a signal tracking process to calculate statistics reporting associations for all 
the millions of combinations of drugs and events in their ADR communications system. Nevertheless, 
these signs alone are not sufficient to establish a causal relationship, being considered early warnings 
that require in-depth evaluation by experts to establish causality. This new evaluation typically consists 
of a complex process in which the evaluators analyze drug safety information, such as time relations, 
published case reports in the literature, biological and clinical plausibility, data from clinical trials and 
epidemiological studies in multiple related health databases(Harpaz et al., 2012).
The analysis of ADR through the data mining process has some limitations in terms of quality and 
distortion of data. Data distortions can compromise the integrity of any information related with detection 
of ADR. In terms of individual cases records, the limitations are related to factors that may impact the 
quality and integrity of the reported information, source of reports, class of drugs, time on the market, the 
database mined, temporal relationship between drug-ADR, information follow-up, etc. Although much 
work has been done to develop statistical algorithms to identify outliers that might be considered signals 
there is still much more to be done to address the impact of the limitations of data, since much human 
intervention is necessary to triage cases detected through data mining(Stephenson & Hauben, 2007).
Disproportionality Analysis
Methods of disproportionality analysis (DPA) in pharmacovigilance represent the main class of analyti-
cal methods for spontaneous report systems data analysis(Harpaz et al., 2012). These reports comprise 
one or more drugs, of one or more ADR, and possibly some basic demographic data.
These methods include the Multi-item Gamma Poisson Shrinker (MGPS), the Proportional Reporting 
Ratio (PRR), Reporting Odds Ratio (ROR), and the Bayesian Confidence Propagation Neural Network 
(BCPNN). These methods identify relevant associations in databases, focusing on projections of lower 
data dimensionality, more specifically two-dimensional contingency tables (see Table 2).
The main objective of a DPA method is the classification of tables in the order of interest. Different 
DPA methods focus on various statistical measures of association as its measure of interest. The MGPS, 
for example, is a Bayesian version of Relative Reporting Ratio (RR)(Harpaz et al., 2012). The RR for the 
combination drug (i) - ADR (j) (RRij) is the observed number of occurrences of the combination drug 
(i) - ADR (j) (40 in the example above), divided by the expected number of occurrences. Specifically, 
in the above example, the ADR (j) occurs in 10% of reports (140/1400). Thus, if the drug (i) and ADR 
(j) are statistically independent, 10% of the reports containing drug (i) must include ADR (j), which 
corresponds to 14 reports in this case. However, 40 reports associate the drug (i) and ADR (j). Thus, 
Table 2. Two-dimensional contingency table; ADR means “adverse drug reaction”. The values refer to 
occurrences.
ADR (j) = Yes ADR (j) = No Total
Drug (i) = Yes (a) = 40 (b) = 100 n = a + b = 140
Drug (i) = No (c) = 100 (d) = 1160 c + d = 1260
Total m = a + c = 140 b + d = 1260 t = a + b + c + d = 1400
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the relative risk for this example is 40/14 or approximately 2,857. Therefore, this combination occurred 
approximately 185% higher than expected.
Natural estimates of several probabilities (although not necessarily unbiased) emerge from Table 2. 
For example, one can compute the conditional probability of ADR (j) given drug (i) by a/(a+b) (i.e. 
40/140, in the example above). That is, the fraction observed reports listing drug (i) that also mentions 
ADR (j). Table 3 presents the formulas for the different association measures most commonly used, 
together with his probability interpretation(Harpaz et al., 2012; Zorych, Madigan, Ryan, & Bate, 2013). 
Here drug  denotes the reports that do not include the target drug. RR, PRR, ROR and IC is the “Infor-
mation Component” used by the BCPNN (Bate et al., 1998; Evans, Waller, & Davis, 2001; Szarfman, 
Machado, & O’Neill, 2002).
For all these four measures, a particular drug that is more likely to cause an ADR specific than any 
other drug usually receives a higher score. If an ADR and a drug are stochastically independent, all 
measures will return a null value(Zorych et al., 2013).
Frequentist approaches using one of the measures shown in Table 3 to estimate associations are usu-
ally accompanied by independence hypothesis tests (Harpaz et al., 2012). The independence hypothesis 
tests are used as an additional precaution, taking into account the size of the sample used in the associa-
tion calculation. On the other hand, Bayesian approaches try to account for the uncertainty in the dis-
proportionality measure associated with small observed counts through the “shrinkage” of the measure 
toward the base case (no association) in proportion to the statistical variability of disproportionality. 
The result of this shrinkage is the reduction in the number of spurious associations that are supported 
by an insufficient set of data.
The MGPS computes a measure known as Empirical Bayesian Geometric Mean (EBGM), which is 
a measure of centrality of the posterior distribution of the actual value of RR in a population(Harpaz 
et al., 2012). MGPS defines an a priori distribution of RR, which encapsulates a previous belief that 
most RR are close to the average value of all RR. Only in the face of substantial evidence of data that 
Table 3. Mathematical definitions of measures of association
Measure of Association Mathematical Definition Probabilistic Interpretation
RR- Relative Reporting Ratio (t. a)/(m n)
P ADR drug
P ADR
( | )
( )
PRR- Proportional Reporting Ratio (a. (t-n))/(c.n)
P ADR drug
P ADR drug
( | )
( | )
ROR- Reporting Odds Ratio (a. d)/(c.b)
P ADR drug
P ADR drug
P ADR drug
P ADR drug
( | )
( | )
( | )
( | )
IC-Information Component Log2 (RR) log
P ADR drug
P ADR2
( | )
( )






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the MGPS outputs an RR that is substantially greater than one. For example, a RR=1000 that derives 
from an observed count of a=1 (see Table 3) can result in an estimate of RR-MGPS (corresponding 
to EBGM) of 1.5 (i.e. the value of the RR is shrunk to a value near 1), while a RR=1000 that derives 
from an observed count of a=100 may result in EBGM estimate of approximately 1000. For the specific 
Bayesian configuration used by MGPS, numbers of reports of value greater than 10 results in estimates 
of RR which normally receive virtually no reduction, although in practice this depends on the threshold 
values used(Hauben, 2004; Hauben & Reich, 2004; Hauben & Zhou, 2003). Typically, ad-hoc thresh-
olds are applied to the association measures in order to highlight strong associations. The thresholds 
selected usually do not have theoretical or empirical justification(Harpaz et al., 2012). Rather, they are 
a preliminary means of filtering or sorting.
EBGM is the average measurement of the posterior distribution of the true RR. Other measures are 
possible. For example, Dumouchel has introduced the measure “EB05”(DuMouchel, 1999). This measure 
corresponds to 5th percentile of the posterior distribution-which means that there is a 95% probability 
that the “true” RR exceeds EB05. As the EB05 is always less than EBGM, the EB05 represents a more 
conservative choice than the EBGM.
The Bayesian approach is more adopted by health authorities. The FDA uses the MGPS, more spe-
cifically EB05(Harpaz et al., 2012). The WHO, uses the BCPNN, which estimates a Bayesian version 
of the Information Component(Harpaz et al., 2012).
It is worth mentioning that there is no consensus on which DPA approach is best, and no gold-standard 
has been established to evaluate the performances of the various approaches (Harpaz et al., 2012; Huang, 
Guo, Zalkikar, & Tiwari, 2014). Frequentist approaches are more computationally efficient that Bayesian 
measures, but may generate more false positives. The Bayesian approaches also incorporate information 
about disproportionality and sample size in a single dimension. Nevertheless, none of the approaches 
can effectively address reporting biases or confounding factors(Harpaz et al., 2012).
Big Data
Big data is a term used to describe datasets whose processing by conventional database management 
systems is problematic, due to any combination of their size (volume), update frequency (speed), or 
diversity (heterogeneity)(Hay, George, Moyes, & Brownstein, 2013).
The concept of Big Data is strongly related to the Data Deluge phenomenon(Hey & Trefethen, 2003). 
The data deluge refers to the situation where the exponential growth in the generation of new data makes 
the management and analysis of these data increasingly complex.
Exponential data growth not only requires new technologies for accessing and integrating these data, 
but also the development of new analytical methods that are computationally efficient and effective data 
processing can be very noisy(Reshef et al., 2011).
Indeed, the processing of a large volume of data can be used to identify unknown associations 
between drugs and AE. For example, White and colleagues investigated the use of search logs in 
pharmacovigilance(White, Tatonetti, Shah, Altman, & Horvitz, 2013). During this research, it was 
observed an association between hyperglycemia and the simultaneous utilization of paroxetine and 
pravastatine. This Association has been subsequently confirmed by other data. This analysis processed 
82 million search logs, obtained from 6 million users during the 2010 year.
The combination of data from multiple sources can make more effective the detection of AE as-
sociated with drugs. One possible combination is the joint analysis of AERS and EHR. Harpaz and 
colleagues(Harpaz et al., 2013) used this combination of heterogeneous data to identify a new associa-
Pharmacovigilance Informatics
308
tion between rasburicase and acute pancreatitis, by processing of 4 million of AERS and 1.2 million of 
EHR. The combined system indicated an association between rasburiscase and a high level of pancreatic 
enzymes. This association was not established before the data collection related to this study, and it was 
confirmed afterwards.
It is worth noting that the use of Big Data in conjunction with a large processing power is also being 
used as a complementary system to traditional epidemiological surveillance networks. For example, you 
can use Google’s search logs for tracking of influenza in a population(Ginsberg et al., 2008). Ginsberg 
and colleagues showed that the relative frequency of certain queries in Google is highly correlated with 
the percentage of doctor visits in which a patient presents with symptoms of influenza. Of the 50 mil-
lion most frequent queries made through Google, 45 consultations with high level of correlation with 
data from medical visits related to influenza, provided by the CDC, were selected to compose the linear 
prediction model. Thus, it was possible to accurately estimate the level of weekly influenza activity in 
each region of the United States, with a lag of information one day. This approach makes possible the 
use of search logs to detect influenza epidemics in areas with a large population of web users. A similar 
system was developed for the monitoring of dengue(Chan, Sahai, Conrad, & Brownstein, 2011).
Searching on Social Networks
Other equivalent systems, this time using Twitter messages as a source of data to monitor flu symptoms, 
are described in the literature(Lampos & Cristianini, 2012; Signorini, Segre, & Polgreen, 2011). It is 
noteworthy, however, that these systems are subject to errors, as overestimations(Butler, 2013).
One research objective is to prove that Twitter can be used as a source to find new and already known 
ADR. This proposal has a prominent social relevance, as it will support already established pharmaco-
vigilance systems. Some preliminary results in that direction were presented at Duval et al. 2014 and 
summarized below. The corresponding processing pipeline is presented in Figure 1.
Twitter(F, ER, OG, & FAB, 2014) is a social network and microblogging service made up of 
140-character messages called tweets. In the pre-processing stage, data is processed in order to facili-
Figure 1. Twitter processing pipeline
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tate the identification of a drug and the potential ADR associated to it. This stage has an initial step 
that consists of collecting tweets to process them afterwards. A filtering process that extracts drugs, 
diseases and symptoms information from tweets to be mapped to Concept Unique Identifiers defined by 
the UMLS(Bodenreider, 2004). The remaining tweets are processed in the disproportionality analysis 
stage, and the main results of this analysis are evaluated against a gold-standard of ADR (see Figure 1).
We calculated the amount of tweets related to some neglected diseases since its creation in 2006, but 
until 2008 there were few per month (less than 200), so we decided to process only tweets from 2008/
Jan to 2014/Jun.
We searched for tuberculosis (n=196790), chagas disease (n=19999), leishmania (n=53338), den-
gue (n=3587284) and malaria (n=2161169) (see Figure 2) and their related drugs: mefloquine, lariam, 
chloroquine, doxycycline and primaquine.
We also queried AIDS/HIV and its drugs: efavirenz, abacavir, stavudine, delavirdine, didanosine, 
etravirine, emtricitabine, zidovudine, nevirapine, lamivudine, rilpivirine (see Table 4).
This system is still under construction, and this is one of multiple pipelines, each one with different 
data sources that will then be combined to obtain new ADR and historical changes in already knew 
ADR. We already found strong indication that tweets can be used as a source for pharmacovigilance.
List of Recommendations
The main recommendations are:
• Give access to pharmacovigilance forms from existing IS or on computer desktops links.
• Implement webservices to exchange ADR information and feedback between the pharmacovigi-
lance IS and other IS (e.g. EHR, prescription software, laboratory software, among others).
Figure 2. Tweets since January 2008
Table 4. Disproportionality analysis results
Disease/Drug/ADR Reporting Ratio
HIV/lamivudine/rash 41.95414
Malaria/ chloroquine/itching 35.57355
Malaria/chloroquine/vomit 12.61881
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• Use websites and social networks to disseminate information on drug safety and promote ADR 
reporting.
• Create data mining processes to search ADR on websites, social networks and EHR.
FUTURE RESEARCH DIRECTIONS
The authors believe that much work can be done to use informatics in improving pharmacovigilance.
As future work, pharmacovigilance websites can be explored to create a personal area for each person 
that submits an ADR, aiming to turn the ADR reporting act in a motivating and informative activity. It 
should provide technical information about the reported adverse reaction and the suspected drug, during 
the ADR report act, and give feedback. Another research plan is to use a pharmacovigilance facebook 
page to encourage ADR report by its members, conducting research work similar to those performed 
by Knezevic et al.
It should also be carefully developed ADR reporting forms adjusted to patients report. These forms 
should be simple and easy to fulfill, with accessible language (not too technical).
Authors see as a promising solution the integration in a single database all the suspected ADR de-
tected within a healthcare institution. These ADR will then be sent to the Authority through regional 
pharmacovigilance centres. These centres will provide feedback related to the reported ADR.
An emerging research topic in pharmacovigilance is that the combination of information from 
multiple data sources may lead to more effective and accurate discovery of ADR. Depending on the 
data sources used, and how they are combined, it is believed that the resulting system could raise the 
statistical significance of results or facilitate new discoveries that are not possible using a single data 
source. It should be establish a database as a reference (gold) standard for adverse reactions, from the 
systematic exploration of heterogeneous data sources and more comprehensive than is recommended 
by Harpaz and colleagues.
CONCLUSION
Pharmacovigilance should use informatics to promote and complement spontaneous ADR report. In-
tegration of pharmacovigilance databases with other healthcare IS seems to be an easy way to promote 
ADR reports among healthcare professionals. In addition, the trend of use of social networks has been 
exploited by pharmacovigilance with mechanism to detect adverse reactions among these networks.
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Abstract
Background: Adverse drug reactions (ADRs) are a well-recognized public health problem and a major cause of
death and hospitalization in developed countries. The safety of a new drug cannot be established until it has been
on the market for several years. Keeping drug reactions under surveillance through pharmacovigilance systems is
indispensable. However, underreporting is a major issue that undermines the effectiveness of spontaneous reports.
Our work presents a systematic review on the use of information systems for the promotion of ADR reporting. The
aim of this work is to describe the state of the art information systems used to promote adverse drug reaction
reporting.
Methods: A systematic review was performed with quantitative analysis of studies describing or evaluating the use
of information systems to promote adverse drug reaction reporting. Studies with data related to the number of
ADRs reported before and after each intervention and the follow-up period were included in the quantitative
analysis.
Results: From a total of 3865 articles, 33 articles were included in the analysis; these articles described 29 different
projects. Most of the projects were on a regional scale (62 %) and were performed in a hospital context (52 %). A
total of 76 % performed passive promotion of ADR reporting and used web-based software (55 %). A total of 72 %
targeted healthcare professionals and 24 % were oriented to patient ADR reporting. We performed a meta-analysis
of 7 of the 29 projects to calculate the aggregated measure of the ADR reporting increase, which had an overall
measure of 2.1 (indicating that the interventions doubled the number of ADRs reported).
Conclusions: We found that most of the projects performed passive promotion of ADR reporting (i.e., facilitating
the process). They were developed in hospitals and were tailored to healthcare professionals. These interventions
doubled the number of ADR reports. We believe that it would be useful to develop systems to assist healthcare
professionals with completing ADR reporting within electronic health records because this approach seems to be
an efficient method to increase the ADR reporting rate. When this approach is not possible, it is essential to have a
tool that is easily accessible on the web to report ADRs. This tool can be promoted by sending emails or through
the inclusion of direct hyperlinks on healthcare professionals’ desktops.
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Background
Adverse drug reactions (ADRs) are a well-recognized
public health problem worldwide and a major cause
of death and hospitalization in developed countries
[1]. Rare and long-term ADRs are difficult to detect
during the drug development stage. Detecting new
ADRs not previously identified during clinical trials is
only possible when the drug begins to be used by a
large population after marketing authorization (MA).
The safety of a new drug cannot be established until
it has been on the market for several years [2]. As
such, it is indispensable to keep drug reactions under
close surveillance after commercialization through a
pharmacovigilance system to continuously evaluate
the drug’s safety profile. In most countries, the phar-
macovigilance system is based on spontaneous ADR
reports made by healthcare professionals and con-
sumers [3]. These reports can be made using paper,
telephone, e-mail or through an on-line form and
consist of a description of an adverse event appar-
ently caused by a medicine. Spontaneous ADR report-
ing has been described as an efficient method to
detect drug safety signs [4]; however, underreporting
is a major issue that undermines the effectiveness of
spontaneous reports. Several studies have suggested
that less than 10 % of detected ADRs are effectively
reported to medicine regulatory authorities [5, 6].
Worldwide, systems using informatics to promote
ADR reporting or to detect the occurrence of ADRs in
healthcare institutions have been tested and used, such
as computer programs that allow voluntary and auto-
mated detection of ADR [7, 8] informatics tools created
to analyse clinical databases [9] or websites that actively
inform healthcare professionals [10].
In addition to signal detection, information and com-
munication technologies can also be used to encourage
and facilitate reporting of suspected ADR.
In the present work, a systematic review is presented
on the use of information systems in pharmacovigilance.
Our main goal is to describe the state of the art informa-
tion systems for the passive or active promotion of ad-
verse drug reaction reporting.
Methods
Eligible studies
Studies describing or evaluating the use of information
systems to promote adverse drug reaction reports were
selected.
Review team
The review team is composed of two pharmacists who
are experts in pharmacovigilance (Inês Ribeiro Vaz (IV)
and Ana Marta Silva (AS)) and the computer scientist
Ricardo Cruz Correia (RC), who is an expert in medical
informatics.
Search methods
Studies were searched in April 2014 in the bibliographic
databases. We developed a search query that included
the concepts adverse drug reaction, adverse drug reac-
tion reporting system, pharmacovigilance and informa-
tion system. Only articles written in English, Portuguese
or French were included. We did not establish any
criteria for the publication date.
Four distinct bibliographic databases were searched:
Medline (via PubMed); ISI (ISI Web of Knowledge); IEEE
(IEEE Xplore) and Scopus. The query search string used in
Medline® was ((ADR OR “adverse drug reaction” OR
“adverse drug reactions” OR “adverse drug event” OR “ad-
verse drug events” OR “adverse dug effect” OR “adverse drug
effects”) OR “pharmacovigilance”). A similar query was used
in the other databases and was adapted to the search
engine.
Selection of studies for the review
The first selection was based on the study title and ab-
stract (when available). Two reviewers on the review
team (IV and AS) were involved in study selection and
read all titles/abstracts. The study was considered eli-
gible when at least one of the reviewers decided that the
title/abstract mentioned the key concept of using infor-
mation systems for ADR reporting. In cases of disagree-
ment, a consensus meeting was held with the third
reviewer (RC) to decide whether the article should be
selected.
The second phase of study selection was based on
the full text. The team leader (IV) reviewed each full-
text article. In this stage, articles were excluded based
on the following criteria: (1) the articles were only
focused on medication errors; (2) the articles focused
on ADR detection; (3) the articles were studies with-
out any information system implemented; (4) the arti-
cles were studies concerning data quality; (5) the
articles were studies focused on website usability; (6)
the articles were only the authors’ reflections on the
theme; (7) the articles were studies only related to
incidents that occurred in health institutions; (8) the
articles were studies concerning signal detection and
(9) the articles were studies concerning electronic
transmission between the authority and other institu-
tions (pharmaceutical companies or regional pharma-
covigilance centres).
The articles remaining after this review were included
in the final statistical analysis.
These articles were grouped into research projects to
avoid the distortion created by multiple papers describing
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the same project (Fig. 1). All statistical analyses were based
on the projects and not on the articles.
Definition of variables
The variables examined in these reviews were related to
the projects, papers and information systems described
in each project.
We used the following data for project identification:
(1) project number; (2) Information system name (if
any); (3) country; (4) publication date; (5) type of study
and (6) reference(s).
According to the description of the projects, the fol-
lowing variables were analysed:
1. Area covered by the project (i.e., region, country, or
hospital)
2. Type of action promoted by the project (passive
promotion of ADR reporting or active promotion of
ADR reporting)
3. Type of software (i.e., web-based or mobile)
4. Type of institution (i.e., regulatory authority or
universities)
5. Target (healthcare professionals or patients)
6. Type of medicine (all, vaccines, chemotherapy, or
others)
7. Type of ADR (all/serious ADRs based on the World
Health Organization seriousness criteria [11])
Statistical analysis
The inclusion criteria for the quantitative analysis were
the availability of data related to the number of ADRs
reported before and after each intervention and a
follow-up period.
Studies that only disclosed the increased ADR rate and
studies that reported zero ADRs before the project im-
plementation were excluded because it was not possible
to perform the analysis in these cases.
For each study with available data, the rate of ADRs
reporting increase (quotient between ADR reports
after and ADR reports before) and the respective
95 % confidence intervals were calculated. A rate of
ADR reporting increase equal to 2 indicated that the
ADR reports doubled after the intervention. Con-
versely, a rate of ADR reporting increase equal to 1
Records identified through
database searching
(n=5382)
Records (after duplicates
removed) screened based on title
and abstract
(n=3835)
Full-text articles assessed for
eligibility
(n=114)
Medline: 2519 papers
IEEE: 68 papers
ISI web of knowledge: 2603 papers
Scopus: 192 papers
Studies included in qualitative
synthesis
(n=33 articles / 29 projects)
Records excluded (n=3721)
- Not related with pharmacovigilance (n=643)
- Not related with information system (n=85)
- Other (n=2993), mostly because the focus was data mining on
big databases, instead of ADR report.
Duplicates removed
(n= 1547)
Full-text articles excluded
(n=81)
Studies included in quantitative
synthesis
(n=7 projects)
Fig. 1 Flowchart of the study selection
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indicated that the number of ADR reports after the
intervention was equal to the number of ADR reports
before the intervention. The aggregated rate of the
ADR reporting increase was calculated with the in-
verse variance method using a random effects model
and a forest plot was presented. The confidence inter-
vals, aggregated rate of ADRs and forest plot were
performed using a Microsoft Excel spreadsheet. The
description of the Microsoft Excel spreadsheet and
the respective statistical methods used were described
by Neyeloff [12].
Results
Our search method found 2519 articles in PubMed,
68 in IEEE, 2603 in ISI and 192 in Scopus. After
eliminating duplicate articles, 3835 articles were
selected.
Two reviewers (IV and AS) read all 3835 titles/ab-
stracts. In cases of disagreement, which occurred with
151 articles, a consensus meeting was held with the
third reviewer (RC) to decide whether the article
should be selected.
A total of 643 studies were excluded because they
were not related to pharmacovigilance, 85 were excluded
because they were not related to information systems
and 2993 were excluded for other reasons (mostly be-
cause their focus was on data mining in large databases
instead of ADR reporting).
A total of 114 of the 3835 articles were selected in this
first selection based on the title and abstract.
The team leader (IV) reviewed each of the 114 full-
text articles. After this review, 33 articles remained
for the final statistical analysis. At this stage, most of
the articles were excluded because: (1) they were only
related to medication errors; (2) they were focused on
ADR detection; (3) they were studies without any in-
formation system implemented; (4) they were studies
concerning data quality; (5) they were studies focused
on website usability; (6) they were only authors’ re-
flections on the theme; (7) they were studies only re-
lated to incidents that occurred at health institutions;
(8) they were studies concerning signal detection or
(9) they were studies concerning electronic transmis-
sion between the authority and other institutions
(pharmaceutical companies or regional pharmacovigi-
lance centres).
These 33 articles were grouped into 29 distinct re-
search projects to avoid the distortion created by
multiple papers describing the same project (Fig. 1.).
All statistical analyses was based on projects and not
on articles.
Table 1 lists all 29 projects, their country, the number
of publications, the publication year and the journal.
The country with the most published projects was the
USA (11), followed by the United Kingdom (3).
Trends
There was an increasing trend in publication, especially
after 2009 (Fig. 2).
Qualitative analysis
The qualitative variables analysed in each project are listed
in Table 2 and described below. Globally, we found that
there was an increase in the publication of projects over
the study period, with 4 projects published before 2001, 4
projects between 2005 and 2007, 8 projects between 2008
and 2010 and 13 projects between 2011 and 2013.
Geographic area covered by the projects
Most of the projects were regional (62 %), followed by
national projects (34 %). We found only 1 international
project based on Facebook®. This international project
was developed in the last time period (2011–2013).
Areas covered by the projects
Most of the projects (52 %) were developed in hospitals,
followed by community projects (21 %). A total of 14 %
covered primary care institutions and 10 % (3 projects)
were developed for use in any type of healthcare institu-
tion. One project was dedicated to a multicentre clinical
trial. We also found that all of the projects oriented to
the community were developed in the last 3 years
(2011–2013).
Types of actions promoted by the projects
The majority of the projects passively promoted ADR
reporting (76 %); the remainder actively promoted
reporting (24 %).
Types of software
More than half of the projects (55 %) used web-based
technology and 41 % used electronic health records.
Only one project used mobile phone technology. There
was an increasing trend in software using web-based
technology over all of the time intervals considered. The
mobile technology appeared during the last time period.
Types of institutions promoting the studies
Most of the projects were promoted by hospitals and
universities (31 % ex aequo). There were 4 projects de-
veloped by national institutions (not regulatory) and 5
projects implemented by regulatory authorities.
Targets
A total of 72 % of the projects were geared to healthcare
professionals, 24 % to patients and one project was
geared to both targets. Most of the projects targeting
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patient ADR reporting were developed in the last years
considered (2011–2013).
Types of medicine
Most of the projects (72 %) covered all medicines, but
17 % were specific to vaccines. There were also projects
specific to reporting ADRs due to chemotherapy, human
albumin and radiopaque agents (1 project for each of
these medicines).
Types of ADR
Only a small percentage of the projects were specific for
serious adverse drug reactions. The majority (93 %) cov-
ered all ADR.
Table 1 Project identification
Project
number
System name
(if any)
Country Number of
publications
Publication date(s) References Journals
4 USA 1 1992 [32] Hospital pharmacy
28 France 1 2001 [26] Fundamental & Clinical Pharmacology
11 Japan 1 2002 [33] Yakugaku Zasshi-Journal of the Pharmaceutical
Society of Japan
17 USA 1 2004 [34] American Journal of Health-System Pharmacy
2 USA 3 2005, 2007 [25, 35, 36] Journal of Clinical Oncology, Journal of American
Medical Information Association
22 USA 2 2005, 2006 [28, 37] Biosecurity and Bioterrorism-Biodefense Strategy
Practice and Science, Health Expectations
10 USA 1 2007 [29] Journal of the American Medical Informatics
Association
9 MEADERS USA 2 2007, 2010 [23, 38] Annals of Family Medicine, AMIA Annual
Symposium proceedings
21 Spain 1 2008 [39] Annals of Pharmacotherapy
7 Sweden 1 2009 [15] European Journal of Clinical Pharmacology
5 Canada 1 2010 [40] International Journal of Medical Informatics
13 Canada 1 2010 [27] Vaccine
18 USA 1 2010 [41] Pharmacoepidemiology and Drug Safety
19 United
Kingdom
1 2010 [42] Archives of Disease in Childhood
23 ALIAS USA 1 2010 [43] Contemporary Clinical Trials
27 Taiwan 1 2010 [14] Value in Health
8 United
Kingdom
1 2011 [44] Journal of Psychiatric and Mental Health Nursing
12 Serbia 1 2011 [20] Drug Safety
14 France 1 2011 [13] Therapie
15 USA 1 2011 [21] Paediatrics
6 United
Kingdom
1 2012 [45] Drug Safety
16 Korea 1 2012 [46] Yonsei Medical Journal.
20 Portugal 1 2012 [16] Drug Safety
25 USA 1 2012 [47] 2012 Ninth International Conference on Information
Technology: New Generations
1 Cambodge 1 2013 [22] Journal of Medical Internet Research
3 Netherlands 1 2013 [18] Studies in health technology and informatics
24 SALUS France 1 2013 [48] Studies in health technology and informatics
26 Spain 1 2013 [49] International Journal of Clinical Pharmacy
29 Denmark 1 2013 [17] European Journal of Hospital Pharmacy-Science
and Practice
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Quantitative analysis
From the 29 projects analysed, seven projects met the
criteria for inclusion in the quantitative analysis (meta-
analysis). The criteria used were the availability of data
related to the number of ADR reported before and after
each intervention and a follow-up period.
From the seven projects included in the quantitative
analysis, six had the same follow-up period (12 months)
and only one (project 14) differed on this item
(18 months of follow-up). The results are described in
Table 3.
We performed a meta-analysis with these seven projects
to calculate the aggregated measure of the ADR reporting
increase. The overall measure was 2.1, which indicated
that the interventions performed in the analysed projects
doubled the number of ADR reports (Fig. 3).
Projects 14, 7 and 6, which had similar ADR reporting
increases, used different approaches. The authors of pro-
ject 14 assessed an online ADR reporting form, in pro-
ject 7 the authors send repeated e-mails with ADR
information to healthcare professionals and project 6
evaluated the inclusion of a reporting system inside the
clinical information system.
Four of the information systems that contributed to the
improvement of ADR reporting used web-based technol-
ogy. Two used an online reporting form (Project 14 [13]
and Project 27 [14]) to facilitate ADR reporting. A Swed-
ish group opted to evaluate the effect of repeated emails
to health care professionals that contained attached ADR
information (Project 7 [15]). A Portuguese study tested
the inclusion of hyperlinks to the online ADR reporting
form on hospitals’ electronic patient records (Project 20
[16]) to facilitate access to the ADR form.
Three projects explored the use of electronic health
records to directly report the ADRs (projects 29, 6 and
17). Among these, project 29 [17], which had the best
result in terms of the ADR reporting increase, was a
system that completed the ADR report whenever a phys-
ician required assistance.
Discussion
Although a limited number of projects was included in
our work (n = 29), our data suggest that the number of
projects that aimed to promote ADR reporting using in-
formation technologies increased over time.
Study selection was performed as a manual review;
this approach caused a huge workload because we ob-
tained more than 3000 articles. An optimized query
would reduce the workload but lose sensitivity.
As expected, most of the projects that aimed to promote
adverse drug reactions reporting were developed in hospi-
tals and tailored to healthcare professionals. In fact, most
of the serious ADRs were detected in hospitals and re-
ported by healthcare professionals [18]. For example, in
Europe direct reporting (ADRs reported by patients) has
only been allowed for every country since 2012 [19]. This
finding may also explain why most of the projects that tar-
geted direct ADR reporting were developed in the last 3
years of the study period (2011–2013) [18, 20–22].
Most of the authors chose to develop systems for the
passive promotion of ADR reporting because busy
healthcare professionals only submit their suspected
ADR if it does not increase their workload [23, 24]. Ac-
tive promotion of ADR reporting is difficult and not al-
ways ethically acceptable because no material reward
can be given to the reporters. Thus, projects that aimed
to actively promote ADR reporting involved teaching
sessions [25] or e-mails containing ADR information
[15, 18, 26, 27].
Our results suggested that there was an increasing
trend in the use of web-based software to promote
ADR reporting, which could be explained by the
Fig. 2 Number of publications by year
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Table 2 Qualitative analysis of the projects
Variable Time period Total
(%)
Project numbers
<2004
(4 projects)
2005–2007
(4 projects)
2008–2010
(8 projects)
2011–2013
(13 projects)
Geographic area covered by the
project
Regional 4 3 5 6 18 (62) 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17,
20, 21, 22, 26, 27, 28, 29
National 0 1 3 6 10 (34) 1, 3, 6, 9, 15, 18, 19, 23, 24, 25
International 0 0 0 1 1 (3) 12
Area covered by the project
Hospital 4 2 5 4 15 (52) 2, 4, 5, 8, 11, 13, 17, 18, 20, 21, 22,
26, 27, 28, 29
Community 0 0 0 6 6 (21) 1, 3, 12, 14, 15, 16
Primary care 0 2 1 1 4 (14) 6, 7, 9, 10
Other healthcare institutions
(different from hospitals or primary
care)
0 0 1 2 3 (10) 19, 24, 25
Clinical trials 0 0 1 0 1 (3) 23
Type of action promoted by the
project
Passive promotion of ADR reporting 3 3 6 10 22 (76) 4, 5, 6, 8, 9, 10, 11, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25, 26, 27, 29
Active promotion of ADR reporting 1 1 2 3 7 (24) 1, 2, 3, 7, 12, 13, 28
Type of software
Web-based 1 3 6 6 16 (55) 2, 3, 5, 7, 9, 12, 13, 14, 15, 16, 19, 20,
22, 23, 27, 28
System inside the Electronic Health
Record
3 1 2 6 12 (41) 4, 6, 8, 10, 11, 17, 21, 24, 25, 26, 18, 29
Mobile 0 0 0 1 1 (3) 1
Type of institution promoting the
study
Hospital 2 1 3 3 9 (31) 2, 4, 8, 17, 18, 21, 26, 27, 29
University 1 1 3 4 9 (31) 5, 10, 11, 12, 13, 19, 20, 24, 25
National institution 0 2 0 2 4 (14) 1, 9, 15, 22
Regulatory authority 1 0 1 3 5 (17) 6, 7, 14, 16, 28
Othera 0 0 1 1 2 (7) 3, 23
Target
Healthcare professionals 4 2 7 8 21 (72) 4, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18,
19, 21, 23, 24, 25, 26, 27, 28, 29.
Patients 0 2 1 4 7 (24) 1, 2, 3, 5, 12, 20, 22
Healthcare professionals and
patients
0 0 0 1 1 (3) 15
Type of medicine
All 4 1 5 11 21 (72) 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 16, 17, 18,
19, 20, 21, 24, 25, 26, 28, 29
Vaccines 0 2 1 2 5 (17) 1, 10, 13, 15, 22
Chemotherapy 0 1 0 0 1 (3) 2
Human albumin 0 0 1 0 1 (3) 23
Radiopaque agents 0 0 1 0 1 (3) 27
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dissemination of internet use. Nevertheless, mobile
technology was also appearing.
Most of the retrieved projects covered all medicines and
ADR, whereas only a few were specific. However, we
found 5 projects dedicated to vaccine adverse reactions
[21, 22, 27–29] and in the last 3 years two projects were
developed to specifically report serious ADR [18, 22].
The institutions that primarily promoted this work
were universities and hospitals because universities have
the know-how to perform these actions and hospitals
have specific needs to be solved. However, regulatory au-
thorities have been increasing their involvement in the
development of this type of project.
A limitation of this study is that a grey literature
search was not performed. However, we think that
this lack does not cause a large bias because regula-
tory authorities are less likely to produce this type of
project. When regulatory authorities are involved in
projects of this scope, they usually associate with uni-
versities and hospitals that have a greater incentive to
publish.
Based on our quantitative analysis, we can conclude
that all of the projects analysed increased the ADR
reporting numbers (most by approximately two-fold).
We found two projects that increased ADR reporting by
more than two-fold [14, 17], perhaps because their basal
values were much lower compared with the other five
projects. A similar effect was noted previously in two
other studies when the same population of health care
professionals was exposed to the same educational inter-
ventions two different times [30, 31]. After the first
intervention, the authors achieved a much higher effect
and ADR reporting increased compared to the second
intervention due to the differences in the initial values.
In our quantitative analysis, we found a limitation con-
cerning the aggregation of the information because we
found only 7 studies that provided data concerning its im-
pact on the increase in ADR reporting. These data were
not available for the other studies even after we contacted
the authors. However, we did not identify any variable that
could distinguish these 7 projects from the other 22 pro-
jects. We must reiterate the importance of providing
quantitative data when publishing studies focused on in-
terventions that aim to promote ADR reporting.
Worldwide underreporting of ADR is a major concern,
and many institutions are aware that it is feasible to use
information systems to improve ADR reporting. The
most commonly used platform is web-based and exhibits
an increasing trend, but interventions inside electronic
health records also have the potential to improve phar-
macovigilance activities and particularly ADR reporting.
Direct ADR reporting is being increasingly taken into
account when the aim is to improve information on
drug safety.
Based on our results, we believe that it would be use-
ful to adopt a system to assist healthcare professionals
with completing ADR reporting within electronic health
records because this approach seems to be an efficient
method to increase the ADR reporting rate. When this
approach is not possible, it is essential to have a tool that
is easily accessible on the web to report ADR. This tool
can be promoted by sending emails or through the in-
clusion of direct hyperlinks on healthcare professionals’
desktops.
Table 2 Qualitative analysis of the projects (Continued)
Type of ADR
All 4 4 8 11 27 (93) 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
Serious 0 0 0 2 2 (7) 1, 3
a Other institutions are: Clinical trial team (project 23) and website producer (project 3)
Table 3 Intervention effect on ADR reporting increase
Study ADR reports before ADR reports after Rate CI lower CI upper
Project 14 287 415 1,44 −0,18 3,07
Project 7 89 111 1,25 −0,51 3,00
Project 29 30 162 5,4 4,56 6,24
Project 6 3279 4716 1,44 −0,20 3,072
Project 17 118 294 2,49 1,25 3,73
Project 27 20 62 3,1 1,99 4,21
Project 20 82 212 2,58 1,37 3,80
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Conclusions
Our systematic review allowed us to note some facts
about interventions that aim to improve ADR reporting
using information systems. According to our aggregation
analysis, these interventions doubled the number of
ADR reports. We also found that most projects passively
promoted ADR reporting (facilitating the reporting
process) and the countries involved in this type of pro-
ject were Northern America countries (USA and
Canada), European countries and in a smaller number
Far East countries.
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ABSTRACT
OBJECTIVE: To describe different approaches to promote adverse drug reaction reporting 
among health care professionals, determining their cost-effectiveness. 
METHODS: We analyzed and compared several approaches taken by the Northern 
Pharmacovigilance Centre (Portugal) to promote adverse drug reaction reporting. Approaches 
were compared regarding the number and relevance of adverse drug reaction reports obtained 
and costs involved. Costs by report were estimated by adding the initial costs and the running 
costs of each intervention. These costs were divided by the number of reports obtained with 
each intervention, to assess its cost-effectiveness.
RESULTS: All the approaches seem to have increased the number of adverse drug reaction reports. 
We noted the biggest increase with protocols (321 reports, costing 1.96 € each), followed by first 
educational approach (265 reports, 20.31 €/report) and by the hyperlink approach (136 reports, 
15.59 €/report). Regarding the severity of adverse drug reactions, protocols were the most efficient 
approach, costing 2.29 €/report, followed by hyperlinks (30.28 €/report, having no running costs). 
Concerning unexpected adverse drug reactions, the best result was obtained with protocols 
(5.12 €/report), followed by first educational approach (38.79 €/report).
CONCLUSIONS: We recommend implementing protocols in other pharmacovigilance centers. 
They seem to be the most efficient intervention, allowing receiving adverse drug reactions reports 
at lower costs. The increase applied not only to the total number of reports, but also to the 
severity, unexpectedness and high degree of causality attributed to the adverse drug reactions. 
Still, hyperlinks have the advantage of not involving running costs, showing the second best 
performance in cost per adverse drug reactions report.
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INTRODUCTION
Adverse drug reactions (ADR) are inherent to medicine use20, and most of them can only 
be detected after the commercialization of the drug14. In fact, during clinical trials, rare 
reactions are hardly detected, as well as the ones associated with chronic utilization 
of the drug. It is also difficult to predict the drug effect among special populations 
(pregnant women, children, older adults), as they usually do not participate in the 
clinical research.
Because of these limitations, post-marketing surveillance is essential, which is 
why most countries have pharmacovigilance centers to monitor detected ADR. 
The fundamental tool used by these centers is the spontaneous reporting of ADR 
by healthcare professionals and consumers. This method consists in describing an 
adverse episode suspected to be caused by one or more drugs and provides valuable 
information to the regulatory health authorities, which is important for the decisions 
about marketed medicines. The biggest problem of this method is the underreporting, 
i.e., ADR are detected but not reported to national regulatory health authorities. Most 
developed countries face this situation15,19. Worldwide, many approaches have been 
completed to fight the major problem of ADR underreporting, such as regular visits 
to health professionals10, questionnaire studies2, educational interventions (including 
workshops, meetings and presentations)4,12,16, among others. 
This study aimed to describe several approaches that intended to improve ADR reporting 
and determine the cost-effectiveness of each one of them.
METHODS
From its creation (in 2000) to 2003, Northern Pharmacovigilance Centre, a Portuguese 
regional pharmacovigilance center, had an extremely low rate of ADR reports, about 43 per 
year/million inhabitants. We realize this value is very low when compared with the World 
Health Organization (WHO) recommendation for an Optimal National Centre, which is at 
least 200 reports per year/million inhabitantsa.
To reach its objectives, in 2004 the Centre established a collaboration protocol (protocol 
approach) with the immunoallergology department of a central hospital (located 
on the same street as the Centre) to collect every suspected case of ADR emerged 
in appointments related to drug allergies. This collaboration includes regular visits 
of the pharmacovigilance staff to the immunoallergology department to collect the 
detected cases in ADR report forms, under the physician supervision. Then, the form 
is signed by the physician and follows the normal course of all the ADR spontaneous 
reports. This approach was replicated two more times, in 2007 and 2009, in two other 
immunoallergology departments, one from a specialized hospital (pediatric hospital, 
located 6 km from the Centre) and another from a central hospital (located 11 km from 
the Centre). These three protocols remain active.
A study conducted in 2004 provided educational interventions (educational approach) for 
physicians and pharmacists4,8. Those interventions were based on a previous case-control 
study that identified the reasons for underreporting6,7. The educational approach includes 
workshops about pharmacovigilance at health care professionals’ working places.
Since the effect of educational interventions decreased over time, the authors of the 
previously described work promote reinforcement interventions (educational and telephone 
approach). We started a new study in 2007, also among physicians and pharmacists. This study 
consisted not only in outreach interventions (workshops), but also in telephone interviews9,17. 
The phone interviews followed a script about ADR and the importance of reporting. Details 
are described in a previous publication17. 
a Governo de Portugal, 
INFARMED – Autoridade 
Nacional do Medicamento 
e Produtos de Saúde. 
Farmacovigilância em Portugal. 
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We propose a new approach: the inclusion of a hyperlink (hyperlink approach) to an online 
ADR reporting form on hospitals’ electronic patient records (EPR). The main aim of this 
study, performed from 2006 to 2010, was to evaluate the impact of these hyperlinks on the 
number of spontaneous ADR reports18. The inclusion of hyperlinks began in December 
2007 and continued over the following five months. The temporal distribution of all these 
approaches is shown in Figure 1.
In the present work, we analyzed the number of ADR reports obtained with each one of the 
described approaches. We know exactly which ADR reports were originated at the three 
departments participating in the protocol intervention and analyzed them separately. Four 
physicians were involved.
The first educational intervention (in 2004) involved three hospitals, 26 healthcare centers, 
and 73 pharmacies. About 900 health care professionals attended these interventions4. 
About 340 health care professionals (physicians and pharmacists) attended the second 
intervention (second workshop + telephone, both in 2007). Five health care centers, 
two hospitals, and 40 pharmacies received the telephone intervention, and 16 health care 
centers, two hospitals, and 23 pharmacies received the second educational intervention.
For the hyperlinks, we estimated 15,000 health care professionals potentially affected by 
the intervention, as this is the total number of professionals working at the 12 participating 
hospital centers (corresponding to 22 hospitals). It was the first exposure to any intervention 
for eight of these hospital centers.
The variables analyzed were: type of approach, ADR relevance, initial costs of the 
interventions, running costs of the interventions, and costs per ADR report. Each of these 
variables is described as follows.
• Type of approach: hyperlink, protocol, educational, and telephone approach.
• Number of ADR reports obtained with each intervention: the difference between ADR 
reports received two years after the intervention and ADR reports received two years 
before the intervention.
• ADR relevance: we adopted the following criteria: (1) ADR severity; (2) ADR expectedness; 
and (3) causality attributed to the ADR report. A serious ADR is any untoward medical 
occurrence that results in death, requires inpatient hospitalization or prolongation of 
existing hospitalization, results in persistent or significant disability or incapacity, or is 
life-threatening2. An unexpected ADR is the one in which the nature or severity is not 
consistent with domestic labeling or market authorization, or expected from characteristics 
of the drug2. We considered an ADR more relevant if one of the two highest degrees of 
causality was attributed to it: (1) definitive or certain, or (2) probable (the medicine was 
the likely causative agent of an observed adverse reaction)b.
• Initial costs of the interventions: we consider as initial costs the expenses needed for 
implementing the approach, as educational material and staff working hours. These 
costs are described in Table 1.
b World Health Organization; 
Uppsala Monitoring Centre 
Uppsala. Uppsala: Uppsala 
Monitoring Centre Uppsala 
[updated 2015 Aug 18; cited 
2013 Aug 9]. Available from: 
http://www.who-umc.org/
DynPage.aspx?id=22682
Figure 1. Timeline of the studied approaches.
January 2001 December 2012
Jan 02 Jan 03 Jan 04 Jan 05 Jan 06 Jan 07 Jan 08 Jan 09 Jan 10 Jan 11 Jan 12
Aug 09
3rd immunoalergology protocol
Dec 07
hyperlink approach
Jul 07
2nd immunoalergology protocol
Jul 07
telephone approach
Apr 07
2nd educational approach
Mar 04
1st educational approach
Apr 04
1st immunoalergology protocol
4Promoting adverse drug reaction reporting Ribeiro-Vaz I et al.
DOI:10.1590/S1518-8787.2016050006122
• Running costs of the interventions: annual running costs are the expenses needed for 
continuing the projects, as fuel, material and staff working hours. These costs are described 
in Table 1. We did not consider the normal (daily) costs of ADR report processing, as we 
only meant to compare the costs involved in obtaining ADR reports.
• Costs per ADR report: costs by ADR report were estimated by adding initial costs and 
running costs. Initial costs per ADR report were obtained by dividing initial costs by 
the difference between ADR reports received two years after the intervention and ADR 
reports received two years before the intervention (which we consider to be the number 
of notifications obtained with each intervention). Running costs were obtained by 
dividing the running costs of the two-year intervention by the number of notifications 
obtained with each intervention. To assess the cost-effectiveness of each intervention, 
we considered the sum of these costs (initial + running costs) as the total cost of each 
ADR obtained in the two years following each intervention.
The pharmacovigilance center website uses a web server and has audit trails that read 
each site visit since 2006. These audit trails are processed using the Webalizer program 
(www.webalizer.org) to estimate site hits, user logins and visits. ADR reports obtained 
by these approaches are included in a database. We collect them by selecting the report 
date and origin.
We presented the total number of reports received in each quarter during the period 
studied. For each health institution, ADR reports made before and after the intervention, 
if any, were measured.
To examine whether each intervention increased the ADR report trend, an interrupted time 
series analysis using autoregressive integrated moving average (ARIMA) was performed 
using quarter data of ADR reports, as well as each intervention ( first and second educational 
approach, telephone approach, and hyperlink approach) as dichotomous variables (before 
and after intervention).
We performed an additional analysis with the hyperlinks approach, to consider the 
institutions exposed to any type of intervention for the first time. With this sub-analysis we 
intended to isolate the ADR reports obtained with each intervention.
This study was approved by the local Ethics Committee of the Faculdade de Medicina of 
the Universidade do Porto (Process PCEDCSS-FMUP 08/2014, approved in May 7, 2014).
Approach
Initial costs Annual running costs
Value Description Value Description
Protocol 
approach
150 €
Pharmacovigilance and clini-
cal service staff working hours
240 €
Fuel, material, and pharma-
covigilance and clinical staff 
working hours
Hyperlink 
approach
2,120 €
Pharmacovigilance and 
software development staff 
working hours
- -
Educational 
approach
200 €
Educational material and 
pharmacovigilance staff 
working hours
2,500 €
Fuel, material, and pharmaco-
vigilance staff working hours
Telephone 
approach
400 €
Telephone calls during the 
pilot study and pharmacovigi-
lance staff working hours
800 €
Telephone calls, material, 
and pharmacovigilance staff 
working hours
Table 1. Estimated costs of each approach.
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RESULTS
We found an increasing trend in the number of ADR reports received by the Northern 
Pharmacovigilance Centre during the studied period: 2000-2012. The number of annual ADR 
reports increased from the year in which the first interventions were made (2004) to the end 
of the study period (Figure 2).
Excluding the ADR reports obtained with the protocol approach, the only intervention that 
significantly increased the ADR report trend was the first educational approach, in the first 
quarter of 2004 (p < 0.001).
We did not find a significant increase in the ADR report trend in the second educational 
approach in second quarter of 2007 (p = 0.203). The telephone approach also failed to 
significantly increase ADR reporting in the third quarter of 2007 (p = 0.243). With the 
hyperlink approach we observed a slight increase in ADR reporting, although without 
statistical significance (p = 0.193). 
All the approaches increased the number of ADR reports, when we compare the two years 
before with the two years after the interventions. We noted the biggest increase with the 
protocol approach (321 ADR reports obtained), followed by the first educational approach, 
with 265 ADR reports obtained, and by the hyperlink approach, with 136 ADR reports. For 
the hyperlink approach, we isolated the institutions exposed to an intervention for the first 
time; these cases obtained 141 ADR reports. 
According to the initial costs involved, our results suggest that the protocol approach is the most 
cost-effective, costing 0.47 € per ADR report, followed by the first educational and telephone 
approach, costing 0.78 € per ADR report. Analyzing running costs, the hyperlinks approach is the 
most favorable, having none. On the other hand, we can conclude that the second educational 
approach is the intervention that entails more costs, with 123.81 € per report (Table 2).
Regarding the relevance of ADR reports, we analyzed the severity, expectedness and degree 
of causality attributed to the reports. Regarding serious ADR, the protocol approach was the 
most cost-effective, costing 2.29 € per report. The hyperlink approach obtained the second 
lowest value (30.28 € per report), having no running costs. We found similar results for the 
relevance criterion of causality assessment. Concerning ADR expectedness, the best result 
belonged to the protocol approach (5.12 € per report), followed by the first educational 
approach (38.79 € per report) (Table 3).
0
50
100
150
200
250
300
350
400
Jul 
2007
Feb 
2001
Educational
Protocol
Educational
Protocol Protocol
Telephone
Hyperlink
Oct
2012
Figure 2. Total number of adverse drug reaction reports received in the Northern Pharmacovigilance 
Centre during the studied period, per trimester (in green, those obtained with protocols).
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Approach Intervention
Adverse drug reaction reports
Costs (€) per report
Before After
2 years 1 year 1 year 2 years Initial costs Running costs (2 years) Total
Protocols 0 0 204 117 0.47 1.49 1.96
Hyperlinks 153 120 277 132 15.59 0.00 15.59
Hyperlinks NPE* 68 47 146 110 15.03 0.00 15.03
Educational
1st workshop 36 24 257 68 0.78 19.53 20.31
Pharmacies 2 8 110 25 1.60 40.00 41.60
Health care centers 25 7 102 17 2.29 57.47 59.77
Hospitals 9 9 45 26 3.77 94.34 98.11
Phone Interview 47 26 87 34 8.33 33.33 41.67
Pharmacies 23 10 37 14 22.22 88.88 111.11
Health care centers 3 1 8 2 66.67 266.67 333.33
Hospitals 21 15 42 18 16.67 66.67 83.33
Educational 
2nd workshop 54 40 106 30 4.76 119.05 123.81
Pharmacies 39 25 69 18 8.70 217.39 226.09
Health care centers 10 13 26 6 22.22 555.55 577.78
Hospitals 5 2 11 6 20.00 500.00 520.00
* NPE: Not previously exposed. Considering only the institutions without any previous intervention.
Table 2. Number and costs of adverse drug reaction reports obtained with each intervention.
Approach Intervention
Adverse drug reaction reports
Costs (€) per report
Before After
2 years 1 year 1 year 2 years Initial costs
Running costs 
(2 years)
Total
Serious
Protocols 0 0 180 94 0.54 1.75 2.29
Hyperlinks 113 96 193 86 30.28 0.00 30.28
Educational 1st workshop 12 15 111 42 1.59 32.68 34.27
Phone interview 29 19 55 21 14.29 57.14 71.43
Educational 2nd workshop 37 23 44 8 - - -
High degree of causality
Protocols 0 0 165 66 0.65 2.08 2.73
Hyperlinks 114 86 232 109 15.03 0.00 15.03
Educational 1st workshop 14 17 169 47 1.08 27.03 28.11
Phone interview 40 17 65 26 11.76 47.06 58.82
Educational 2nd workshop 37 27 74 22 6.25 156.25 162.50
Unexpected
Protocols 0 0 70 53 1.22 3.90 5.12
Hyperlinks 63 40 69 37 706.67 0.00 706.67
Educational 1st workshop 10 7 111 40 1.49 37.30 38.79
Phone interview 17 11 22 7 400.00 1,600.00 2,000.00
Educational 2nd workshop 24 17 28 6 - - -
Table 3. Number and costs of serious, unexpected, and classified with a high degree of causality adverse drug reaction reports obtained 
with each intervention.
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DISCUSSION
Although there is some overlap of interventions, making it difficult sometimes to differentiate 
the gains from each one of them, our results show that, in general, all interventions increased 
the number of ADR reports when comparing two years before with two years after.
Protocols in hospital immunoallergology departments seem to be the most efficient 
intervention. In fact, this intervention is the one that allows obtaining ADR reports with 
lower costs involved, with an increase not only in the total number of ADR reports, but 
also in the severity, unexpectedness, and high degree of causality attributed to the ADR.
Nevertheless, these protocols have the disadvantage of increasing the reports of ADR 
in patients of a specific population (patients with allergies), which can bias the global 
pharmacovigilance data. We started to establish these protocols at the request of one 
of the immunoallergology departments, but we are trying to establish similar protocols 
in other departments (as oncology departments, hospital pharmacies, among others), 
to solve the bias issue.
On the other hand, the hyperlink approach has the great advantage of not involving running 
costs, and seems to have the second best performance in costs per ADR report. Even when 
we consider only the hospitals exposed to an intervention for the first time (to avoid the 
overlap effect), this behavior remains. 
We also concluded that the first educational intervention was much more efficient than 
the second one. In fact, the second intervention seemed to be counterproductive, as shown 
by the results of serious and unexpected ADR reports (these numbers decreased after 
the intervention). We already had this conviction since this intervention was performed. 
In fact, in most health care institutions where the second intervention took place, we found 
professionals less receptive than in the first intervention, as they already knew the subject 
and did not seem to believe they needed another workshop about it.
Unfortunately, we are not able to compare our results with other authors’ results, as we 
failed to find any study addressing the issue of ADR report costs. Many studies proposed 
strategies to improve ADR reports1,11,13 and some authors have already studied the costs of 
an ADR3,5. However, no one had studied the costs involved in obtaining ADR reports before, 
which is the novelty of our work.
Although there might be some overlap and eventual contamination among the interventions, 
we believe that this did not introduce an important bias in our conclusions. First, we knew 
exactly which reports were originated at the departments participating in the protocols. 
Moreover, we included in our results the ADR reports obtained after the hyperlink inclusion 
in the hospitals that had an intervention for the first time. Thus, we could infer that the gain 
in ADR reports after hyperlink inclusion was caused by this intervention. Furthermore, there 
is no problem of overlapping for the first educational approach (workshops in 2004) because 
this was the first intervention made. The only interventions for which we cannot resolve the 
overlapping limitation is the second educational intervention and the phone intervention. 
However, these two interventions were planned as complementary to the first one.
We believe that our work can help pharmacovigilance centers worldwide choose the best 
set of interventions to promote adverse drug reactions report. This choice must be based on 
the particular characteristics of each center, such as available staff and budget, geographic 
location, proximity to hospitals, among others.
Based on our results, we recommend the implementation of protocols with hospital 
immunoallergology departments, as they seem to be the most cost-effective intervention, 
followed by hyperlinks to ADR reporting forms, and the promotion of educational 
interventions to health care professionals for the first time.
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Abstract Background: Spontaneous adverse drug reaction (ADR) reporting has been
described as an efficient method to detect drug safety signals. However, un-
der-reporting is a major issue undermining the effectiveness of spontaneous
reports. Among hospitalized patients, ADRs are a particularly serious prob-
lem because these patients are often treated with more than one drug, and
these drugs are often new and aggressive.
Objective: To promote spontaneous ADR reporting by healthcare profes-
sionals working in hospitals in the northern regions of Portugal, we propose
the inclusion of a hyperlink to an online ADR reporting form on hospitals’
electronic patient records (EPRs). The main aim of this study was to evaluate
the impact of these hyperlinks on the number of spontaneous ADR reports to
the Northern Pharmacovigilance Centre (UFN – Unidade de Farm-
acovigilaˆncia do Norte). We also assess the number of daily UFN website
visits before and after the inclusion of the hyperlinks.
Methods:An ecological study was performed in northern Portuguese hospitals
from 2006 to 2010. The hyperlinks were included in either EPRs or on com-
puter desktops. The median of spontaneous ADR reports (total and online)
per month and the respective ranges were presented before and after the in-
tervention in all hospitals in this study. The comparisons were performed using
the Mann-Whitney U-test.
Results: Sixteen hospital centres were involved in the study (27 hospitals).
Eleven centres (18 hospitals) included the hyperlinks. Considering the hos-
pitals with hyperlink access to the EPRs, the median ADR reports per month
significantly increased, from two (range 0–12) to five reports (range 1–17).
The median of ADR reports per month using the online form also increased
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significantly, from one (range 0–5) before the intervention to four (range
1–17) after it. Moreover, serious ADRs increased 3-fold, and non-previously
described ADRs increased 4.5-fold. None of these significant increases were
observed in the hospitals where the hyperlink was not installed. We also
found a significant increase in daily UFN website visits, from ten before the
intervention to 27 after it (p < 0.001).
Conclusion: The increase in ADR reporting shows that the inclusion of hy-
perlinks to online ADR reporting forms is an easy and cost-effective way to
change health professional behaviours with regard to spontaneous ADR reports.
Introduction
Adverse drug reactions (ADRs) are a well rec-
ognized public health problem worldwide and
a major cause of death and hospitalization in
developed countries.[1] In fact, rare and long-term
ADRs are difficult to detect during the drug
development stage. Only when the drugs begin to
be used by a large population after marketing
authorization is it possible to detect new ADRs
not previously identified during clinical trials.
In reality, the safety of a new drug cannot be
established until it has been on the market for
several years.[2] As such, it is essential to keep re-
actions to drugs under close surveillance, especially
after marketing, through a pharmacovigilance
system.
In Portugal, this system is based on sponta-
neous ADR reports made by healthcare profes-
sionals.[3] These reports can be made using paper,
telephone, e-mail or through an online form,[4]
and they consist of a description of an adverse
event supposedly caused by a medicine. Spon-
taneous ADR reporting has been described as
an efficient method for detecting drug safety
signals.[5] However, under-reporting is a major
issue undermining the effectiveness of spontane-
ous reporting. Several studies suggest that less
than 10% of detected ADRs are effectively re-
ported to medicine regulatory authorities.[6,7] In
addition, the spontaneous ADR report rate in
northern Portugal was 90 reports/million in-
habitants in 2009, which is highly unsatisfactory
according to the WHO recommendations (200
reports/million inhabitants[8]).
Worldwide, systems using informatics to pro-
mote ADR reporting or to detect ADRs that
have occurred in healthcare institutions have
been tested and are currently being used. Com-
puter programs that allow voluntary and auto-
mated detection of ADRs,[9,10] informatics tools
created to analyse clinical databases,[11] or web-
sites that actively inform healthcare profes-
sionals[12] are examples of such systems.
Among hospitalized patients, ADRs are a par-
ticularly serious problem. In fact, these patients are
often treated with more than one drug, and these
drugs are often new and aggressive. Despite these
treatments, there is currently no specific system
for monitoring or reporting ADRs in Portuguese
hospitals. We believe that making the reporting
system easier would considerably increase the
number of reported ADRs.
With the intention of promoting spontaneous
ADR reporting by healthcare professionals work-
ing in hospitals, we proposed the inclusion of a
hyperlink to an online ADR reporting form (part
of the Northern Pharmacovigilance Centre [UFN]
website) on the electronic patient records (EPRs)
or on the desktops of hospital computers. With
this system, we expected to reach not only the
physicians but also the pharmacists and nurses
working at these hospitals. In Portuguese hospi-
tals, pharmacists have an important role in ADR
detection and reporting because physicians dis-
cuss with them the adverse events that occurred
during medical treatment, asking for alternative
drugs available at the pharmacy. In addition,
some pharmacists are part of the clinical visit and
frequently detect ADRs themselves.
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Aim
Our main aim was to evaluate the impact of the
hyperlinks installed in Portuguese hospitals on the
number of ADRs reported by these hospitals using
the hyperlink versus those that did not, and we also
evaluated the number of visits to the UFN website.
Methods
Intervention
Hyperlinks to the ADR online reporting UFN
form were proposed to the 18 northern Portu-
guese hospitals. The hyperlinks can be included
either in healthcare professional-specific software
(typically EPRs or pharmacy-specific applications
used by doctors, nurses and pharmacists) or on
hospital computer desktops (see figure 1 for ex-
amples of both situations). Notably, most of the
Portuguese EPRs are web-based, so the hyperlink
automatically opens the UFN form in a new
browser window.
The online reporting UFN form requires the
health professional to log in with their personal
account. Patient data are collected in an anon-
ymous way (only the initials of the patient name
are required, aiming to help the health professional
identify each case) and are secured in an Oracle
database with appropriate access restrictions.
In the beginning of October 2007, a letter was
sent to the chief physicians of these 18 northern
Portuguese hospitals suggesting the inclusion of
the hyperlink. If there was no response within
2 weeks, clinical administration boards were re-
minded by telephone. Thirteen centres forwarded
this announcement to the respective computer
departments, and only one hospital forwarded it
to the pharmaceutical department. Five of the
centres failed to respond by the end of 2010. After
approval by the hospital board and after being
forwarded to the respective departments, UFN
made a third contact to explain technical specifi-
cations and to send the specific hyperlink for each
hospital.
Hyperlinks to
ADR Form
Fig. 1. Examples of hyperlinks on a computer desktop (back image) and in an electronic patient record (front image).
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Study Design and Data Collection
An ecological study was carried out in north-
ern Portuguese hospitals from 2006 to 2010. The
number of spontaneous ADR reports and online
spontaneous ADR reports originating from hos-
pitals were analysed before and after the above-
mentioned intervention, without a control group.
Five hospital centres implemented the hyperlink in
December 2007, and the other six implemented it
over the course of the next 5 months.We looked at
the 23 months before and the 31 months after im-
plementation in each hospital.
The UFN website uses an Apache web-server
and has a record of the web logs related to the site
visits since January 2006. These logs were initially
processed usingWebalizer software (www.webalizer.
org) to calculate site hits, user logins and visits.
Telephone interviews with the computer de-
partments of each hospital were performed to
collect where each institution installed the hy-
perlink to the UFN website, and screen-shots
illustrating the interventions were taken.
Variables
The main variables collected for analysis were
as follows:
 Date – date and time of the ADR report.
 Hospital – institution where the ADR was
detected.
 Health professional – type of health profes-
sional that reported the ADR (doctor, nurse,
pharmacist or other).
 Seriousness – seriousness of the ADR,
grouped as ‘Serious’ or ‘Non-serious’ accord-
ing to the WHO criteria.
 Previous knowledge – whether the ADR was
previously described in the Summary of Prod-
uct Characteristics for the drug or not.
Bias
From the initial 18 centres (31 hospitals) we
excluded four hospitals that established other
cooperation protocols with UFN to avoid a
possible confounder bias (see figure 2). For the
other 16 centres, we believe that there were no
external interventions that could potentially ex-
plain the observed results.
Statistical Methods
The number of spontaneous ADR reports and
online spontaneous ADR reports per month were
compared between the two periods (before and
after the intervention). The number of ADR re-
ports per quarter, before and after the installation
2 centres (3 hospitals) and 1 hospital
from another centre that established
cooperation protocols with the
Pharmacovigilance Centre were
excluded
Northern Portuguese
Hospitals
18 centres (31 hospitals)
Included Northern
Portuguese Hospitals
16 centres (27 hospitals)
Included Northern
Portuguese Hospitals
with the hyperlink
11 centres (18 hospitals)
5 centres (9 hospitals) did not 
include the hyperlink
Hyperlink in the
Electronic Patient 
Record
8 centres (12 hospitals)
Hyperlink in the
Desktop
2 centres (5 hospitals)
Hyperlink in both the 
desktop and in the
Electronic Patient Record
1 centre (1 hospital)
Fig. 2. Diagrammatic representation of the hospitals and hospital centres of northern Portugal that were included and excluded from the study.
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of the hyperlinks, is presented graphically (see
figure 3). The number of ADR reports per quar-
ter in the excluded hospitals and in the hospitals
that did not participate (those that did not install
the hyperlinks) is presented in figure 4.
Median values of the number of daily UFN
website visits were reported because of the
skewed distribution of the data. The number of
daily UFN website visits was compared before
and after the intervention using the Mann-
Whitney U-test. The significance level was set at
p< 0.05.
Results
Participants
Of the 16 centres involved in the study, 11
centres (18 hospitals) included the hyperlinks.
Eight centres included the hyperlink only in the
EPRs, two centres included the hyperlink on the
computer desktops, and one included it both on
the desktops and in the EPRs (see figure 2). Of
the 18 hospitals involved, one is a university
hospital, and three are specialized hospitals
Main Results
Considering the 16 centres that implemented
the project, the median number of ADR reports
per month significantly increased after project
implementation. In fact, before the intervention
the median of total ADR reports per month was
2, ranging from 0 to 12, and 31 months after the
intervention the median was 5, ranging from 1 to
17 (p = 0.043). Four months after the project was
implemented the median number of reports per
month was 4.
Considering only the reports using the online
form, before the project was implemented the
median total online ADR reports permonth was 1,
ranging from 0 to 5, and after the intervention, this
number was 4, ranging from 1 to 17 (p= 0.009).
Figure 3 shows the number of ADR reports
per quarter before and after the intervention.
Figure 4 presents the number of ADR reports per
quarter in the excluded hospitals and in the hos-
pitals that did not install the hyperlinks.
The 11 centres included reported 17 serious
ADRs in 23 months using the online form before
the intervention, and 69 in 31 months (a 3-fold
increase) after the intervention. These centres re-
ported seven non-previously described ADRs
using the online form before the intervention and
42 after (increase of 4.5-fold).
The hospital with the largest increase in ADR
reports submitted online was the one that in-
cluded the hyperlink both in the EPRs and on the
computer desktops, with a mean of three online
reports per year before the intervention and 18 after.
The three hospitals that included the hyperlink on
0
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Fig. 3. Evolution of adverse drug reaction (ADR) reports (total and only online) in hospitals with the intervention. The quarters were adjusted
for the time of intervention. Five hospital centres implemented the hyperlink in December 2007, two in January 2008, one in February, one in
March, one in April and one in May.
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the desktops (including the one that simulta-
neously included it in the EPRs) were in the top
five of the hospitals with higher increases in ADR
reports submitted online.
There were no ADR reports sent in both paper
and online formats by the same professional.
Other Analysis
There was a significant increase in daily UFN
website visits after the intervention (p < 0.001).
Before the intervention there was a median of
ten daily UFN website visits, and after the inter-
vention, the median increased to 27 visits.
Discussion
Our results show that the inclusion of hyper-
links to an online ADR reporting form in the
EPRs does change health professional behaviours
in ADR reporting. In reality, there was an increase
in ADR reporting in the hospitals involved in this
project, in the total number of ADR reports (more
than 2-fold), in the number of ADR reports sub-
mitted online (4-fold), in serious ADRs reported
online (3-fold) and in non-previously described
ADRs (more than 4-fold). Additionally, daily
visits to the UFN website increased approxi-
mately 3-fold after the intervention.
A similar intervention based on changing the
EPRs of a hospital to facilitate ADR reporting is
presented in Ortega et al.[13] Compared with our
ADR reporting growth, the measured impact was
higher in their study as they moved from zero to
1.6 ADRs per month in just one hospital. We
argue that this difference may be due to the fact
that theywere able to fine-tune theEPRs to increase
ADR reporting because they hadmore control over
its application, while in our case we were limited to
placing hyperlinks in existing heterogeneous EPRs.
Therefore, our approach seems more easily im-
plementable because hospitals are known to have
many different information systems[14] and a na-
tional pharmacovigilance institution is probably
not able to impose the changes described in Ortega
et al.[13] to most commercial EPRs.
In the study by Figueiras et al.,[15] which
was performed in the same region as our study,
an educational intervention to improve physician
reporting is described, namely by performing
outreach visits to groups of health professionals.
Their results present a very impressive increase
(10-fold) in ADR reporting in the intervention
group, and a 6-fold increase in the reporting of
serious ADRs. When compared with our results,
it is clear that the educational intervention has
proven to be much more effective, but also re-
quires more resources (human and financial).
100
Hospital without the hyperlink
Hospitals with cooperation protocols
90
80
N
o.
 o
f A
DR
 re
po
rts
Quarter and Year
70
60
50
40
30
20
10
0
1s
t 2
00
6
2n
d 2
00
6
3rd
 20
06
4th
 20
06
1s
t 2
00
7
2n
d 2
00
7
3rd
 20
07
4th
 20
07
1s
t 2
00
8
2n
d 2
00
8
3rd
 20
08
4th
 20
08
1s
t 2
00
9
2n
d 2
00
9
3rd
 20
09
4th
 20
09
1s
t 2
01
0
2n
d 2
01
0
3rd
 20
10
4th
 20
10
Fig. 4. Evolution of adverse drug reaction (ADR) reports in the excluded hospitals (with cooperation protocols) and in the hospitals that did not
install the hyperlinks.
392 Ribeiro-Vaz et al.
Adis ª 2012 Springer International Publishing AG. All rights reserved. Drug Saf 2012; 35 (5)
Also, the effectiveness of these interventions appears
to decrease through time. In the study by Pedro´s
et al.,[16] an educational (periodic meetings) and
economic incentives-based intervention strategy
was initiated in 2003. Their results present an in-
crease of 5.6-fold in all ADRs and a 2-fold increase
in serious ADR reports. Their impact is similar to
our study, but again used more financial resources.
When compared with other types of interven-
tions, such as solely educational[15] or educational
combined with economic incentives,[16] our in-
tervention seems to have less impact although it is
more long lasting and less expensive.
As an additional outcome, we can see that the
hospital with the highest increase in ADR reports
submitted online was the one that simultaneously
included the hyperlink in the EPRs and on the
computer desktop. According to our results for
hyperlink placement, the computer desktop is
likely more efficient than the EPR homepage. It is
our opinion that these improvements could also
be effective in other countries because they are
more related to generic usage of graphic user in-
terfaces than to local practices.
Notably, making the ADR forms easily acces-
sible might also promote future ADR reporting
initiatives that can take advantage of the visibility
of the hyperlink to the users. Therefore, we argue
that our solution is cost effective, appropriate for
widespread use inmany healthcare institutions, and
can consistently increase ADR reporting over time.
Limitations
In some hospitals, we found that although the
hyperlink was included, the professionals did not
know about it. In the near future, we aim to in-
crease the knowledge of the hyperlink by more
actively informing health professionals using fly-
ers sent to the hospitals, posters and an e-mail
showing specifically how to find the hyperlink.
Another problem detected was the inability to use
the hyperlink in some hospitals because the users
did not have permission to access to the internet.
Future Work
To solve the problem of not being able to ac-
cess the Internet, we are now developing Web-
services[17] to be used by other systems available
on hospital intranets. With this tool, it will not be
necessary to access the UFN website and health-
care professionals can simply use the existing in-
formation systems as proposed in Ortega et al.[13]
With this future work, we expect to eliminate all
the technical obstacles to ADR reporting, further
increasing the reporting rate. Meanwhile, we also
aim to implement this project in northern Portugal
primary-care healthcare centres and to provide the
hyperlink to general practitioners and nurses.
Conclusions
The inclusion of hyperlinks on computer desk-
tops and in EPRs to online ADR reporting forms is
an easy and cost-effective way to change health
professionals’ behaviours with regard to spontane-
ous ADR reports. In fact, daily visits to the UFN
website significantly increased after the inclusion of
the hyperlinks, but even more importantly, the
amount and relevance of ADR reports significantly
increased after the inclusion of the hyperlink in the
hospitals involved in this project.
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drug benefit outweighs its risks. Worldwide, pharmacovigilance 
systems are mostly based on spontaneous ADR reports made 
by healthcare professionals and consumers. Spontaneous ADR 
reporting has been described as an essential method to detect 
drug safety signals; however, underreporting is a major issue 
undermining the effectiveness of spontaneous reports. Several 
studies suggest that fewer than 10% of detected ADR are 
effectively reported to medicine regulatory authorities (e.g. Food 
and Drug Administration - FDA, European Medicines Agency - 
EMA, etc.) [1,2].
It is known that, one of the main reasons why healthcare 
professionals do not report ADR is due to an increase in their 
workload [3,4]. So, in order to reduce ADR reporting efforts, 
Information Systems (IS) to promote ADR reporting or to detect 
ADR in healthcare institutions have been tested and used, such 
as software for voluntary and automated detection of ADR, tools 
that analyse clinical databases or web-sites that actively inform 
healthcare professionals [5]. Information and communication 
technologies can also be used to facilitate and promote ADR 
reporting, such as the creation of on-line reporting forms and the 
development of tools to collect safety data from Electronic Health 
Records (EHR), among others [6,7].
In Portugal, there is a multi centre research project, in the field 
of gastric diseases (Study Group of Inflammatory Bowel Disease – 
GEDII) [8] whose members use the same electronic health record 
to collect patient information. As these patients are often treated 
with new and potent drugs (e.g. immunomodulating agents), the 
EHR has a field related to medication and ADR. Since the group 
members already fill in this field, it was considered an advantage 
to create a tool to send the data to the pharmacovigilance system.
Aim
The aim of this work was to implement and describe the 
implementation of a web service in an EHR to collect ADR reports 
and analyse the number of ADR reports sent to the Portuguese 
regulatory authority (INFARMED), through a regional 
pharmacovigilance centre. 
Abstract
Purpose: Adverse Drug Reaction (ADR) reporting is an efficient 
method to assess the safety of drugs. However, underreporting is a 
major issue undermining the effectiveness this method. Among patients 
with Inflammatory Bowel Disease (IBD), ADR are a serious problem, 
because these patients are often treated with new and potent drugs. 
Electronic registries usually include information on ADR, recorded by 
physicians. To promote ADR reporting by gastroenterologists working 
in a multicentre IBD study group, we proposed the utilisation of a web 
service in their usual Electronic Health Records (EHR) to collect ADR. 
The aim of this work was to describe the impact of this intervention 
on the number of ADR reported to the regulatory authority through a 
regional pharmacovigilance centre.
Methods: A study was performed between 2013 and 2015. A web 
service was created and implemented in an EHR in use. We analysed 
the trends and type of ADR reported through this service.
Results: From April 2013 to February 2015, 167 ADR reports 
were sent to the Northern Pharmacovigilance Centre through the web 
service, comprising 10% of the total ADR reports received in the same 
period. Of these, 118 cases were serious (one was life-threatening). 
In the northern region of Portugal, GEDII physicians reported 9 ADR 
during the 23 months previous to web service implementation and 
121 ADR during the 23 months after web service implementation, i.e. 
an increase of 81%.
Conclusions: This solution allowed for reporting 167 ADR during 
the first 23 months of implementation, simply by clicking a button 
included in the usual EHR used by gastroenterologists. These results 
suggest that information systems (IS) should facilitate the reporting 
of ADR. 
Keywords: Adverse Drug Reactions; Inflammatory Bowel 
Disease; Pharmacovigilance; Electronic Health Records
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Introduction
All medicines have adverse effects, some of them unknown 
until the drug is commercialised. Thus, it is crucial to implement 
strategies to monitor drug safety. Pharmacovigilance is the 
activity of drug surveillance, after its launch onto the market, 
with the main goal of public health protection, ensuring that the 
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Methods
Intervention
The multi-centre research project, the Study Group of 
Inflammatory Bowel Disease – GEDII [8], has its own Electronic 
Health Record (EHR) to collect patient information, with a field 
related to medications and ADR. 
The GEDII members asked for collaboration with the Northern 
Pharmacovigilance Centre (UFN in Portuguese) and the Health 
Information and Decision Sciences Department (CIDES) of the 
Faculty of Medicine to develop a tool to allow for easy reporting 
of ADR included in the EHR to the pharmacovigilance system. The 
two entities had, at the time, released a new information service 
(a web service) to collect suspected adverse reactions directly 
from prescription and medical records. This system was easily 
adapted to the EHR used by the GEDII group.
The Northern Pharmacovigilance Centre, as part of the 
Portuguese Pharmacovigilance System, receives ADR reports 
from healthcare professionals (and, since 2012, from consumers 
as well) through an on-line form, a paper form, e-mail and by 
telephone. Since 2013, UFN has also received ADR reports 
through the web service.
The web service anonymises patient data (converting the full 
name of the patient into initials), according to the data protection 
standards of the Portuguese Pharmacovigilance System. Figure 1 
shows the information flow from the electronic health record to 
the pharmacovigilance system.
To use this service, there is a button asking the doctor if he/
she will allow the information to be sent to the pharmacovigilance 
database (see Figure 2). If the physician does not allow for this 
information to be sent to the system, it will only be stored in the 
health record.
Study design and data collection
The web service was implemented in the GEDII electronic 
health record (used only by gastroenterologists) in April 2013. 
There are 15 hospitals using this information system, covering 
a total of 4031 patients. The database has 39 registered users, 
which means that, potentially, 39 physicians could report ADR 
through this information system [8].
In order to use this web service, it is necessary to access a 
specific URL, provided by the Northern Pharmacovigilance Centre 
and CIDES. The service was incorporated in the GEDII software to 
collect the ADR already stored by the physicians in the system. 
Each physician, in the context of the patient, sends the ADR to the 
Regional Pharmacovigilance Centre. 
After the ADR report is received by the Regional 
Pharmacovigilance Centre, their technical staff process the report 
according to the pharmacovigilance guidelines [9], sending it to 
the Portuguese Regulatory Authority (INFARMED).
If the doctor does not want to send the information to the 
pharmacovigilance system, it will only be stored in the medical 
history.
To analyse the trends and type of ADR reported through 
this service, we performed a descriptive analysis on the 
number and seriousness of ADR reported. The seriousness was 
assessed using the World Health Organisation [10] seriousness 
criterion [11]. According to this criterion, a serious ADR is any 
untoward medical occurrence that at any dose: results in death, 
requires inpatient hospitalisation or prolongation of existing 
hospitalisation, results in persistent or significant disability/
incapacity or is life-threatening. 
Results
From April 2013 to February 2015, physicians from GEDII 
reported 167 ADR through the described web service. 
Of the 167 reported ADR, 118 (71%) were serious ADR, 
considering the World Health Organisation seriousness criterion 
[11]. One of the cases was life-threatening and none were fatal.
To calculate the increase in ADR reporting in this period, we 
used data from the northern region, which is the delimited area 
of the Northern Pharmacovigilance Centre, as we did not have 
access to national ADR reporting data. Thus, considering the 
physicians from the GEDII group that work in at the northern 
region of Portugal, 9 ADR were reported during the 23 months 
prior to web service implementation and 121 ADR were reported 
during the 23 months after web service implementation, i.e. an 
increase of 81%.
Figure 1: Information flow
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Drugs involved in the Reported ADR
Most of the cases had one only suspected drug, but in six 
cases there were two suspected drugs involved.
Of the reported ADR, 106 cases (63%) were presumably due 
to azathioprine, 23 cases (14%) to infliximab, 14 cases (8%) to 
adalimumab and 9 (5%) cases to methotrexate (Figure 3).
All of these drugs are classified as antineoplastic 
and immunomodulating agents, according to the WHO 
Anatomical Therapeutic Chemical (ATC) classification 
system [12]. Azathioprine, infliximab and adalimumab are 
immunosuppressants and methotrexate is an antimetabolite.
Discussion
Worldwide, many systems use electronic health records to 
facilitate adverse event reporting, with the same goal as our work, 
which is to not overload healthcare professionals with additional 
administrative work to report ADR [7, 13, 14]. These systems can be 
included in the EHR and be easily completed [13] or can actively 
help in form filling with the automatic input of certain information 
already included in the EHR [7]. During the ALIAS (Albumin in 
Acute Stroke Trial) experience, authors decided to integrate an 
electronic safety reporting module into the existing web-based 
system to deal with safety reporting obligations of a multicentre 
clinical trial [15]. This system pre-populates the reporting form 
with the existing information, which needs to be completed and 
validated by clinical staff. The ASTER pilot study also brought 
an important contribution to the development of these systems, 
as it triggered ADR within the EHR, collected patient data, 
populated the ADR reporting form and made the report available 
to the physician for review [16]. This work is different from ours, 
because it asks the clinician to provide additional information on 
the adverse event and then submits the report. All these systems 
incur extra work on the part of physicians, which is difficult to 
eliminate. The novelty of our work is the detail of allowing the 
physician to report ADR without any additional administrative 
work beyond the usual clinical registry. In addition, the EHR 
remained the same, without the need to change the physicians’ 
routine. This system adapts to the routines of the healthcare 
professionals and not vice versa, which can explain the increasing 
of ADR reporting among the studied group.
It is also important to note that most of the reported ADR 
were serious. In fact, the studied group deals with innovative 
and powerful drugs those often cause serious adverse events. 
This finding reinforces the importance of our work, as 
Pharmacovigilance Systems seek mainly information about 
serious (and unexpected) ADR [17].
Our study has some limitations, such that it only included 
gastroenterologists. However, this web service is available to 
be used in several software. Even so, it is currently in use only 
in two software systems: the one described in this study and an 
electronic prescription software system. Another issue is that our 
study does not have a control group, which limits the conclusions 
drawn. For this reason, the only comparison that the authors 
were able to perform was for the number of ADR reports made 
by the same group of gastroenterologists before the web service 
implementation.
Conclusions
The simple solution described in our work allowed for 
 “Do you want this information to be sent to the National Pharmacovigilance System?”  
List of adverse drug  
Drug 
Patient 
 
Figure 2: Screen shot of the ADR section on the GEDII electronic health record
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Figure 3: Drugs involved in the reported ADR
reporting 167 ADR during the first 23 months of implementation, 
simply by clicking a button included in the usual electronic health 
record used by gastroenterologists. Our results suggest that 
doctors would report more ADR if they do not have to take on 
any further workload to do it. We propose that IS used to support 
multicentre studies should be used to report detected ADR.
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